[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fb2kHYv38Ji9rQN7BUm0dX7R1DEbV33-uPOIVUpu4Zu8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":89,"rows":96},"VA Office of Research and Development",[4],1720,false,462,83,3618627,116,1438,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Stroke",74,{"name":18,"count":19},"PTSD",69,{"name":21,"count":22},"Depression",62,{"name":24,"count":25},"Posttraumatic Stress Disorder",56,{"name":27,"count":28},"Obesity",46,{"name":30,"count":31},"Spinal Cord Injury",44,{"name":33,"count":34},"Schizophrenia",43,{"name":36,"count":37},"Stress Disorders, Post-Traumatic",36,[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05035810","A Pragmatic Trial to Determine the Benefit of Behaviorally Enhanced Exercise Incentives and Corticosteroid Injections in Osteoarthritis of the Knee Marching On for Veterans With Osteoarthritis of the Knee","2024-11-30","Corticosteroid Injection given in A-B order",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT03994172","Novel Combination Therapy for Osteoporosis in Men","2025-06-30","Teriparatide or human parathyroid hormone (PTH) 1-34",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03642028","Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress","2025-12-31","Suvorexant",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT03539614","Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests","2026-01-01","Prazosin",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04104893","A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation","2026-02-02","Pembrolizumab",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT05888233","Allopurinol Improves Heart Function in African Americans With Resistant Hypertension","2026-04-30","Allopurinol",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT04698031","Efficacy of Clopidogrel on Incidence of Silent Brain Infarction","2026-05-01","Clopidogrel treatment",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04661995","Notched Noise Therapy for Suppression of Tinnitus","2026-05-31","Hearing Aid and Notched Noise Therapy",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT04118387","Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment","2026-06-30","Acetazolamide + supplemental oxygen + PAP therapy",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT05776056","Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints","2026-07-06","Methylphenidate",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,163,218,272,310,342,393,423,449,475,493,520,541,559,577,600,618,644,670,701,719,737,755,777,795,819,846,864,890,908,931,957,995,1027,1052,1079,1097,1115,1133,1151,1177,1199,1217,1235,1259,1283,1308,1335,1353,1391,1409,1427,1445,1463,1481,1499,1517,1542,1610,1655,1718,1753,1779,1814,1835,1863,1881,1899,1921,1946,1972,1996,2014,2040,2066,2084,2107,2133,2151,2169,2196,2214,2238,2256,2281,2305,2329,2349,2374,2392,2418,2443,2461,2487,2505,2530,2548,2572,2599,2634,2671,2705,2723,2741,2764,2788,2811,2829,2854,2877,2901,2926,2949,2975,3000,3022,3040,3081,3130,3175,3203,3241,3278,3314,3348,3375,3400,3426,3444,3462,3486,3511,3529,3547,3565,3587,3611,3636,3665,3683,3711,3729,3753,3777,3795,3813,3839,3871,3898,3916,3943,3961,3987,4005,4032,4050,4074,4092,4115,4142,4160,4178,4203,4227,4252,4277,4295,4319,4346,4364,4393,4411,4436,4459,4497,4541,4576,4611,4643,4675,4701,4723,4749,4774,4799,4817,4841,4859,4882,4906,4924,4950,4975,5002,5020,5043,5061,5079,5097,5121,5146,5170,5198,5216,5234,5262,5287,5305,5329,5353,5376,5402,5420,5438,5464,5490,5508,5532,5556,5584,5602,5627,5651,5694,5725,5759,5794,5816,5839,5866,5884,5902,5927,5945,5970,5988,6012,6039,6062,6088,6112,6137,6155,6179,6204,6222,6247,6271,6289,6312,6330,6354,6380,6398,6421,6446,6464,6489,6512,6536,6561,6585,6608,6634,6657,6682,6700,6725,6748,6774,6792,6810,6836,6854,6879,6897,6922,6940,6958,6976,6994,7025,7043,7061,7079,7097,7122,7144,7168,7186,7209,7227,7248,7273,7291,7309,7333,7357,7381,7412,7430,7452,7475,7498,7520,7543,7566,7586,7610,7628,7650,7674,7696,7719,7737,7763,7781,7804,7838,7860,7886,7919,7950,7985,8007,8031,8055,8078,8096,8120,8145,8163,8181,8204,8222,8246,8264,8282,8300,8318,8344,8369,8387,8410,8433,8455,8481,8507],{"intervention":98,"totalTrials":99,"cells":100},"Empagliflozin",4,{"EARLY_PHASE1":101,"PHASE1":104,"PHASE2":106,"PHASE3":133,"PHASE4":135,"NA":161},{"trials":102,"activeCount":103},[],0,{"trials":105,"activeCount":103},[],{"trials":107,"activeCount":132,"soonestReadout":113},[108,120],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"NCT06745063","Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity","RECRUITING",[92],"2028-12-31","2029-12-31","2025-05-30",50,[27,118],"Vascular Health",[98],{"nctId":121,"briefTitle":122,"status":123,"phases":124,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":131},"NCT07060417","Vascular Effects of SGLT2i in Non-diabetic CKD","NOT_YET_RECRUITING",[92],"2029-03-31","2029-09-30","2026-08-01",52,[130],"Non-diabetic Chronic Kidney Disease",[98],2,{"trials":134,"activeCount":103},[],{"trials":136,"activeCount":132,"soonestReadout":141},[137,150],{"nctId":138,"briefTitle":139,"status":111,"phases":140,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":149},"NCT06625073","Randomized Trial of SGLT2i in Heart Transplant Recipients",[94],"2029-08-31","2030-02-28","2026-01-20",200,[146,147,148],"Heart Transplant","Cardiovascular Disease","Kidney Disease",[98],{"nctId":151,"briefTitle":152,"status":111,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":160},"NCT06013865","Empagliflozin Treatment in Kidney Transplant Recipients",[94],"2030-03-31","2024-04-05",264,[158,159],"Kidney Transplant","Chronic Kidney Disease",[98],{"trials":162,"activeCount":103},[],{"intervention":88,"totalTrials":99,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":181,"PHASE4":183,"NA":216},{"trials":166,"activeCount":103},[],{"trials":168,"activeCount":103},[],{"trials":170,"activeCount":103},[171],{"nctId":172,"briefTitle":173,"status":174,"phases":175,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":180},"NCT04885257","Methylphenidate for Ptsd and Stroke Veterans","COMPLETED",[91,92],"2025-05-05","2022-01-14",20,[18,15],[88],{"trials":182,"activeCount":103},[],{"trials":184,"activeCount":132,"soonestReadout":87},[185,198,208],{"nctId":186,"briefTitle":187,"status":174,"phases":188,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":197},"NCT00495820","Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study",[94],"2010-03","2010-06","2007-08",60,[194,195,196],"Alzheimer's Disease","Apathy","Dementia",[88],{"nctId":199,"briefTitle":200,"status":111,"phases":201,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":207},"NCT04419272","Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits",[94],"2028-05-31","2023-08-14",226,[206],"Epilepsy",[88,88],{"nctId":85,"briefTitle":86,"status":111,"phases":209,"primaryCompletion":87,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":215},[94],"2027-03-31","2024-02-05",70,[214],"Posttraumatic Stress Disorder (PTSD)",[88],{"trials":217,"activeCount":103},[],{"intervention":219,"totalTrials":220,"cells":221},"Acetazolamide",3,{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":241,"PHASE4":257,"NA":270},{"trials":223,"activeCount":103},[],{"trials":225,"activeCount":103},[],{"trials":227,"activeCount":240,"soonestReadout":232},[228],{"nctId":229,"briefTitle":230,"status":111,"phases":231,"primaryCompletion":232,"completion":210,"start":233,"enrollment":234,"conditions":235,"interventions":239},"NCT05589753","Sleep Disordered Breathing With Opioid Use",[91,92],"2026-12-31","2019-05-02",150,[236,237,238],"Sleep Apnea","Opioid Use","Sleep Disordered Breathing",[219],1,{"trials":242,"activeCount":103},[243],{"nctId":244,"briefTitle":245,"status":246,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":255},"NCT00746954","Buspirone as a Potential Treatment for Recurrent Central Apnea","TERMINATED",[93],"2011-09","2011-12","2008-09",8,[253,254],"Central Apnea","Heart Failure",[219,256],"Buspirone",{"trials":258,"activeCount":240,"soonestReadout":263},[259],{"nctId":260,"briefTitle":261,"status":111,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT02703220","Sleep Apnea in Elderly",[94],"2026-07-31","2015-07-03",100,[236,267],"Elderly Adults",[219,269],"Finasteride",{"trials":271,"activeCount":103},[],{"intervention":273,"totalTrials":132,"cells":274},"pimavanserin",{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":291,"PHASE4":293,"NA":308},{"trials":276,"activeCount":103},[],{"trials":278,"activeCount":103},[],{"trials":280,"activeCount":240,"soonestReadout":285},[281],{"nctId":282,"briefTitle":283,"status":111,"phases":284,"primaryCompletion":285,"completion":285,"start":286,"enrollment":192,"conditions":287,"interventions":290},"NCT05441280","Pimavanserin for Insomnia in Veterans With PTSD",[92],"2027-07-12","2023-12-28",[288,289],"Post-traumatic Stress Disorder","Insomnia",[273],{"trials":292,"activeCount":103},[],{"trials":294,"activeCount":240,"soonestReadout":299},[295],{"nctId":296,"briefTitle":297,"status":111,"phases":298,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},"NCT04373317","Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis",[94],"2026-10-24","2027-08-24","2022-10-24",358,[304],"Parkinson's Disease Psychosis",[306,307],"Pimavanserin","Quetiapine",{"trials":309,"activeCount":103},[],{"intervention":53,"totalTrials":132,"cells":311},{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":318,"PHASE4":320,"NA":340},{"trials":313,"activeCount":103},[],{"trials":315,"activeCount":103},[],{"trials":317,"activeCount":103},[],{"trials":319,"activeCount":103},[],{"trials":321,"activeCount":132,"soonestReadout":52},[322,332],{"nctId":323,"briefTitle":324,"status":123,"phases":325,"primaryCompletion":326,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":331},"NCT06788522","The Effects of Orexin Antagonism on Fear Extinction in PTSD",[94],"2032-03-01","2032-06-30","2026-06-01",40120,[289,18],[53],{"nctId":50,"briefTitle":51,"status":111,"phases":333,"primaryCompletion":52,"completion":52,"start":334,"enrollment":335,"conditions":336,"interventions":339},[94],"2019-08-30",190,[337,338],"Sleep Initiation and Maintenance Disorders","Stress Disorders, Posttraumatic",[53],{"trials":341,"activeCount":103},[],{"intervention":269,"totalTrials":220,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":383,"PHASE4":385,"NA":391},{"trials":345,"activeCount":103},[],{"trials":347,"activeCount":103},[],{"trials":349,"activeCount":103},[350,364],{"nctId":351,"briefTitle":352,"status":174,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":192,"conditions":357,"interventions":362},"NCT00475501","5-Alpha Reductase and Anabolic Effects of Testosterone",[92],"2012-03","2014-10","2007-01",[358,359,360,361],"Male Hypogonadism","Muscle Atrophy","Sarcopenia","Benign Prostate Hypertrophy",[363,269],"Testosterone Enanthate",{"nctId":365,"briefTitle":366,"status":246,"phases":367,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":382},"NCT02248701","Testosterone Plus Finasteride Treatment After Spinal Cord Injury",[92],"2021-08-13","2017-04-27",33,[30,372,373,374,375,376,377,378,379,380,381],"Spinal Cord Injuries","Trauma, Nervous System","Wounds and Injuries","Central Nervous System Diseases","Nervous System Diseases","Spinal Cord Diseases","Gonadal Disorders","Endocrine System Diseases","Hypogonadism","Genital Diseases, Male",[363,269],{"trials":384,"activeCount":103},[],{"trials":386,"activeCount":240,"soonestReadout":263},[387],{"nctId":260,"briefTitle":261,"status":111,"phases":388,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":389,"interventions":390},[94],[236,267],[219,269],{"trials":392,"activeCount":103},[],{"intervention":307,"totalTrials":132,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":421},{"trials":396,"activeCount":103},[],{"trials":398,"activeCount":103},[],{"trials":400,"activeCount":103},[],{"trials":402,"activeCount":103},[],{"trials":404,"activeCount":240,"soonestReadout":299},[405,417],{"nctId":406,"briefTitle":407,"status":174,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":415},"NCT00292370","Quetiapine Augmentation for Treatment-resistant PTSD",[94],"2008-12","2009-05","2006-01",124,[414,36],"Combat Disorders",[416,307],"Open Label (OL) Paroxetine",{"nctId":296,"briefTitle":297,"status":111,"phases":418,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":419,"interventions":420},[94],[304],[306,307],{"trials":422,"activeCount":103},[],{"intervention":424,"totalTrials":240,"cells":425},"Colchicine",{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":447},{"trials":427,"activeCount":103},[],{"trials":429,"activeCount":103},[],{"trials":431,"activeCount":103},[],{"trials":433,"activeCount":103},[],{"trials":435,"activeCount":240,"soonestReadout":440},[436],{"nctId":437,"briefTitle":438,"status":111,"phases":439,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":446},"NCT05618353","The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial",[94],"2028-07-31","2029-04-30","2023-08-21",700,[445],"Coronary Artery Disease",[424],{"trials":448,"activeCount":103},[],{"intervention":450,"totalTrials":240,"cells":451},"Trazodone + PAP therapy",{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":473},{"trials":453,"activeCount":103},[],{"trials":455,"activeCount":103},[],{"trials":457,"activeCount":103},[],{"trials":459,"activeCount":103},[],{"trials":461,"activeCount":240,"soonestReadout":466},[462],{"nctId":463,"briefTitle":464,"status":123,"phases":465,"primaryCompletion":466,"completion":467,"start":468,"enrollment":144,"conditions":469,"interventions":471},"NCT07210606","Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment",[94],"2030-06-30","2030-12-31","2026-10-01",[238,470],"Able Bodied",[450,472],"Oxygen + PAP therapy",{"trials":474,"activeCount":103},[],{"intervention":472,"totalTrials":240,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":485,"NA":491},{"trials":478,"activeCount":103},[],{"trials":480,"activeCount":103},[],{"trials":482,"activeCount":103},[],{"trials":484,"activeCount":103},[],{"trials":486,"activeCount":240,"soonestReadout":466},[487],{"nctId":463,"briefTitle":464,"status":123,"phases":488,"primaryCompletion":466,"completion":467,"start":468,"enrollment":144,"conditions":489,"interventions":490},[94],[238,470],[450,472],{"trials":492,"activeCount":103},[],{"intervention":494,"totalTrials":240,"cells":495},"Medication optimization",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":504,"NA":518},{"trials":497,"activeCount":103},[],{"trials":499,"activeCount":103},[],{"trials":501,"activeCount":103},[],{"trials":503,"activeCount":103},[],{"trials":505,"activeCount":240,"soonestReadout":510},[506],{"nctId":507,"briefTitle":508,"status":111,"phases":509,"primaryCompletion":510,"completion":114,"start":511,"enrollment":512,"conditions":513,"interventions":517},"NCT06574009","Better Options for Chronic Cancer Pain",[94],"2029-04-01","2025-10-07",294,[514,515,516],"Chronic Pain","Cancer Survivor","Opioid Dependence",[494],{"trials":519,"activeCount":103},[],{"intervention":83,"totalTrials":240,"cells":521},{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":530,"NA":539},{"trials":523,"activeCount":103},[],{"trials":525,"activeCount":103},[],{"trials":527,"activeCount":103},[],{"trials":529,"activeCount":103},[],{"trials":531,"activeCount":240,"soonestReadout":82},[532],{"nctId":80,"briefTitle":81,"status":111,"phases":533,"primaryCompletion":82,"completion":232,"start":534,"enrollment":144,"conditions":535,"interventions":536},[94],"2021-01-07",[238,470],[83,537,538],"Zolpidem + PAP therapy","Buspirone + PAP therapy",{"trials":540,"activeCount":103},[],{"intervention":537,"totalTrials":240,"cells":542},{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":551,"NA":557},{"trials":544,"activeCount":103},[],{"trials":546,"activeCount":103},[],{"trials":548,"activeCount":103},[],{"trials":550,"activeCount":103},[],{"trials":552,"activeCount":240,"soonestReadout":82},[553],{"nctId":80,"briefTitle":81,"status":111,"phases":554,"primaryCompletion":82,"completion":232,"start":534,"enrollment":144,"conditions":555,"interventions":556},[94],[238,470],[83,537,538],{"trials":558,"activeCount":103},[],{"intervention":538,"totalTrials":240,"cells":560},{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":567,"PHASE4":569,"NA":575},{"trials":562,"activeCount":103},[],{"trials":564,"activeCount":103},[],{"trials":566,"activeCount":103},[],{"trials":568,"activeCount":103},[],{"trials":570,"activeCount":240,"soonestReadout":82},[571],{"nctId":80,"briefTitle":81,"status":111,"phases":572,"primaryCompletion":82,"completion":232,"start":534,"enrollment":144,"conditions":573,"interventions":574},[94],[238,470],[83,537,538],{"trials":576,"activeCount":103},[],{"intervention":48,"totalTrials":240,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":585,"PHASE4":587,"NA":598},{"trials":580,"activeCount":103},[],{"trials":582,"activeCount":103},[],{"trials":584,"activeCount":103},[],{"trials":586,"activeCount":103},[],{"trials":588,"activeCount":240,"soonestReadout":47},[589],{"nctId":45,"briefTitle":46,"status":590,"phases":591,"primaryCompletion":47,"completion":82,"start":592,"enrollment":593,"conditions":594,"interventions":596},"ACTIVE_NOT_RECRUITING",[94],"2019-07-01",40,[595],"Male Osteoporosis",[48,597],"Cinacalcet",{"trials":599,"activeCount":103},[],{"intervention":597,"totalTrials":240,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":608,"PHASE4":610,"NA":616},{"trials":603,"activeCount":103},[],{"trials":605,"activeCount":103},[],{"trials":607,"activeCount":103},[],{"trials":609,"activeCount":103},[],{"trials":611,"activeCount":240,"soonestReadout":47},[612],{"nctId":45,"briefTitle":46,"status":590,"phases":613,"primaryCompletion":47,"completion":82,"start":592,"enrollment":593,"conditions":614,"interventions":615},[94],[595],[48,597],{"trials":617,"activeCount":103},[],{"intervention":619,"totalTrials":240,"cells":620},"Atomoxetine",{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":629,"NA":642},{"trials":622,"activeCount":103},[],{"trials":624,"activeCount":103},[],{"trials":626,"activeCount":103},[],{"trials":628,"activeCount":103},[],{"trials":630,"activeCount":240,"soonestReadout":635},[631],{"nctId":632,"briefTitle":633,"status":123,"phases":634,"primaryCompletion":635,"completion":636,"start":637,"enrollment":638,"conditions":639,"interventions":641},"NCT06573970","Atomoxetine and Executive Function in PTSD",[94],"2029-06-29","2029-09-28","2026-04-01",160,[640],"Posttraumatic Stress Disorder With Attention Defic",[619],{"trials":643,"activeCount":103},[],{"intervention":645,"totalTrials":240,"cells":646},"Pentoxifylline",{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":653,"PHASE4":655,"NA":668},{"trials":648,"activeCount":103},[],{"trials":650,"activeCount":103},[],{"trials":652,"activeCount":103},[],{"trials":654,"activeCount":103},[],{"trials":656,"activeCount":240,"soonestReadout":661},[657],{"nctId":658,"briefTitle":659,"status":590,"phases":660,"primaryCompletion":661,"completion":662,"start":663,"enrollment":664,"conditions":665,"interventions":667},"NCT03625648","Pentoxifylline in Diabetic Kidney Disease",[94],"2028-01-03","2030-07-08","2019-11-18",2376,[666],"Diabetic Kidney Disease",[645],{"trials":669,"activeCount":103},[],{"intervention":671,"totalTrials":240,"cells":672},"Motivation-Phase Varenicline",{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":679,"PHASE4":681,"NA":699},{"trials":674,"activeCount":103},[],{"trials":676,"activeCount":103},[],{"trials":678,"activeCount":103},[],{"trials":680,"activeCount":103},[],{"trials":682,"activeCount":240,"soonestReadout":687},[683],{"nctId":684,"briefTitle":685,"status":123,"phases":686,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":690,"interventions":695},"NCT06966362","Varenicline for Smoking Reduction in Veterans Not Ready To Quit",[94],"2030-06-28","2026-07-01",400,[691,692,693,694],"Veterans","Tobacco Use Disorder","Cigarette Smoking","Tobacco Dependence",[671,696,697,698],"Motivation-Phase Nicotine Mini-Lozenge","Cessation-Phase Combination Nicotine Replacement Therapy","Cessation-Phase Varenicline",{"trials":700,"activeCount":103},[],{"intervention":696,"totalTrials":240,"cells":702},{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":711,"NA":717},{"trials":704,"activeCount":103},[],{"trials":706,"activeCount":103},[],{"trials":708,"activeCount":103},[],{"trials":710,"activeCount":103},[],{"trials":712,"activeCount":240,"soonestReadout":687},[713],{"nctId":684,"briefTitle":685,"status":123,"phases":714,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":715,"interventions":716},[94],[691,692,693,694],[671,696,697,698],{"trials":718,"activeCount":103},[],{"intervention":697,"totalTrials":240,"cells":720},{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":727,"PHASE4":729,"NA":735},{"trials":722,"activeCount":103},[],{"trials":724,"activeCount":103},[],{"trials":726,"activeCount":103},[],{"trials":728,"activeCount":103},[],{"trials":730,"activeCount":240,"soonestReadout":687},[731],{"nctId":684,"briefTitle":685,"status":123,"phases":732,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":733,"interventions":734},[94],[691,692,693,694],[671,696,697,698],{"trials":736,"activeCount":103},[],{"intervention":698,"totalTrials":240,"cells":738},{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":745,"PHASE4":747,"NA":753},{"trials":740,"activeCount":103},[],{"trials":742,"activeCount":103},[],{"trials":744,"activeCount":103},[],{"trials":746,"activeCount":103},[],{"trials":748,"activeCount":240,"soonestReadout":687},[749],{"nctId":684,"briefTitle":685,"status":123,"phases":750,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":751,"interventions":752},[94],[691,692,693,694],[671,696,697,698],{"trials":754,"activeCount":103},[],{"intervention":73,"totalTrials":240,"cells":756},{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":763,"PHASE4":765,"NA":775},{"trials":758,"activeCount":103},[],{"trials":760,"activeCount":103},[],{"trials":762,"activeCount":103},[],{"trials":764,"activeCount":103},[],{"trials":766,"activeCount":240,"soonestReadout":72},[767],{"nctId":70,"briefTitle":71,"status":590,"phases":768,"primaryCompletion":72,"completion":688,"start":769,"enrollment":770,"conditions":771,"interventions":773},[94],"2022-03-30",134,[772],"Silent Brain Infarction",[73,774],"Aspirin treatment",{"trials":776,"activeCount":103},[],{"intervention":774,"totalTrials":240,"cells":778},{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":785,"PHASE4":787,"NA":793},{"trials":780,"activeCount":103},[],{"trials":782,"activeCount":103},[],{"trials":784,"activeCount":103},[],{"trials":786,"activeCount":103},[],{"trials":788,"activeCount":240,"soonestReadout":72},[789],{"nctId":70,"briefTitle":71,"status":590,"phases":790,"primaryCompletion":72,"completion":688,"start":769,"enrollment":770,"conditions":791,"interventions":792},[94],[772],[73,774],{"trials":794,"activeCount":103},[],{"intervention":796,"totalTrials":240,"cells":797},"mirabegron",{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":802,"PHASE3":804,"PHASE4":806,"NA":817},{"trials":799,"activeCount":103},[],{"trials":801,"activeCount":103},[],{"trials":803,"activeCount":103},[],{"trials":805,"activeCount":103},[],{"trials":807,"activeCount":240,"soonestReadout":154},[808],{"nctId":809,"briefTitle":810,"status":123,"phases":811,"primaryCompletion":154,"completion":466,"start":688,"enrollment":812,"conditions":813,"interventions":816},"NCT07187466","Behavioral and\u002For Mirabegron to Treat Urinary Symptoms in Parkinson Disease",[94],146,[814,815],"Overactive Bladder","Parkinson Disease",[796],{"trials":818,"activeCount":103},[],{"intervention":820,"totalTrials":240,"cells":821},"Sublingual buprenorphine with naloxone",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":828,"PHASE4":830,"NA":844},{"trials":823,"activeCount":103},[],{"trials":825,"activeCount":103},[],{"trials":827,"activeCount":103},[],{"trials":829,"activeCount":103},[],{"trials":831,"activeCount":240,"soonestReadout":836},[832],{"nctId":833,"briefTitle":834,"status":111,"phases":835,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":842},"NCT04375033","A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder",[94],"2028-09-30","2029-05-31","2020-11-03",952,[841],"Opioid Use Disorder",[820,843],"Injectable subcutaneous buprenorphine",{"trials":845,"activeCount":103},[],{"intervention":843,"totalTrials":240,"cells":847},{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":856,"NA":862},{"trials":849,"activeCount":103},[],{"trials":851,"activeCount":103},[],{"trials":853,"activeCount":103},[],{"trials":855,"activeCount":103},[],{"trials":857,"activeCount":240,"soonestReadout":836},[858],{"nctId":833,"briefTitle":834,"status":111,"phases":859,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":860,"interventions":861},[94],[841],[820,843],{"trials":863,"activeCount":103},[],{"intervention":865,"totalTrials":240,"cells":866},"Apixaban",{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":873,"PHASE4":875,"NA":888},{"trials":868,"activeCount":103},[],{"trials":870,"activeCount":103},[],{"trials":872,"activeCount":103},[],{"trials":874,"activeCount":103},[],{"trials":876,"activeCount":240,"soonestReadout":881},[877],{"nctId":878,"briefTitle":879,"status":123,"phases":880,"primaryCompletion":881,"completion":882,"start":328,"enrollment":883,"conditions":884,"interventions":886},"NCT06953726","Comparing the Safety and Efficacy of Apixaban and Rivaroxaban",[94],"2032-10-04","2033-10-03",10000,[885],"Atrial Fibrillation",[865,887],"Rivaroxaban",{"trials":889,"activeCount":103},[],{"intervention":887,"totalTrials":240,"cells":891},{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":898,"PHASE4":900,"NA":906},{"trials":893,"activeCount":103},[],{"trials":895,"activeCount":103},[],{"trials":897,"activeCount":103},[],{"trials":899,"activeCount":103},[],{"trials":901,"activeCount":240,"soonestReadout":881},[902],{"nctId":878,"briefTitle":879,"status":123,"phases":903,"primaryCompletion":881,"completion":882,"start":328,"enrollment":883,"conditions":904,"interventions":905},[94],[885],[865,887],{"trials":907,"activeCount":103},[],{"intervention":909,"totalTrials":240,"cells":910},"Lorazepam 1 mg",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":919,"NA":929},{"trials":912,"activeCount":103},[],{"trials":914,"activeCount":103},[],{"trials":916,"activeCount":103},[],{"trials":918,"activeCount":103},[],{"trials":920,"activeCount":240,"soonestReadout":925},[921],{"nctId":922,"briefTitle":923,"status":111,"phases":924,"primaryCompletion":925,"completion":925,"start":926,"enrollment":234,"conditions":927,"interventions":928},"NCT06852469","Computational Assessment of GABA Receptor Modulation in PTSD",[94],"2029-06-30","2025-07-01",[36],[909],{"trials":930,"activeCount":103},[],{"intervention":932,"totalTrials":240,"cells":933},"Metformin XR",{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":942,"NA":955},{"trials":935,"activeCount":103},[],{"trials":937,"activeCount":103},[],{"trials":939,"activeCount":103},[],{"trials":941,"activeCount":103},[],{"trials":943,"activeCount":240,"soonestReadout":636},[944],{"nctId":945,"briefTitle":946,"status":111,"phases":947,"primaryCompletion":636,"completion":636,"start":948,"enrollment":949,"conditions":950,"interventions":954},"NCT02915198","Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes",[94],"2023-04-03",7410,[951,952,953],"Prediabetic State","Atherosclerosis","Metformin",[932],{"trials":956,"activeCount":103},[],{"intervention":958,"totalTrials":132,"cells":959},"Carvedilol",{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":978,"PHASE4":991,"NA":993},{"trials":961,"activeCount":103},[],{"trials":963,"activeCount":103},[],{"trials":965,"activeCount":103},[966],{"nctId":967,"briefTitle":968,"status":174,"phases":969,"primaryCompletion":970,"completion":970,"start":971,"enrollment":972,"conditions":973,"interventions":976},"NCT02230891","Biomarker Guided Therapies in Stage A\u002FB Heart Failure",[92],"2020-12-15","2014-10-01",58,[974,975,147],"Hypertension","Diabetes",[958,977],"Spironolactone",{"trials":979,"activeCount":240,"soonestReadout":232},[980],{"nctId":981,"briefTitle":982,"status":111,"phases":983,"primaryCompletion":232,"completion":113,"start":984,"enrollment":985,"conditions":986,"interventions":989},"NCT05931276","CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes",[93],"2024-05-22",2540,[987,988],"End-Stage Kidney Disease","End-Stage Renal Disease",[990,958],"Metoprolol Succinate",{"trials":992,"activeCount":103},[],{"trials":994,"activeCount":103},[],{"intervention":58,"totalTrials":132,"cells":996},{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1003,"PHASE4":1023,"NA":1025},{"trials":998,"activeCount":103},[],{"trials":1000,"activeCount":103},[],{"trials":1002,"activeCount":103},[],{"trials":1004,"activeCount":240,"soonestReadout":57},[1005,1011],{"nctId":55,"briefTitle":56,"status":590,"phases":1006,"primaryCompletion":57,"completion":328,"start":1007,"enrollment":1008,"conditions":1009,"interventions":1010},[93],"2018-06-04",87,[24],[58],{"nctId":1012,"briefTitle":1013,"status":174,"phases":1014,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":1019,"interventions":1021},"NCT00532493","Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD",[93],"2013-02-28","2013-05-31","2010-01-06",304,[18,1020],"Sleep Disorders",[1022],"prazosin",{"trials":1024,"activeCount":103},[],{"trials":1026,"activeCount":103},[],{"intervention":1028,"totalTrials":240,"cells":1029},"5% Imiquimod cream",{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1036,"PHASE4":1048,"NA":1050},{"trials":1031,"activeCount":103},[],{"trials":1033,"activeCount":103},[],{"trials":1035,"activeCount":103},[],{"trials":1037,"activeCount":240,"soonestReadout":1042},[1038],{"nctId":1039,"briefTitle":1040,"status":123,"phases":1041,"primaryCompletion":1042,"completion":1042,"start":1043,"enrollment":1044,"conditions":1045,"interventions":1047},"NCT05212246","Basal Cell Carcinoma Chemoprevention Trial",[93],"2032-08-03","2026-08-03",1630,[1046],"Basal Cell Carcinoma",[1028],{"trials":1049,"activeCount":103},[],{"trials":1051,"activeCount":103},[],{"intervention":1053,"totalTrials":240,"cells":1054},"Bismuth quadruple therapy with optimized PPI",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1061,"PHASE4":1075,"NA":1077},{"trials":1056,"activeCount":103},[],{"trials":1058,"activeCount":103},[],{"trials":1060,"activeCount":103},[],{"trials":1062,"activeCount":240,"soonestReadout":925},[1063],{"nctId":1064,"briefTitle":1065,"status":123,"phases":1066,"primaryCompletion":925,"completion":466,"start":688,"enrollment":1067,"conditions":1068,"interventions":1070},"NCT07104318","Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans",[93],360,[1069],"Helicobacter Pylori",[1053,1071,1072,1073,1074],"Bismuth quadruple therapy with standard PPI","Clarithromycin triple therapy with optimized PPI","Clarithromycin triple therapy with standard PPI","Standard bismuth quadruple therapy",{"trials":1076,"activeCount":103},[],{"trials":1078,"activeCount":103},[],{"intervention":1071,"totalTrials":240,"cells":1080},{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1087,"PHASE4":1093,"NA":1095},{"trials":1082,"activeCount":103},[],{"trials":1084,"activeCount":103},[],{"trials":1086,"activeCount":103},[],{"trials":1088,"activeCount":240,"soonestReadout":925},[1089],{"nctId":1064,"briefTitle":1065,"status":123,"phases":1090,"primaryCompletion":925,"completion":466,"start":688,"enrollment":1067,"conditions":1091,"interventions":1092},[93],[1069],[1053,1071,1072,1073,1074],{"trials":1094,"activeCount":103},[],{"trials":1096,"activeCount":103},[],{"intervention":1072,"totalTrials":240,"cells":1098},{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1105,"PHASE4":1111,"NA":1113},{"trials":1100,"activeCount":103},[],{"trials":1102,"activeCount":103},[],{"trials":1104,"activeCount":103},[],{"trials":1106,"activeCount":240,"soonestReadout":925},[1107],{"nctId":1064,"briefTitle":1065,"status":123,"phases":1108,"primaryCompletion":925,"completion":466,"start":688,"enrollment":1067,"conditions":1109,"interventions":1110},[93],[1069],[1053,1071,1072,1073,1074],{"trials":1112,"activeCount":103},[],{"trials":1114,"activeCount":103},[],{"intervention":1073,"totalTrials":240,"cells":1116},{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1123,"PHASE4":1129,"NA":1131},{"trials":1118,"activeCount":103},[],{"trials":1120,"activeCount":103},[],{"trials":1122,"activeCount":103},[],{"trials":1124,"activeCount":240,"soonestReadout":925},[1125],{"nctId":1064,"briefTitle":1065,"status":123,"phases":1126,"primaryCompletion":925,"completion":466,"start":688,"enrollment":1067,"conditions":1127,"interventions":1128},[93],[1069],[1053,1071,1072,1073,1074],{"trials":1130,"activeCount":103},[],{"trials":1132,"activeCount":103},[],{"intervention":1074,"totalTrials":240,"cells":1134},{"EARLY_PHASE1":1135,"PHASE1":1137,"PHASE2":1139,"PHASE3":1141,"PHASE4":1147,"NA":1149},{"trials":1136,"activeCount":103},[],{"trials":1138,"activeCount":103},[],{"trials":1140,"activeCount":103},[],{"trials":1142,"activeCount":240,"soonestReadout":925},[1143],{"nctId":1064,"briefTitle":1065,"status":123,"phases":1144,"primaryCompletion":925,"completion":466,"start":688,"enrollment":1067,"conditions":1145,"interventions":1146},[93],[1069],[1053,1071,1072,1073,1074],{"trials":1148,"activeCount":103},[],{"trials":1150,"activeCount":103},[],{"intervention":1152,"totalTrials":240,"cells":1153},"Somatropin",{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1160,"PHASE4":1173,"NA":1175},{"trials":1155,"activeCount":103},[],{"trials":1157,"activeCount":103},[],{"trials":1159,"activeCount":103},[],{"trials":1161,"activeCount":240,"soonestReadout":1166},[1162],{"nctId":1163,"briefTitle":1164,"status":111,"phases":1165,"primaryCompletion":1166,"completion":126,"start":1167,"enrollment":1168,"conditions":1169,"interventions":1172},"NCT04867317","Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)",[93],"2027-02-28","2025-01-13",172,[1170,1171],"Adult Growth Hormone Deficiency","Mild Traumatic Brain Injury",[1152],{"trials":1174,"activeCount":103},[],{"trials":1176,"activeCount":103},[],{"intervention":43,"totalTrials":240,"cells":1178},{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1185,"PHASE4":1195,"NA":1197},{"trials":1180,"activeCount":103},[],{"trials":1182,"activeCount":103},[],{"trials":1184,"activeCount":103},[],{"trials":1186,"activeCount":240,"soonestReadout":42},[1187],{"nctId":40,"briefTitle":41,"status":590,"phases":1188,"primaryCompletion":42,"completion":52,"start":1189,"enrollment":1190,"conditions":1191,"interventions":1193},[93],"2022-03-14",221,[1192],"Osteoarthritis of the Knee",[43,1194],"Procedure: Corticosteroid Injection given in B-A order",{"trials":1196,"activeCount":103},[],{"trials":1198,"activeCount":103},[],{"intervention":1194,"totalTrials":240,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1207,"PHASE4":1213,"NA":1215},{"trials":1202,"activeCount":103},[],{"trials":1204,"activeCount":103},[],{"trials":1206,"activeCount":103},[],{"trials":1208,"activeCount":240,"soonestReadout":42},[1209],{"nctId":40,"briefTitle":41,"status":590,"phases":1210,"primaryCompletion":42,"completion":52,"start":1189,"enrollment":1190,"conditions":1211,"interventions":1212},[93],[1192],[43,1194],{"trials":1214,"activeCount":103},[],{"trials":1216,"activeCount":103},[],{"intervention":990,"totalTrials":240,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1231,"NA":1233},{"trials":1220,"activeCount":103},[],{"trials":1222,"activeCount":103},[],{"trials":1224,"activeCount":103},[],{"trials":1226,"activeCount":240,"soonestReadout":232},[1227],{"nctId":981,"briefTitle":982,"status":111,"phases":1228,"primaryCompletion":232,"completion":113,"start":984,"enrollment":985,"conditions":1229,"interventions":1230},[93],[987,988],[990,958],{"trials":1232,"activeCount":103},[],{"trials":1234,"activeCount":103},[],{"intervention":1236,"totalTrials":240,"cells":1237},"Metformin ER",{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1255,"NA":1257},{"trials":1239,"activeCount":103},[],{"trials":1241,"activeCount":103},[],{"trials":1243,"activeCount":103},[],{"trials":1245,"activeCount":240,"soonestReadout":1166},[1246],{"nctId":1247,"briefTitle":1248,"status":111,"phases":1249,"primaryCompletion":1166,"completion":1250,"start":1251,"enrollment":144,"conditions":1252,"interventions":1254},"NCT05132439","MetfOrmin BenefIts Lower Extremities With Intermittent Claudication",[93],"2032-02-28","2022-03-01",[1253],"Intermittent Claudication",[1236],{"trials":1256,"activeCount":103},[],{"trials":1258,"activeCount":103},[],{"intervention":1260,"totalTrials":240,"cells":1261},"Simvastatin 40mg",{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1268,"PHASE4":1279,"NA":1281},{"trials":1263,"activeCount":103},[],{"trials":1265,"activeCount":103},[],{"trials":1267,"activeCount":103},[],{"trials":1269,"activeCount":240,"soonestReadout":232},[1270],{"nctId":1271,"briefTitle":1272,"status":590,"phases":1273,"primaryCompletion":232,"completion":232,"start":1274,"enrollment":1275,"conditions":1276,"interventions":1278},"NCT03654053","Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis",[93],"2020-10-02",142,[1277],"Cirrhosis",[1260],{"trials":1280,"activeCount":103},[],{"trials":1282,"activeCount":103},[],{"intervention":1284,"totalTrials":240,"cells":1285},"Semaglutide",{"EARLY_PHASE1":1286,"PHASE1":1288,"PHASE2":1290,"PHASE3":1292,"PHASE4":1304,"NA":1306},{"trials":1287,"activeCount":103},[],{"trials":1289,"activeCount":103},[],{"trials":1291,"activeCount":103},[],{"trials":1293,"activeCount":240,"soonestReadout":1298},[1294],{"nctId":1295,"briefTitle":1296,"status":123,"phases":1297,"primaryCompletion":1298,"completion":1299,"start":688,"enrollment":1300,"conditions":1301,"interventions":1303},"NCT07218354","Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder",[93],"2028-04-28","2029-05-26",622,[1302],"Alcohol Use Disorder",[1284],{"trials":1305,"activeCount":103},[],{"trials":1307,"activeCount":103},[],{"intervention":1309,"totalTrials":240,"cells":1310},"Full Dose MDMA",{"EARLY_PHASE1":1311,"PHASE1":1313,"PHASE2":1315,"PHASE3":1317,"PHASE4":1331,"NA":1333},{"trials":1312,"activeCount":103},[],{"trials":1314,"activeCount":103},[],{"trials":1316,"activeCount":103},[],{"trials":1318,"activeCount":240,"soonestReadout":1323},[1319],{"nctId":1320,"briefTitle":1321,"status":111,"phases":1322,"primaryCompletion":1323,"completion":1324,"start":1325,"enrollment":1326,"conditions":1327,"interventions":1329},"NCT07118839","MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder",[92,93],"2030-05-01","2030-05-30","2026-05-18",80,[1328,1302],"Post Traumatic Stress Disorder",[1309,1330],"Active Placebo Dose MDMA",{"trials":1332,"activeCount":103},[],{"trials":1334,"activeCount":103},[],{"intervention":1330,"totalTrials":240,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1349,"NA":1351},{"trials":1338,"activeCount":103},[],{"trials":1340,"activeCount":103},[],{"trials":1342,"activeCount":103},[],{"trials":1344,"activeCount":240,"soonestReadout":1323},[1345],{"nctId":1320,"briefTitle":1321,"status":111,"phases":1346,"primaryCompletion":1323,"completion":1324,"start":1325,"enrollment":1326,"conditions":1347,"interventions":1348},[92,93],[1328,1302],[1309,1330],{"trials":1350,"activeCount":103},[],{"trials":1352,"activeCount":103},[],{"intervention":1354,"totalTrials":240,"cells":1355},"Goserelin, Histrelin, Leuprolide & Triptorelin",{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1362,"PHASE4":1387,"NA":1389},{"trials":1357,"activeCount":103},[],{"trials":1359,"activeCount":103},[],{"trials":1361,"activeCount":103},[],{"trials":1363,"activeCount":240,"soonestReadout":1368},[1364],{"nctId":1365,"briefTitle":1366,"status":111,"phases":1367,"primaryCompletion":1368,"completion":1369,"start":1370,"enrollment":1371,"conditions":1372,"interventions":1379},"NCT04787744","Veterans Affairs Seamless Phase II\u002FIII Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer",[92,93],"2026-09-30","2029-03-30","2021-07-01",464,[1373,1374,1375,1376,1377,1378],"Prostate Cancer","Oligometastasis","Oligorecurrence","Recurrent Prostate Cancer","Metastatic Prostate Cancer","De Novo Prostate Cancer",[1354,1380,1381,1382,1383,1384,1385,1386],"ADT + Nilutamide, Flutamide, & Bicalutamide","Degarelix & Relugolix","ADT + Docetaxel +\u002F- prednisone","ADT + Abiraterone + Prednisone","ADT + Abiraterone + Methylprednisolone","ADT + Apalutamide","ADT + Enzalutamide",{"trials":1388,"activeCount":103},[],{"trials":1390,"activeCount":103},[],{"intervention":1380,"totalTrials":240,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1399,"PHASE4":1405,"NA":1407},{"trials":1394,"activeCount":103},[],{"trials":1396,"activeCount":103},[],{"trials":1398,"activeCount":103},[],{"trials":1400,"activeCount":240,"soonestReadout":1368},[1401],{"nctId":1365,"briefTitle":1366,"status":111,"phases":1402,"primaryCompletion":1368,"completion":1369,"start":1370,"enrollment":1371,"conditions":1403,"interventions":1404},[92,93],[1373,1374,1375,1376,1377,1378],[1354,1380,1381,1382,1383,1384,1385,1386],{"trials":1406,"activeCount":103},[],{"trials":1408,"activeCount":103},[],{"intervention":1381,"totalTrials":240,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1423,"NA":1425},{"trials":1412,"activeCount":103},[],{"trials":1414,"activeCount":103},[],{"trials":1416,"activeCount":103},[],{"trials":1418,"activeCount":240,"soonestReadout":1368},[1419],{"nctId":1365,"briefTitle":1366,"status":111,"phases":1420,"primaryCompletion":1368,"completion":1369,"start":1370,"enrollment":1371,"conditions":1421,"interventions":1422},[92,93],[1373,1374,1375,1376,1377,1378],[1354,1380,1381,1382,1383,1384,1385,1386],{"trials":1424,"activeCount":103},[],{"trials":1426,"activeCount":103},[],{"intervention":1382,"totalTrials":240,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1441,"NA":1443},{"trials":1430,"activeCount":103},[],{"trials":1432,"activeCount":103},[],{"trials":1434,"activeCount":103},[],{"trials":1436,"activeCount":240,"soonestReadout":1368},[1437],{"nctId":1365,"briefTitle":1366,"status":111,"phases":1438,"primaryCompletion":1368,"completion":1369,"start":1370,"enrollment":1371,"conditions":1439,"interventions":1440},[92,93],[1373,1374,1375,1376,1377,1378],[1354,1380,1381,1382,1383,1384,1385,1386],{"trials":1442,"activeCount":103},[],{"trials":1444,"activeCount":103},[],{"intervention":1383,"totalTrials":240,"cells":1446},{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1451,"PHASE3":1453,"PHASE4":1459,"NA":1461},{"trials":1448,"activeCount":103},[],{"trials":1450,"activeCount":103},[],{"trials":1452,"activeCount":103},[],{"trials":1454,"activeCount":240,"soonestReadout":1368},[1455],{"nctId":1365,"briefTitle":1366,"status":111,"phases":1456,"primaryCompletion":1368,"completion":1369,"start":1370,"enrollment":1371,"conditions":1457,"interventions":1458},[92,93],[1373,1374,1375,1376,1377,1378],[1354,1380,1381,1382,1383,1384,1385,1386],{"trials":1460,"activeCount":103},[],{"trials":1462,"activeCount":103},[],{"intervention":1384,"totalTrials":240,"cells":1464},{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1471,"PHASE4":1477,"NA":1479},{"trials":1466,"activeCount":103},[],{"trials":1468,"activeCount":103},[],{"trials":1470,"activeCount":103},[],{"trials":1472,"activeCount":240,"soonestReadout":1368},[1473],{"nctId":1365,"briefTitle":1366,"status":111,"phases":1474,"primaryCompletion":1368,"completion":1369,"start":1370,"enrollment":1371,"conditions":1475,"interventions":1476},[92,93],[1373,1374,1375,1376,1377,1378],[1354,1380,1381,1382,1383,1384,1385,1386],{"trials":1478,"activeCount":103},[],{"trials":1480,"activeCount":103},[],{"intervention":1385,"totalTrials":240,"cells":1482},{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1489,"PHASE4":1495,"NA":1497},{"trials":1484,"activeCount":103},[],{"trials":1486,"activeCount":103},[],{"trials":1488,"activeCount":103},[],{"trials":1490,"activeCount":240,"soonestReadout":1368},[1491],{"nctId":1365,"briefTitle":1366,"status":111,"phases":1492,"primaryCompletion":1368,"completion":1369,"start":1370,"enrollment":1371,"conditions":1493,"interventions":1494},[92,93],[1373,1374,1375,1376,1377,1378],[1354,1380,1381,1382,1383,1384,1385,1386],{"trials":1496,"activeCount":103},[],{"trials":1498,"activeCount":103},[],{"intervention":1386,"totalTrials":240,"cells":1500},{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1507,"PHASE4":1513,"NA":1515},{"trials":1502,"activeCount":103},[],{"trials":1504,"activeCount":103},[],{"trials":1506,"activeCount":103},[],{"trials":1508,"activeCount":240,"soonestReadout":1368},[1509],{"nctId":1365,"briefTitle":1366,"status":111,"phases":1510,"primaryCompletion":1368,"completion":1369,"start":1370,"enrollment":1371,"conditions":1511,"interventions":1512},[92,93],[1373,1374,1375,1376,1377,1378],[1354,1380,1381,1382,1383,1384,1385,1386],{"trials":1514,"activeCount":103},[],{"trials":1516,"activeCount":103},[],{"intervention":1518,"totalTrials":240,"cells":1519},"Psilocybin",{"EARLY_PHASE1":1520,"PHASE1":1522,"PHASE2":1524,"PHASE3":1526,"PHASE4":1538,"NA":1540},{"trials":1521,"activeCount":103},[],{"trials":1523,"activeCount":103},[],{"trials":1525,"activeCount":103},[],{"trials":1527,"activeCount":240,"soonestReadout":1532},[1528],{"nctId":1529,"briefTitle":1530,"status":123,"phases":1531,"primaryCompletion":1532,"completion":1533,"start":328,"enrollment":1534,"conditions":1535,"interventions":1537},"NCT07226232","Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression",[93],"2030-12-02","2031-04-30",240,[1536],"Major Depression",[1518,1518],{"trials":1539,"activeCount":103},[],{"trials":1541,"activeCount":103},[],{"intervention":1543,"totalTrials":1544,"cells":1545},"Pregnenolone",5,{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1550,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1547,"activeCount":103},[],{"trials":1549,"activeCount":103},[],{"trials":1551,"activeCount":132,"soonestReadout":1598},[1552,1562,1572,1584,1594],{"nctId":1553,"briefTitle":1554,"status":174,"phases":1555,"primaryCompletion":1556,"completion":1556,"start":1557,"enrollment":1558,"conditions":1559,"interventions":1561},"NCT01336413","Neuroactive Steroids and Traumatic Brain Injury (TBI) in OEF\u002FOIF Veterans",[92],"2016-02","2013-10",53,[1560],"Brain Injuries, Traumatic",[1543],{"nctId":1563,"briefTitle":1564,"status":123,"phases":1565,"primaryCompletion":1566,"completion":114,"start":328,"enrollment":1567,"conditions":1568,"interventions":1570},"NCT05935761","Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial",[92],"2029-10-01",108,[1569],"Chronic Low Back Pain",[1543,1571],"DHEA",{"nctId":1573,"briefTitle":1574,"status":174,"phases":1575,"primaryCompletion":1576,"completion":1576,"start":1577,"enrollment":1578,"conditions":1579,"interventions":1583},"NCT01956279","Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)",[92],"2018-10-10","2013-10-01",170,[1580,1581,1582],"Fatigue","Musculoskeletal Pain","Cognitive Decline",[1543],{"nctId":1585,"briefTitle":1586,"status":174,"phases":1587,"primaryCompletion":1588,"completion":1589,"start":1590,"enrollment":1591,"conditions":1592,"interventions":1593},"NCT03799562","Neurosteroids for PTSD in Veterans",[92],"2025-07-07","2025-07-14","2019-05-01",96,[24],[1543],{"nctId":1595,"briefTitle":1596,"status":111,"phases":1597,"primaryCompletion":1598,"completion":836,"start":1599,"enrollment":1600,"conditions":1601,"interventions":1603},"NCT06188923","A New Intervention to Improve Function in Veterans With Anxiety and Depression",[92],"2028-06-30","2025-08-14",84,[1602],"Anxiety and Depression",[1543],{"trials":1605,"activeCount":103},[],{"trials":1607,"activeCount":103},[],{"trials":1609,"activeCount":103},[],{"intervention":1611,"totalTrials":220,"cells":1612},"nicotine replacement therapy",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1627,"PHASE4":1639,"NA":1653},{"trials":1614,"activeCount":103},[],{"trials":1616,"activeCount":103},[],{"trials":1618,"activeCount":240,"soonestReadout":1623},[1619],{"nctId":1620,"briefTitle":1621,"status":111,"phases":1622,"primaryCompletion":1623,"completion":1623,"start":1624,"enrollment":116,"conditions":1625,"interventions":1626},"NCT05723588","Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD",[92],"2027-11-01","2023-10-31",[692],[1611],{"trials":1628,"activeCount":103},[1629],{"nctId":1630,"briefTitle":1631,"status":174,"phases":1632,"primaryCompletion":1633,"completion":1633,"start":1634,"enrollment":19,"conditions":1635,"interventions":1637},"NCT01901848","CPT and Smoking Cessation",[92,93],"2017-07-30","2013-12-11",[36,1636],"Smoking",[1638,1611],"Bupropion",{"trials":1640,"activeCount":103},[1641],{"nctId":1642,"briefTitle":1643,"status":174,"phases":1644,"primaryCompletion":1645,"completion":1646,"start":663,"enrollment":1647,"conditions":1648,"interventions":1650},"NCT04135937","Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)",[94],"2021-07-15","2021-11-10",12,[1649,1636],"Human Immunodeficiency Virus",[1638,1651,1652],"Varenicline","Nicotine Replacement Therapy",{"trials":1654,"activeCount":103},[],{"intervention":1656,"totalTrials":1544,"cells":1657},"Ketamine",{"EARLY_PHASE1":1658,"PHASE1":1660,"PHASE2":1662,"PHASE3":1703,"PHASE4":1714,"NA":1716},{"trials":1659,"activeCount":103},[],{"trials":1661,"activeCount":103},[],{"trials":1663,"activeCount":240,"soonestReadout":126},[1664,1673,1685,1694],{"nctId":1665,"briefTitle":1666,"status":174,"phases":1667,"primaryCompletion":926,"completion":511,"start":1668,"enrollment":1669,"conditions":1670,"interventions":1671},"NCT04560660","Ketamine-enhanced Prolonged Exposure Therapy in PTSD",[92],"2021-03-09",75,[18],[1656,1672],"Midazolam",{"nctId":1674,"briefTitle":1675,"status":174,"phases":1676,"primaryCompletion":1677,"completion":1678,"start":1679,"enrollment":22,"conditions":1680,"interventions":1682},"NCT02360280","Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression",[92],"2018-10-22","2019-03-19","2015-04-01",[1681],"Treatment-resistant Depression",[1683,1684],"ketamine","midazolam",{"nctId":1686,"briefTitle":1687,"status":174,"phases":1688,"primaryCompletion":1689,"completion":1689,"start":1690,"enrollment":1691,"conditions":1692,"interventions":1693},"NCT02655692","CAP-Ketamine for Antidepressant Resistant PTSD",[92],"2020-07-01","2016-04-18",163,[18,24],[1656],{"nctId":1695,"briefTitle":1696,"status":111,"phases":1697,"primaryCompletion":126,"completion":126,"start":1698,"enrollment":1326,"conditions":1699,"interventions":1701},"NCT06231563","Ketamine for Veterans With Parkinson's Disease",[92],"2026-03-01",[1700],"Parkinson's Disease",[1656,1702],"Remimazolam",{"trials":1704,"activeCount":103},[1705],{"nctId":1706,"briefTitle":1707,"status":174,"phases":1708,"primaryCompletion":1709,"completion":1709,"start":1710,"enrollment":370,"conditions":1711,"interventions":1713},"NCT02556606","Ketamine for Treatment Resistant Late-Life Depression",[93],"2020-03-31","2015-10-01",[1712],"Treatment Resistant Depressive Disorder",[1656,1656,1656,1672],{"trials":1715,"activeCount":103},[],{"trials":1717,"activeCount":103},[],{"intervention":1719,"totalTrials":132,"cells":1720},"Hydroxychloroquine",{"EARLY_PHASE1":1721,"PHASE1":1723,"PHASE2":1725,"PHASE3":1747,"PHASE4":1749,"NA":1751},{"trials":1722,"activeCount":103},[],{"trials":1724,"activeCount":103},[],{"trials":1726,"activeCount":240,"soonestReadout":126},[1727,1737],{"nctId":1728,"briefTitle":1729,"status":174,"phases":1730,"primaryCompletion":1731,"completion":1731,"start":1732,"enrollment":265,"conditions":1733,"interventions":1736},"NCT03636152","Management of Cardiovascular Disease in Kidney Disease (MaCK) Study",[92],"2024-01-31","2018-12-14",[159,147,1734,952,1735],"Inflammation","Aortic Stiffness",[1719],{"nctId":1738,"briefTitle":1739,"status":111,"phases":1740,"primaryCompletion":126,"completion":1741,"start":637,"enrollment":1742,"conditions":1743,"interventions":1745},"NCT05842174","Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma",[91,92],"2030-10-15",93,[1744],"Hepatocellular Carcinoma",[1719,1746],"Lipiodol",{"trials":1748,"activeCount":103},[],{"trials":1750,"activeCount":103},[],{"trials":1752,"activeCount":103},[],{"intervention":1571,"totalTrials":132,"cells":1754},{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1773,"PHASE4":1775,"NA":1777},{"trials":1756,"activeCount":103},[],{"trials":1758,"activeCount":103},[],{"trials":1760,"activeCount":240,"soonestReadout":1566},[1761,1765],{"nctId":1563,"briefTitle":1564,"status":123,"phases":1762,"primaryCompletion":1566,"completion":114,"start":328,"enrollment":1567,"conditions":1763,"interventions":1764},[92],[1569],[1543,1571],{"nctId":1766,"briefTitle":1767,"status":246,"phases":1768,"primaryCompletion":1769,"completion":1769,"start":1770,"enrollment":1544,"conditions":1771,"interventions":1772},"NCT03491007","Neurosteroids in PTSD - Biomarkers to Therapeutics",[92],"2020-11-16","2019-07-08",[24],[1571],{"trials":1774,"activeCount":103},[],{"trials":1776,"activeCount":103},[],{"trials":1778,"activeCount":103},[],{"intervention":1780,"totalTrials":132,"cells":1781},"Tadalafil",{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1786,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1783,"activeCount":103},[],{"trials":1785,"activeCount":103},[],{"trials":1787,"activeCount":240,"soonestReadout":1801},[1788,1797],{"nctId":1789,"briefTitle":1790,"status":174,"phases":1791,"primaryCompletion":1792,"completion":1792,"start":1577,"enrollment":31,"conditions":1793,"interventions":1796},"NCT01862536","Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease",[92],"2019-08-31",[1794,1795],"Pulmonary Hypertension","Chronic Obstructive Pulmonary Disease (COPD)",[1780],{"nctId":1798,"briefTitle":1799,"status":111,"phases":1800,"primaryCompletion":1801,"completion":1801,"start":1802,"enrollment":1803,"conditions":1804,"interventions":1807},"NCT05937854","Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH",[92],"2029-03-01","2024-04-01",126,[1805,1794,1806],"Chronic Obstructive Pulmonary Disease","Dyspnea",[1780],{"trials":1809,"activeCount":103},[],{"trials":1811,"activeCount":103},[],{"trials":1813,"activeCount":103},[],{"intervention":68,"totalTrials":240,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1829,"PHASE4":1831,"NA":1833},{"trials":1817,"activeCount":103},[],{"trials":1819,"activeCount":103},[],{"trials":1821,"activeCount":240,"soonestReadout":67},[1822],{"nctId":65,"briefTitle":66,"status":590,"phases":1823,"primaryCompletion":67,"completion":688,"start":1824,"enrollment":593,"conditions":1825,"interventions":1828},[92],"2024-09-30",[1826,1827],"Heart Failure Preserved Ejection Fraction","Resistant Hypertension",[68],{"trials":1830,"activeCount":103},[],{"trials":1832,"activeCount":103},[],{"trials":1834,"activeCount":103},[],{"intervention":1836,"totalTrials":240,"cells":1837},"THC",{"EARLY_PHASE1":1838,"PHASE1":1840,"PHASE2":1842,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1839,"activeCount":103},[],{"trials":1841,"activeCount":103},[],{"trials":1843,"activeCount":240,"soonestReadout":1848},[1844],{"nctId":1845,"briefTitle":1846,"status":111,"phases":1847,"primaryCompletion":1848,"completion":837,"start":1849,"enrollment":1850,"conditions":1851,"interventions":1854},"NCT05351801","Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain",[92],"2028-09-29","2023-06-21",320,[1852,1853],"Neuropathic Pain","Peripheral Neuropathic Pain",[1836,1855,1856],"CBD","THC + CBD",{"trials":1858,"activeCount":103},[],{"trials":1860,"activeCount":103},[],{"trials":1862,"activeCount":103},[],{"intervention":1855,"totalTrials":240,"cells":1864},{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1875,"PHASE4":1877,"NA":1879},{"trials":1866,"activeCount":103},[],{"trials":1868,"activeCount":103},[],{"trials":1870,"activeCount":240,"soonestReadout":1848},[1871],{"nctId":1845,"briefTitle":1846,"status":111,"phases":1872,"primaryCompletion":1848,"completion":837,"start":1849,"enrollment":1850,"conditions":1873,"interventions":1874},[92],[1852,1853],[1836,1855,1856],{"trials":1876,"activeCount":103},[],{"trials":1878,"activeCount":103},[],{"trials":1880,"activeCount":103},[],{"intervention":1856,"totalTrials":240,"cells":1882},{"EARLY_PHASE1":1883,"PHASE1":1885,"PHASE2":1887,"PHASE3":1893,"PHASE4":1895,"NA":1897},{"trials":1884,"activeCount":103},[],{"trials":1886,"activeCount":103},[],{"trials":1888,"activeCount":240,"soonestReadout":1848},[1889],{"nctId":1845,"briefTitle":1846,"status":111,"phases":1890,"primaryCompletion":1848,"completion":837,"start":1849,"enrollment":1850,"conditions":1891,"interventions":1892},[92],[1852,1853],[1836,1855,1856],{"trials":1894,"activeCount":103},[],{"trials":1896,"activeCount":103},[],{"trials":1898,"activeCount":103},[],{"intervention":1900,"totalTrials":240,"cells":1901},"CORT108297",{"EARLY_PHASE1":1902,"PHASE1":1904,"PHASE2":1906,"PHASE3":1915,"PHASE4":1917,"NA":1919},{"trials":1903,"activeCount":103},[],{"trials":1905,"activeCount":103},[],{"trials":1907,"activeCount":240,"soonestReadout":232},[1908],{"nctId":1909,"briefTitle":1910,"status":111,"phases":1911,"primaryCompletion":232,"completion":232,"start":1912,"enrollment":593,"conditions":1913,"interventions":1914},"NCT04452500","Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)",[92],"2022-10-15",[18],[1900],{"trials":1916,"activeCount":103},[],{"trials":1918,"activeCount":103},[],{"trials":1920,"activeCount":103},[],{"intervention":1922,"totalTrials":240,"cells":1923},"High dose testosterone",{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1925,"activeCount":103},[],{"trials":1927,"activeCount":103},[],{"trials":1929,"activeCount":240,"soonestReadout":1934},[1930],{"nctId":1931,"briefTitle":1932,"status":111,"phases":1933,"primaryCompletion":1934,"completion":1935,"start":1936,"enrollment":1937,"conditions":1938,"interventions":1939},"NCT05011383","High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers",[92],"2026-08-31","2027-08-31","2021-08-31",51,[1377],[1922],{"trials":1941,"activeCount":103},[],{"trials":1943,"activeCount":103},[],{"trials":1945,"activeCount":103},[],{"intervention":1947,"totalTrials":240,"cells":1948},"Microbiota transplant therapy (MTT)",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1966,"PHASE4":1968,"NA":1970},{"trials":1950,"activeCount":103},[],{"trials":1952,"activeCount":103},[],{"trials":1954,"activeCount":240,"soonestReadout":1959},[1955],{"nctId":1956,"briefTitle":1957,"status":123,"phases":1958,"primaryCompletion":1959,"completion":1960,"start":1961,"enrollment":1962,"conditions":1963,"interventions":1965},"NCT07528690","Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)",[92],"2030-10-31","2031-03-03","2026-10-30",162,[1964,1277],"Hepatic Encephalopathy",[1947],{"trials":1967,"activeCount":103},[],{"trials":1969,"activeCount":103},[],{"trials":1971,"activeCount":103},[],{"intervention":1973,"totalTrials":240,"cells":1974},"Oxytocin nasal spray",{"EARLY_PHASE1":1975,"PHASE1":1977,"PHASE2":1979,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1976,"activeCount":103},[],{"trials":1978,"activeCount":103},[],{"trials":1980,"activeCount":240,"soonestReadout":836},[1981],{"nctId":1982,"briefTitle":1983,"status":111,"phases":1984,"primaryCompletion":836,"completion":836,"start":1985,"enrollment":1534,"conditions":1986,"interventions":1988},"NCT06194851","Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD",[92],"2024-10-28",[1987],"Post-Traumatic Stress Disorder (PTSD)",[1973,1989],"Saline nasal spray",{"trials":1991,"activeCount":103},[],{"trials":1993,"activeCount":103},[],{"trials":1995,"activeCount":103},[],{"intervention":1989,"totalTrials":240,"cells":1997},{"EARLY_PHASE1":1998,"PHASE1":2000,"PHASE2":2002,"PHASE3":2008,"PHASE4":2010,"NA":2012},{"trials":1999,"activeCount":103},[],{"trials":2001,"activeCount":103},[],{"trials":2003,"activeCount":240,"soonestReadout":836},[2004],{"nctId":1982,"briefTitle":1983,"status":111,"phases":2005,"primaryCompletion":836,"completion":836,"start":1985,"enrollment":1534,"conditions":2006,"interventions":2007},[92],[1987],[1973,1989],{"trials":2009,"activeCount":103},[],{"trials":2011,"activeCount":103},[],{"trials":2013,"activeCount":103},[],{"intervention":2015,"totalTrials":240,"cells":2016},"Tulmimetostat",{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2021,"PHASE3":2034,"PHASE4":2036,"NA":2038},{"trials":2018,"activeCount":103},[],{"trials":2020,"activeCount":103},[],{"trials":2022,"activeCount":240,"soonestReadout":2027},[2023],{"nctId":2024,"briefTitle":2025,"status":111,"phases":2026,"primaryCompletion":2027,"completion":2028,"start":2029,"enrollment":2030,"conditions":2031,"interventions":2033},"NCT05467748","EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer",[91,92],"2027-12-08","2029-12-07","2025-12-08",66,[2032],"Non Small Cell Lung Cancer",[2015],{"trials":2035,"activeCount":103},[],{"trials":2037,"activeCount":103},[],{"trials":2039,"activeCount":103},[],{"intervention":2041,"totalTrials":240,"cells":2042},"Carboplatin",{"EARLY_PHASE1":2043,"PHASE1":2045,"PHASE2":2047,"PHASE3":2060,"PHASE4":2062,"NA":2064},{"trials":2044,"activeCount":103},[],{"trials":2046,"activeCount":103},[],{"trials":2048,"activeCount":240,"soonestReadout":1935},[2049],{"nctId":2050,"briefTitle":2051,"status":111,"phases":2052,"primaryCompletion":1935,"completion":1935,"start":2053,"enrollment":265,"conditions":2054,"interventions":2058},"NCT04038502","Carboplatin or Olaparib for BRcA Deficient Prostate Cancer",[92],"2019-10-01",[2055,2056,2057],"Metastatic Castrate Resistant Prostate Cancer","BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2","RAD51B, RAD51C, RAD51D, or RAD54L Mutations",[2041,2059],"Olaparib",{"trials":2061,"activeCount":103},[],{"trials":2063,"activeCount":103},[],{"trials":2065,"activeCount":103},[],{"intervention":2059,"totalTrials":240,"cells":2067},{"EARLY_PHASE1":2068,"PHASE1":2070,"PHASE2":2072,"PHASE3":2078,"PHASE4":2080,"NA":2082},{"trials":2069,"activeCount":103},[],{"trials":2071,"activeCount":103},[],{"trials":2073,"activeCount":240,"soonestReadout":1935},[2074],{"nctId":2050,"briefTitle":2051,"status":111,"phases":2075,"primaryCompletion":1935,"completion":1935,"start":2053,"enrollment":265,"conditions":2076,"interventions":2077},[92],[2055,2056,2057],[2041,2059],{"trials":2079,"activeCount":103},[],{"trials":2081,"activeCount":103},[],{"trials":2083,"activeCount":103},[],{"intervention":2085,"totalTrials":240,"cells":2086},"Ketamine hydrochloride",{"EARLY_PHASE1":2087,"PHASE1":2089,"PHASE2":2091,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2088,"activeCount":103},[],{"trials":2090,"activeCount":103},[],{"trials":2092,"activeCount":240,"soonestReadout":2097},[2093],{"nctId":2094,"briefTitle":2095,"status":111,"phases":2096,"primaryCompletion":2097,"completion":925,"start":2098,"enrollment":31,"conditions":2099,"interventions":2100},"NCT06419439","Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression",[92],"2028-12-01","2025-12-03",[1569,21],[2085],{"trials":2102,"activeCount":103},[],{"trials":2104,"activeCount":103},[],{"trials":2106,"activeCount":103},[],{"intervention":2108,"totalTrials":240,"cells":2109},"Stenoparib\u002FTemozolomide",{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2114,"PHASE3":2127,"PHASE4":2129,"NA":2131},{"trials":2111,"activeCount":103},[],{"trials":2113,"activeCount":103},[],{"trials":2115,"activeCount":240,"soonestReadout":114},[2116],{"nctId":2117,"briefTitle":2118,"status":111,"phases":2119,"primaryCompletion":114,"completion":467,"start":2120,"enrollment":2121,"conditions":2122,"interventions":2125},"NCT06681220","Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC",[91,92],"2026-02-23",166,[2123,2124],"Relapsed Small Cell Lung Cancer","Recurrent Small Cell Lung Cancer",[2108,2126,2108],"Lurbinectedin",{"trials":2128,"activeCount":103},[],{"trials":2130,"activeCount":103},[],{"trials":2132,"activeCount":103},[],{"intervention":2126,"totalTrials":240,"cells":2134},{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2139,"PHASE3":2145,"PHASE4":2147,"NA":2149},{"trials":2136,"activeCount":103},[],{"trials":2138,"activeCount":103},[],{"trials":2140,"activeCount":240,"soonestReadout":114},[2141],{"nctId":2117,"briefTitle":2118,"status":111,"phases":2142,"primaryCompletion":114,"completion":467,"start":2120,"enrollment":2121,"conditions":2143,"interventions":2144},[91,92],[2123,2124],[2108,2126,2108],{"trials":2146,"activeCount":103},[],{"trials":2148,"activeCount":103},[],{"trials":2150,"activeCount":103},[],{"intervention":1746,"totalTrials":240,"cells":2152},{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2163,"PHASE4":2165,"NA":2167},{"trials":2154,"activeCount":103},[],{"trials":2156,"activeCount":103},[],{"trials":2158,"activeCount":240,"soonestReadout":126},[2159],{"nctId":1738,"briefTitle":1739,"status":111,"phases":2160,"primaryCompletion":126,"completion":1741,"start":637,"enrollment":1742,"conditions":2161,"interventions":2162},[91,92],[1744],[1719,1746],{"trials":2164,"activeCount":103},[],{"trials":2166,"activeCount":103},[],{"trials":2168,"activeCount":103},[],{"intervention":2170,"totalTrials":240,"cells":2171},"Capivasertib",{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2190,"PHASE4":2192,"NA":2194},{"trials":2173,"activeCount":103},[],{"trials":2175,"activeCount":103},[],{"trials":2177,"activeCount":240,"soonestReadout":2182},[2178],{"nctId":2179,"briefTitle":2180,"status":111,"phases":2181,"primaryCompletion":2182,"completion":2183,"start":2184,"enrollment":2185,"conditions":2186,"interventions":2188},"NCT05593497","A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss",[92],"2027-05-01","2027-08-01","2024-05-31",30,[2187],"High-Risk Prostate Cancer",[2170,2189],"abiraterone acetate",{"trials":2191,"activeCount":103},[],{"trials":2193,"activeCount":103},[],{"trials":2195,"activeCount":103},[],{"intervention":2189,"totalTrials":240,"cells":2197},{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2199,"activeCount":103},[],{"trials":2201,"activeCount":103},[],{"trials":2203,"activeCount":240,"soonestReadout":2182},[2204],{"nctId":2179,"briefTitle":2180,"status":111,"phases":2205,"primaryCompletion":2182,"completion":2183,"start":2184,"enrollment":2185,"conditions":2206,"interventions":2207},[92],[2187],[2170,2189],{"trials":2209,"activeCount":103},[],{"trials":2211,"activeCount":103},[],{"trials":2213,"activeCount":103},[],{"intervention":2215,"totalTrials":240,"cells":2216},"Pluvicto",{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2221,"PHASE3":2232,"PHASE4":2234,"NA":2236},{"trials":2218,"activeCount":103},[],{"trials":2220,"activeCount":103},[],{"trials":2222,"activeCount":240,"soonestReadout":2227},[2223],{"nctId":2224,"briefTitle":2225,"status":111,"phases":2226,"primaryCompletion":2227,"completion":113,"start":2228,"enrollment":192,"conditions":2229,"interventions":2230},"NCT06084338","Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc",[92],"2027-11-29","2023-12-14",[1373],[2215,2231],"topical testosterone",{"trials":2233,"activeCount":103},[],{"trials":2235,"activeCount":103},[],{"trials":2237,"activeCount":103},[],{"intervention":2231,"totalTrials":240,"cells":2239},{"EARLY_PHASE1":2240,"PHASE1":2242,"PHASE2":2244,"PHASE3":2250,"PHASE4":2252,"NA":2254},{"trials":2241,"activeCount":103},[],{"trials":2243,"activeCount":103},[],{"trials":2245,"activeCount":240,"soonestReadout":2227},[2246],{"nctId":2224,"briefTitle":2225,"status":111,"phases":2247,"primaryCompletion":2227,"completion":113,"start":2228,"enrollment":192,"conditions":2248,"interventions":2249},[92],[1373],[2215,2231],{"trials":2251,"activeCount":103},[],{"trials":2253,"activeCount":103},[],{"trials":2255,"activeCount":103},[],{"intervention":2257,"totalTrials":240,"cells":2258},"Imipramine",{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2260,"activeCount":103},[],{"trials":2262,"activeCount":103},[],{"trials":2264,"activeCount":240,"soonestReadout":1369},[2265],{"nctId":2266,"briefTitle":2267,"status":111,"phases":2268,"primaryCompletion":1369,"completion":1369,"start":2269,"enrollment":2270,"conditions":2271,"interventions":2274},"NCT06778434","The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans",[92],"2025-04-01",48,[2272,2257,2273],"Actinic Keratosis","Photodynamic Therapy",[2257],{"trials":2276,"activeCount":103},[],{"trials":2278,"activeCount":103},[],{"trials":2280,"activeCount":103},[],{"intervention":2282,"totalTrials":240,"cells":2283},"Resistant Potato Starch",{"EARLY_PHASE1":2284,"PHASE1":2286,"PHASE2":2288,"PHASE3":2299,"PHASE4":2301,"NA":2303},{"trials":2285,"activeCount":103},[],{"trials":2287,"activeCount":103},[],{"trials":2289,"activeCount":240,"soonestReadout":2294},[2290],{"nctId":2291,"briefTitle":2292,"status":111,"phases":2293,"primaryCompletion":2294,"completion":1598,"start":2295,"enrollment":128,"conditions":2296,"interventions":2298},"NCT05820893","Resistant Potato Starch to Alleviate GWI",[92],"2027-06-30","2025-02-03",[2297],"Gulf War Illness",[2282],{"trials":2300,"activeCount":103},[],{"trials":2302,"activeCount":103},[],{"trials":2304,"activeCount":103},[],{"intervention":2306,"totalTrials":240,"cells":2307},"Nivolumab",{"EARLY_PHASE1":2308,"PHASE1":2310,"PHASE2":2312,"PHASE3":2323,"PHASE4":2325,"NA":2327},{"trials":2309,"activeCount":103},[],{"trials":2311,"activeCount":103},[],{"trials":2313,"activeCount":240,"soonestReadout":1166},[2314],{"nctId":2315,"briefTitle":2316,"status":111,"phases":2317,"primaryCompletion":1166,"completion":154,"start":2318,"enrollment":2319,"conditions":2320,"interventions":2322},"NCT06275360","Repositioning Immunotherapy in VetArans With Lung Cancer",[92],"2024-03-01",25,[2321],"Non-Small Cell Lung Cancer",[2306],{"trials":2324,"activeCount":103},[],{"trials":2326,"activeCount":103},[],{"trials":2328,"activeCount":103},[],{"intervention":63,"totalTrials":240,"cells":2330},{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2335,"PHASE3":2343,"PHASE4":2345,"NA":2347},{"trials":2332,"activeCount":103},[],{"trials":2334,"activeCount":103},[],{"trials":2336,"activeCount":240,"soonestReadout":62},[2337],{"nctId":60,"briefTitle":61,"status":590,"phases":2338,"primaryCompletion":62,"completion":232,"start":2339,"enrollment":593,"conditions":2340,"interventions":2342},[92],"2020-02-20",[2341],"Metastatic Castration Resistant Prostate Cancer",[63],{"trials":2344,"activeCount":103},[],{"trials":2346,"activeCount":103},[],{"trials":2348,"activeCount":103},[],{"intervention":2350,"totalTrials":240,"cells":2351},"Synthroid",{"EARLY_PHASE1":2352,"PHASE1":2354,"PHASE2":2356,"PHASE3":2368,"PHASE4":2370,"NA":2372},{"trials":2353,"activeCount":103},[],{"trials":2355,"activeCount":103},[],{"trials":2357,"activeCount":240,"soonestReadout":114},[2358],{"nctId":2359,"briefTitle":2360,"status":111,"phases":2361,"primaryCompletion":114,"completion":114,"start":2362,"enrollment":2363,"conditions":2364,"interventions":2367},"NCT05526144","Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans",[92],"2023-04-01",128,[2365,2366],"Nonalcoholic Steatohepatitis","Liver Fibrosis",[2350],{"trials":2369,"activeCount":103},[],{"trials":2371,"activeCount":103},[],{"trials":2373,"activeCount":103},[],{"intervention":1702,"totalTrials":240,"cells":2375},{"EARLY_PHASE1":2376,"PHASE1":2378,"PHASE2":2380,"PHASE3":2386,"PHASE4":2388,"NA":2390},{"trials":2377,"activeCount":103},[],{"trials":2379,"activeCount":103},[],{"trials":2381,"activeCount":240,"soonestReadout":126},[2382],{"nctId":1695,"briefTitle":1696,"status":111,"phases":2383,"primaryCompletion":126,"completion":126,"start":1698,"enrollment":1326,"conditions":2384,"interventions":2385},[92],[1700],[1656,1702],{"trials":2387,"activeCount":103},[],{"trials":2389,"activeCount":103},[],{"trials":2391,"activeCount":103},[],{"intervention":2393,"totalTrials":240,"cells":2394},"Cal-Mag Butyrate",{"EARLY_PHASE1":2395,"PHASE1":2397,"PHASE2":2399,"PHASE3":2412,"PHASE4":2414,"NA":2416},{"trials":2396,"activeCount":103},[],{"trials":2398,"activeCount":103},[],{"trials":2400,"activeCount":240,"soonestReadout":2405},[2401],{"nctId":2402,"briefTitle":2403,"status":111,"phases":2404,"primaryCompletion":2405,"completion":210,"start":2406,"enrollment":2407,"conditions":2408,"interventions":2411},"NCT05367245","Ca-Mg Butyrate in GWI",[92],"2026-10-10","2024-01-15",120,[2297,2409,2410],"Chronic Fatigue","Neurocognitive Dysfunction",[2393],{"trials":2413,"activeCount":103},[],{"trials":2415,"activeCount":103},[],{"trials":2417,"activeCount":103},[],{"intervention":2419,"totalTrials":240,"cells":2420},"Venetoclax",{"EARLY_PHASE1":2421,"PHASE1":2423,"PHASE2":2425,"PHASE3":2437,"PHASE4":2439,"NA":2441},{"trials":2422,"activeCount":103},[],{"trials":2424,"activeCount":103},[],{"trials":2426,"activeCount":240,"soonestReadout":466},[2427],{"nctId":2428,"briefTitle":2429,"status":111,"phases":2430,"primaryCompletion":466,"completion":467,"start":2431,"enrollment":265,"conditions":2432,"interventions":2435},"NCT06520098","A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL)",[92],"2025-10-01",[2433,2434],"Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma",[2419,2436],"Ibrutinib, Acalabrutinib, Zanubrutinib",{"trials":2438,"activeCount":103},[],{"trials":2440,"activeCount":103},[],{"trials":2442,"activeCount":103},[],{"intervention":2436,"totalTrials":240,"cells":2444},{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2455,"PHASE4":2457,"NA":2459},{"trials":2446,"activeCount":103},[],{"trials":2448,"activeCount":103},[],{"trials":2450,"activeCount":240,"soonestReadout":466},[2451],{"nctId":2428,"briefTitle":2429,"status":111,"phases":2452,"primaryCompletion":466,"completion":467,"start":2431,"enrollment":265,"conditions":2453,"interventions":2454},[92],[2433,2434],[2419,2436],{"trials":2456,"activeCount":103},[],{"trials":2458,"activeCount":103},[],{"trials":2460,"activeCount":103},[],{"intervention":2462,"totalTrials":240,"cells":2463},"Romosozumab",{"EARLY_PHASE1":2464,"PHASE1":2466,"PHASE2":2468,"PHASE3":2481,"PHASE4":2483,"NA":2485},{"trials":2465,"activeCount":103},[],{"trials":2467,"activeCount":103},[],{"trials":2469,"activeCount":240,"soonestReadout":127},[2470],{"nctId":2471,"briefTitle":2472,"status":590,"phases":2473,"primaryCompletion":127,"completion":2474,"start":2475,"enrollment":37,"conditions":2476,"interventions":2479},"NCT04232657","Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI",[92],"2027-03-01","2021-03-01",[2477,2478],"Spinal Cord Injury (=3 Years)","Sublesional Bone Loss Secondary to SCI",[2462,2480],"Denosumab",{"trials":2482,"activeCount":103},[],{"trials":2484,"activeCount":103},[],{"trials":2486,"activeCount":103},[],{"intervention":2480,"totalTrials":240,"cells":2488},{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2499,"PHASE4":2501,"NA":2503},{"trials":2490,"activeCount":103},[],{"trials":2492,"activeCount":103},[],{"trials":2494,"activeCount":240,"soonestReadout":127},[2495],{"nctId":2471,"briefTitle":2472,"status":590,"phases":2496,"primaryCompletion":127,"completion":2474,"start":2475,"enrollment":37,"conditions":2497,"interventions":2498},[92],[2477,2478],[2462,2480],{"trials":2500,"activeCount":103},[],{"trials":2502,"activeCount":103},[],{"trials":2504,"activeCount":103},[],{"intervention":2506,"totalTrials":240,"cells":2507},"15-day taper prednisone",{"EARLY_PHASE1":2508,"PHASE1":2510,"PHASE2":2512,"PHASE3":2524,"PHASE4":2526,"NA":2528},{"trials":2509,"activeCount":103},[],{"trials":2511,"activeCount":103},[],{"trials":2513,"activeCount":240,"soonestReadout":1801},[2514],{"nctId":2515,"briefTitle":2516,"status":111,"phases":2517,"primaryCompletion":1801,"completion":2518,"start":2519,"enrollment":144,"conditions":2520,"interventions":2522},"NCT06072768","Dynamic Treatment Regiments for Glucocorticoid Tapering",[92],"2030-03-01","2023-03-09",[2521],"Rheumatoid Arthritis",[2506,2523],"150-day taper prednisone",{"trials":2525,"activeCount":103},[],{"trials":2527,"activeCount":103},[],{"trials":2529,"activeCount":103},[],{"intervention":2523,"totalTrials":240,"cells":2531},{"EARLY_PHASE1":2532,"PHASE1":2534,"PHASE2":2536,"PHASE3":2542,"PHASE4":2544,"NA":2546},{"trials":2533,"activeCount":103},[],{"trials":2535,"activeCount":103},[],{"trials":2537,"activeCount":240,"soonestReadout":1801},[2538],{"nctId":2515,"briefTitle":2516,"status":111,"phases":2539,"primaryCompletion":1801,"completion":2518,"start":2519,"enrollment":144,"conditions":2540,"interventions":2541},[92],[2521],[2506,2523],{"trials":2543,"activeCount":103},[],{"trials":2545,"activeCount":103},[],{"trials":2547,"activeCount":103},[],{"intervention":2549,"totalTrials":240,"cells":2550},"Allopregnanolone",{"EARLY_PHASE1":2551,"PHASE1":2553,"PHASE2":2555,"PHASE3":2566,"PHASE4":2568,"NA":2570},{"trials":2552,"activeCount":103},[],{"trials":2554,"activeCount":103},[],{"trials":2556,"activeCount":240,"soonestReadout":2561},[2557],{"nctId":2558,"briefTitle":2559,"status":123,"phases":2560,"primaryCompletion":2561,"completion":2561,"start":328,"enrollment":2562,"conditions":2563,"interventions":2565},"NCT04003285","Allopregnanolone in Chronic Complex Traumatic Brain Injury",[92],"2027-06-01",132,[2564],"Traumatic Brain Injury (TBI)",[2549,2549],{"trials":2567,"activeCount":103},[],{"trials":2569,"activeCount":103},[],{"trials":2571,"activeCount":103},[],{"intervention":2573,"totalTrials":240,"cells":2574},"Itraconazole",{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2579,"PHASE3":2593,"PHASE4":2595,"NA":2597},{"trials":2576,"activeCount":103},[],{"trials":2578,"activeCount":103},[],{"trials":2580,"activeCount":240,"soonestReadout":441},[2581],{"nctId":2582,"briefTitle":2583,"status":111,"phases":2584,"primaryCompletion":441,"completion":2585,"start":2586,"enrollment":2587,"conditions":2588,"interventions":2592},"NCT05563766","A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer",[92],"2029-06-15","2024-10-01",78,[2589,2590,2591],"Esophageal Adenocarcinoma","Esophageal Squamous Cell Carcinoma","Gastroesophageal Junction Carcinoma",[2573],{"trials":2594,"activeCount":103},[],{"trials":2596,"activeCount":103},[],{"trials":2598,"activeCount":103},[],{"intervention":2600,"totalTrials":132,"cells":2601},"Dronabinol",{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2606,"PHASE3":2616,"PHASE4":2618,"NA":2620},{"trials":2603,"activeCount":103},[],{"trials":2605,"activeCount":103},[],{"trials":2607,"activeCount":240,"soonestReadout":232},[2608],{"nctId":2609,"briefTitle":2610,"status":111,"phases":2611,"primaryCompletion":232,"completion":232,"start":2612,"enrollment":2407,"conditions":2613,"interventions":2615},"NCT06477952","DRonabinol Treatment of OSA",[91,92],"2025-08-25",[2614],"Obstructive Sleep Apnea",[2600],{"trials":2617,"activeCount":103},[],{"trials":2619,"activeCount":103},[],{"trials":2621,"activeCount":103},[2622],{"nctId":2623,"briefTitle":2624,"status":174,"phases":2625,"primaryCompletion":2626,"completion":2627,"start":2628,"enrollment":2629,"conditions":2630,"interventions":2632},"NCT00757822","Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients",[95],"2013-12","2015-04","2009-12",216,[2631],"Postoperative Nausea and Vomiting",[2600,2633],"Ondansetron",{"intervention":2635,"totalTrials":132,"cells":2636},"BH4",{"EARLY_PHASE1":2637,"PHASE1":2639,"PHASE2":2653,"PHASE3":2665,"PHASE4":2667,"NA":2669},{"trials":2638,"activeCount":103},[],{"trials":2640,"activeCount":240,"soonestReadout":836},[2641],{"nctId":2642,"briefTitle":2643,"status":111,"phases":2644,"primaryCompletion":836,"completion":2645,"start":2646,"enrollment":2647,"conditions":2648,"interventions":2650},"NCT06312748","Novel Approaches for Improving Vascular Function in Veterans With HFpEF",[91],"2030-09-30","2021-05-19",90,[2649,1734],"Heart Failure With Preserved Ejection Fraction",[2651,2635,2652],"L-Citrulline","Atorvastatin",{"trials":2654,"activeCount":103},[2655],{"nctId":2656,"briefTitle":2657,"status":174,"phases":2658,"primaryCompletion":2659,"completion":2660,"start":2661,"enrollment":1647,"conditions":2662,"interventions":2664},"NCT02530996","Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment",[91,92],"2016-06-01","2019-12-31","2016-01-01",[2663],"Rheumatologic Disease",[2635],{"trials":2666,"activeCount":103},[],{"trials":2668,"activeCount":103},[],{"trials":2670,"activeCount":103},[],{"intervention":2672,"totalTrials":132,"cells":2673},"Mesenchymal Stem Cells",{"EARLY_PHASE1":2674,"PHASE1":2676,"PHASE2":2688,"PHASE3":2699,"PHASE4":2701,"NA":2703},{"trials":2675,"activeCount":103},[],{"trials":2677,"activeCount":240,"soonestReadout":232},[2678],{"nctId":2679,"briefTitle":2680,"status":111,"phases":2681,"primaryCompletion":232,"completion":2682,"start":2683,"enrollment":593,"conditions":2684,"interventions":2686},"NCT05925036","Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis",[91],"2027-12-31","2024-01-01",[2685,514],"Chronic Pancreatitis",[2687],"Mesenchymal stem cells",{"trials":2689,"activeCount":103},[2690],{"nctId":2691,"briefTitle":2692,"status":2693,"phases":2694,"primaryCompletion":2695,"completion":2695,"start":2695,"enrollment":103,"conditions":2696,"interventions":2698},"NCT05284604","Mesenchymal Stem Cells for Age-Related Frailty","WITHDRAWN",[91,92],"2023-01-31",[2697],"Frailty",[2672],{"trials":2700,"activeCount":103},[],{"trials":2702,"activeCount":103},[],{"trials":2704,"activeCount":103},[],{"intervention":2651,"totalTrials":240,"cells":2706},{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2715,"PHASE3":2717,"PHASE4":2719,"NA":2721},{"trials":2708,"activeCount":103},[],{"trials":2710,"activeCount":240,"soonestReadout":836},[2711],{"nctId":2642,"briefTitle":2643,"status":111,"phases":2712,"primaryCompletion":836,"completion":2645,"start":2646,"enrollment":2647,"conditions":2713,"interventions":2714},[91],[2649,1734],[2651,2635,2652],{"trials":2716,"activeCount":103},[],{"trials":2718,"activeCount":103},[],{"trials":2720,"activeCount":103},[],{"trials":2722,"activeCount":103},[],{"intervention":2652,"totalTrials":240,"cells":2724},{"EARLY_PHASE1":2725,"PHASE1":2727,"PHASE2":2733,"PHASE3":2735,"PHASE4":2737,"NA":2739},{"trials":2726,"activeCount":103},[],{"trials":2728,"activeCount":240,"soonestReadout":836},[2729],{"nctId":2642,"briefTitle":2643,"status":111,"phases":2730,"primaryCompletion":836,"completion":2645,"start":2646,"enrollment":2647,"conditions":2731,"interventions":2732},[91],[2649,1734],[2651,2635,2652],{"trials":2734,"activeCount":103},[],{"trials":2736,"activeCount":103},[],{"trials":2738,"activeCount":103},[],{"trials":2740,"activeCount":103},[],{"intervention":2742,"totalTrials":240,"cells":2743},"Atibuclimab",{"EARLY_PHASE1":2744,"PHASE1":2746,"PHASE2":2756,"PHASE3":2758,"PHASE4":2760,"NA":2762},{"trials":2745,"activeCount":103},[],{"trials":2747,"activeCount":240,"soonestReadout":2561},[2748],{"nctId":2749,"briefTitle":2750,"status":123,"phases":2751,"primaryCompletion":2561,"completion":2752,"start":328,"enrollment":2185,"conditions":2753,"interventions":2755},"NCT07481474","Pilot and Feasibility Study of Intra-articular Anti-CD14 for the Treatment of Knee Osteoarthritis",[91],"2028-01-01",[2754],"Knee Osteoarthritis (Knee OA)",[2742],{"trials":2757,"activeCount":103},[],{"trials":2759,"activeCount":103},[],{"trials":2761,"activeCount":103},[],{"trials":2763,"activeCount":103},[],{"intervention":2765,"totalTrials":240,"cells":2766},"PLZ4-coated paclitaxel-loaded micelles",{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2780,"PHASE3":2782,"PHASE4":2784,"NA":2786},{"trials":2768,"activeCount":103},[],{"trials":2770,"activeCount":240,"soonestReadout":1934},[2771],{"nctId":2772,"briefTitle":2773,"status":111,"phases":2774,"primaryCompletion":1934,"completion":1934,"start":2775,"enrollment":2776,"conditions":2777,"interventions":2779},"NCT05519241","A Phase I Intravesical PPM Therapy for NMIBC",[91],"2022-10-10",29,[2778],"Non-muscle-invasive Bladder Cancer",[2765],{"trials":2781,"activeCount":103},[],{"trials":2783,"activeCount":103},[],{"trials":2785,"activeCount":103},[],{"trials":2787,"activeCount":103},[],{"intervention":2789,"totalTrials":240,"cells":2790},"Natesto testosterone intranasal gel",{"EARLY_PHASE1":2791,"PHASE1":2801,"PHASE2":2803,"PHASE3":2805,"PHASE4":2807,"NA":2809},{"trials":2792,"activeCount":240,"soonestReadout":1368},[2793],{"nctId":2794,"briefTitle":2795,"status":111,"phases":2796,"primaryCompletion":1368,"completion":1368,"start":1802,"enrollment":2797,"conditions":2798,"interventions":2799},"NCT06130449","Testosterone and Neural Function",[90],15,[30],[2789,2800],"Ayr Saline Nasal Gel",{"trials":2802,"activeCount":103},[],{"trials":2804,"activeCount":103},[],{"trials":2806,"activeCount":103},[],{"trials":2808,"activeCount":103},[],{"trials":2810,"activeCount":103},[],{"intervention":2800,"totalTrials":240,"cells":2812},{"EARLY_PHASE1":2813,"PHASE1":2819,"PHASE2":2821,"PHASE3":2823,"PHASE4":2825,"NA":2827},{"trials":2814,"activeCount":240,"soonestReadout":1368},[2815],{"nctId":2794,"briefTitle":2795,"status":111,"phases":2816,"primaryCompletion":1368,"completion":1368,"start":1802,"enrollment":2797,"conditions":2817,"interventions":2818},[90],[30],[2789,2800],{"trials":2820,"activeCount":103},[],{"trials":2822,"activeCount":103},[],{"trials":2824,"activeCount":103},[],{"trials":2826,"activeCount":103},[],{"trials":2828,"activeCount":103},[],{"intervention":2830,"totalTrials":240,"cells":2831},"Sinemet CR",{"EARLY_PHASE1":2832,"PHASE1":2844,"PHASE2":2846,"PHASE3":2848,"PHASE4":2850,"NA":2852},{"trials":2833,"activeCount":240,"soonestReadout":2682},[2834],{"nctId":2835,"briefTitle":2836,"status":2837,"phases":2838,"primaryCompletion":2682,"completion":113,"start":2839,"enrollment":2840,"conditions":2841,"interventions":2843},"NCT05132660","Treating Early Stage Diabetic Retinopathy","ENROLLING_BY_INVITATION",[90],"2022-07-01",244,[2842],"Diabetic Retinopathy",[2830],{"trials":2845,"activeCount":103},[],{"trials":2847,"activeCount":103},[],{"trials":2849,"activeCount":103},[],{"trials":2851,"activeCount":103},[],{"trials":2853,"activeCount":103},[],{"intervention":2855,"totalTrials":240,"cells":2856},"Ovidrel",{"EARLY_PHASE1":2857,"PHASE1":2867,"PHASE2":2869,"PHASE3":2871,"PHASE4":2873,"NA":2875},{"trials":2858,"activeCount":240,"soonestReadout":2863},[2859],{"nctId":2860,"briefTitle":2861,"status":123,"phases":2862,"primaryCompletion":2863,"completion":126,"start":468,"enrollment":116,"conditions":2864,"interventions":2866},"NCT07557615","hCG Treatment for Rehabilitation From a TBI",[90],"2029-07-01",[2865],"Traumatic Brain Injury",[2855],{"trials":2868,"activeCount":103},[],{"trials":2870,"activeCount":103},[],{"trials":2872,"activeCount":103},[],{"trials":2874,"activeCount":103},[],{"trials":2876,"activeCount":103},[],{"intervention":2878,"totalTrials":240,"cells":2879},"Medication for Addiction Treatment",{"EARLY_PHASE1":2880,"PHASE1":2882,"PHASE2":2884,"PHASE3":2886,"PHASE4":2888,"NA":2890},{"trials":2881,"activeCount":103},[],{"trials":2883,"activeCount":103},[],{"trials":2885,"activeCount":103},[],{"trials":2887,"activeCount":103},[],{"trials":2889,"activeCount":103},[],{"trials":2891,"activeCount":240,"soonestReadout":2645},[2892],{"nctId":2893,"briefTitle":2894,"status":123,"phases":2895,"primaryCompletion":2645,"completion":2645,"start":468,"enrollment":2896,"conditions":2897,"interventions":2900},"NCT07141394","Coordinated Access for Addiction Recovery and Equity in VA Supportive Housing",[95],7908,[2898,2899],"Homelessness","Substance Use Disorder (SUD)",[2878],{"intervention":2902,"totalTrials":240,"cells":2903},"NG-Monomethyl-L-Arginine",{"EARLY_PHASE1":2904,"PHASE1":2906,"PHASE2":2908,"PHASE3":2910,"PHASE4":2912,"NA":2914},{"trials":2905,"activeCount":103},[],{"trials":2907,"activeCount":103},[],{"trials":2909,"activeCount":103},[],{"trials":2911,"activeCount":103},[],{"trials":2913,"activeCount":103},[],{"trials":2915,"activeCount":240,"soonestReadout":2920},[2916],{"nctId":2917,"briefTitle":2918,"status":590,"phases":2919,"primaryCompletion":2920,"completion":2920,"start":2921,"enrollment":2922,"conditions":2923,"interventions":2925},"NCT03625349","Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation",[],"2027-10-29","2015-09-01",130,[2924,147],"Aging",[2902],{"intervention":2927,"totalTrials":240,"cells":2928},"Precision screening intervention",{"EARLY_PHASE1":2929,"PHASE1":2931,"PHASE2":2933,"PHASE3":2935,"PHASE4":2937,"NA":2939},{"trials":2930,"activeCount":103},[],{"trials":2932,"activeCount":103},[],{"trials":2934,"activeCount":103},[],{"trials":2936,"activeCount":103},[],{"trials":2938,"activeCount":103},[],{"trials":2940,"activeCount":240,"soonestReadout":126},[2941],{"nctId":2942,"briefTitle":2943,"status":111,"phases":2944,"primaryCompletion":126,"completion":2645,"start":2945,"enrollment":2946,"conditions":2947,"interventions":2948},"NCT05926102","The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)",[95],"2024-02-01",5000,[1373],[2927],{"intervention":2950,"totalTrials":240,"cells":2951},"Regular Diet Plus FMD",{"EARLY_PHASE1":2952,"PHASE1":2954,"PHASE2":2956,"PHASE3":2958,"PHASE4":2960,"NA":2962},{"trials":2953,"activeCount":103},[],{"trials":2955,"activeCount":103},[],{"trials":2957,"activeCount":103},[],{"trials":2959,"activeCount":103},[],{"trials":2961,"activeCount":103},[],{"trials":2963,"activeCount":240,"soonestReadout":114},[2964],{"nctId":2965,"briefTitle":2966,"status":111,"phases":2967,"primaryCompletion":114,"completion":467,"start":2968,"enrollment":2030,"conditions":2969,"interventions":2974},"NCT06671613","Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer",[95],"2025-10-27",[2970,2971,2972,2973],"Stage IV NSCLC","NSCLC","Immunotherapy","Fasting Mimicking Diet",[2950],{"intervention":2976,"totalTrials":240,"cells":2977},"Pharmacogenetic and polygenic risk testing",{"EARLY_PHASE1":2978,"PHASE1":2980,"PHASE2":2982,"PHASE3":2984,"PHASE4":2986,"NA":2988},{"trials":2979,"activeCount":103},[],{"trials":2981,"activeCount":103},[],{"trials":2983,"activeCount":103},[],{"trials":2985,"activeCount":103},[],{"trials":2987,"activeCount":103},[],{"trials":2989,"activeCount":240,"soonestReadout":2994},[2990],{"nctId":2991,"briefTitle":2992,"status":111,"phases":2993,"primaryCompletion":2994,"completion":2995,"start":2269,"enrollment":2996,"conditions":2997,"interventions":2999},"NCT06568601","Pharmacogenomic Informed Statin Prescribing",[95],"2027-05-31","2028-07-28",410,[2998],"Hypercholesterolemia",[2976],{"intervention":78,"totalTrials":240,"cells":3001},{"EARLY_PHASE1":3002,"PHASE1":3004,"PHASE2":3006,"PHASE3":3008,"PHASE4":3010,"NA":3012},{"trials":3003,"activeCount":103},[],{"trials":3005,"activeCount":103},[],{"trials":3007,"activeCount":103},[],{"trials":3009,"activeCount":103},[],{"trials":3011,"activeCount":103},[],{"trials":3013,"activeCount":240,"soonestReadout":77},[3014],{"nctId":75,"briefTitle":76,"status":111,"phases":3015,"primaryCompletion":77,"completion":77,"start":3016,"enrollment":1567,"conditions":3017,"interventions":3020},[95],"2023-03-01",[3018,3019],"Tinnitus","Notched Noise Therapy",[78,3021],"Hearing Aid and Broadband Noise",{"intervention":3021,"totalTrials":240,"cells":3023},{"EARLY_PHASE1":3024,"PHASE1":3026,"PHASE2":3028,"PHASE3":3030,"PHASE4":3032,"NA":3034},{"trials":3025,"activeCount":103},[],{"trials":3027,"activeCount":103},[],{"trials":3029,"activeCount":103},[],{"trials":3031,"activeCount":103},[],{"trials":3033,"activeCount":103},[],{"trials":3035,"activeCount":240,"soonestReadout":77},[3036],{"nctId":75,"briefTitle":76,"status":111,"phases":3037,"primaryCompletion":77,"completion":77,"start":3016,"enrollment":1567,"conditions":3038,"interventions":3039},[95],[3018,3019],[78,3021],{"intervention":1638,"totalTrials":99,"cells":3041},{"EARLY_PHASE1":3042,"PHASE1":3044,"PHASE2":3046,"PHASE3":3048,"PHASE4":3054,"NA":3079},{"trials":3043,"activeCount":103},[],{"trials":3045,"activeCount":103},[],{"trials":3047,"activeCount":103},[],{"trials":3049,"activeCount":103},[3050],{"nctId":1630,"briefTitle":1631,"status":174,"phases":3051,"primaryCompletion":1633,"completion":1633,"start":1634,"enrollment":19,"conditions":3052,"interventions":3053},[92,93],[36,1636],[1638,1611],{"trials":3055,"activeCount":103},[3056,3064,3075],{"nctId":3057,"briefTitle":3058,"status":174,"phases":3059,"primaryCompletion":3060,"completion":3060,"start":3061,"enrollment":2407,"conditions":3062,"interventions":3063},"NCT03978442","CPT-SMART for Treatment of PTSD and Cigarette Smoking",[94],"2025-10-08","2019-11-07",[1636,36],[1638],{"nctId":3065,"briefTitle":3066,"status":174,"phases":3067,"primaryCompletion":3068,"completion":3069,"start":971,"enrollment":3070,"conditions":3071,"interventions":3072},"NCT02245308","Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers",[94],"2018-03-30","2018-09-28",133,[692,2898],[3073,3074,1638],"Nicotine Patches","Nicotine rescue method",{"nctId":1642,"briefTitle":1643,"status":174,"phases":3076,"primaryCompletion":1645,"completion":1646,"start":663,"enrollment":1647,"conditions":3077,"interventions":3078},[94],[1649,1636],[1638,1651,1652],{"trials":3080,"activeCount":103},[],{"intervention":3082,"totalTrials":220,"cells":3083},"baclofen",{"EARLY_PHASE1":3084,"PHASE1":3086,"PHASE2":3088,"PHASE3":3101,"PHASE4":3114,"NA":3128},{"trials":3085,"activeCount":103},[],{"trials":3087,"activeCount":103},[],{"trials":3089,"activeCount":103},[3090],{"nctId":3091,"briefTitle":3092,"status":246,"phases":3093,"primaryCompletion":409,"completion":409,"start":3094,"enrollment":3095,"conditions":3096,"interventions":3099},"NCT00257894","Baclofen Effects on Smoking Urge and Withdrawal",[92],"2005-12",41,[3097,3098,1636,692],"Nicotine Use Disorder","Nicotine Dependence",[3100],"Baclofen",{"trials":3102,"activeCount":103},[3103],{"nctId":3104,"briefTitle":3105,"status":174,"phases":3106,"primaryCompletion":3107,"completion":3107,"start":3108,"enrollment":3109,"conditions":3110,"interventions":3112},"NCT01265550","A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors",[93],"2016-12-30","2012-08-13",366,[3111],"GERD",[3082,3113],"Desipramine",{"trials":3115,"activeCount":103},[3116],{"nctId":3117,"briefTitle":3118,"status":174,"phases":3119,"primaryCompletion":3120,"completion":3121,"start":3122,"enrollment":3123,"conditions":3124,"interventions":3127},"NCT01008280","Baclofen to Reduce Alcohol Use in Veterans With HCV",[94],"2014-03","2015-09","2010-10",180,[3125,3126],"Hepatitis C","Alcohol Use Disorders",[3082],{"trials":3129,"activeCount":103},[],{"intervention":3131,"totalTrials":220,"cells":3132},"Topiramate",{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3149,"PHASE4":3162,"NA":3173},{"trials":3134,"activeCount":103},[],{"trials":3136,"activeCount":103},[],{"trials":3138,"activeCount":103},[3139],{"nctId":3140,"briefTitle":3141,"status":174,"phases":3142,"primaryCompletion":3143,"completion":3144,"start":3145,"enrollment":2562,"conditions":3146,"interventions":3148},"NCT00802412","Topiramate to Aid Smoking Cessation in Alcohol Dependent Men",[92],"2014-11","2015-06","2009-01",[3098,3147],"Alcohol Dependence",[3131],{"trials":3150,"activeCount":103},[3151],{"nctId":3152,"briefTitle":3153,"status":174,"phases":3154,"primaryCompletion":3155,"completion":3156,"start":3157,"enrollment":265,"conditions":3158,"interventions":3160},"NCT03176953","Topiramate and Prolonged Exposure",[92,93],"2022-10-31","2023-09-30","2017-11-01",[3159],"PTSD and Alcohol Use Disorder",[3161],"topiramate",{"trials":3163,"activeCount":103},[3164],{"nctId":3165,"briefTitle":3166,"status":246,"phases":3167,"primaryCompletion":3168,"completion":3168,"start":3169,"enrollment":3170,"conditions":3171,"interventions":3172},"NCT03018704","Topiramate Treatment of Alcohol Use Disorders in African Americans",[94],"2021-12-31","2017-08-01",79,[1302],[3131],{"trials":3174,"activeCount":103},[],{"intervention":977,"totalTrials":132,"cells":3176},{"EARLY_PHASE1":3177,"PHASE1":3179,"PHASE2":3181,"PHASE3":3187,"PHASE4":3189,"NA":3201},{"trials":3178,"activeCount":103},[],{"trials":3180,"activeCount":103},[],{"trials":3182,"activeCount":103},[3183],{"nctId":967,"briefTitle":968,"status":174,"phases":3184,"primaryCompletion":970,"completion":970,"start":971,"enrollment":972,"conditions":3185,"interventions":3186},[92],[974,975,147],[958,977],{"trials":3188,"activeCount":103},[],{"trials":3190,"activeCount":103},[3191],{"nctId":3192,"briefTitle":3193,"status":174,"phases":3194,"primaryCompletion":3195,"completion":3195,"start":3196,"enrollment":2647,"conditions":3197,"interventions":3199},"NCT04495712","Antiarrhythmic Effects of Spironolactone in Patients With ICDs",[94],"2008-05-28","2004-07-28",[3198],"Ventricular Arrhythmias",[3200],"spironolactone",{"trials":3202,"activeCount":103},[],{"intervention":3204,"totalTrials":132,"cells":3205},"prazosin hydrochloride",{"EARLY_PHASE1":3206,"PHASE1":3208,"PHASE2":3210,"PHASE3":3225,"PHASE4":3227,"NA":3239},{"trials":3207,"activeCount":103},[],{"trials":3209,"activeCount":103},[],{"trials":3211,"activeCount":103},[3212],{"nctId":3213,"briefTitle":3214,"status":174,"phases":3215,"primaryCompletion":3216,"completion":3156,"start":3217,"enrollment":3218,"conditions":3219,"interventions":3224},"NCT02266329","Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin",[91,92],"2023-05-31","2016-01-04",89,[3220,414,3221,3222,1171,3223],"Posttraumatic Headache","Post Concussion Syndrome","Headache","Posttraumatic Migraine",[3204],{"trials":3226,"activeCount":103},[],{"trials":3228,"activeCount":103},[3229],{"nctId":3230,"briefTitle":3231,"status":246,"phases":3232,"primaryCompletion":3233,"completion":3234,"start":3235,"enrollment":3236,"conditions":3237,"interventions":3238},"NCT03221751","Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)",[94],"2023-01-03","2023-12-05","2016-12-01",9,[196],[3204],{"trials":3240,"activeCount":103},[],{"intervention":3242,"totalTrials":132,"cells":3243},"sertraline",{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3248,"PHASE3":3250,"PHASE4":3263,"NA":3276},{"trials":3245,"activeCount":103},[],{"trials":3247,"activeCount":103},[],{"trials":3249,"activeCount":103},[],{"trials":3251,"activeCount":103},[3252],{"nctId":3253,"briefTitle":3254,"status":174,"phases":3255,"primaryCompletion":3256,"completion":3257,"start":3258,"enrollment":3259,"conditions":3260,"interventions":3261},"NCT00946998","Chronic Kidney Disease Antidepressant Sertraline Trial",[93],"2016-11-23","2017-11","2010-02-08",201,[159,21],[3262],"Sertraline",{"trials":3264,"activeCount":103},[3265],{"nctId":3266,"briefTitle":3267,"status":246,"phases":3268,"primaryCompletion":3269,"completion":3270,"start":3271,"enrollment":3272,"conditions":3273,"interventions":3275},"NCT04183205","Predicting SSRI Efficacy in Veterans With PTSD",[94],"2025-03-30","2025-03-31","2019-09-11",26,[24,3274],"Major Depressive Disorder",[3242],{"trials":3277,"activeCount":103},[],{"intervention":3279,"totalTrials":132,"cells":3280},"D-cycloserine",{"EARLY_PHASE1":3281,"PHASE1":3293,"PHASE2":3295,"PHASE3":3297,"PHASE4":3299,"NA":3312},{"trials":3282,"activeCount":103},[3283],{"nctId":3284,"briefTitle":3285,"status":246,"phases":3286,"primaryCompletion":3287,"completion":3287,"start":3288,"enrollment":116,"conditions":3289,"interventions":3291},"NCT03780829","AIH for Spinal Cord Repair",[90],"2026-02-05","2020-02-25",[3290],"SCI",[3279,3292],"sham-NMDA agonist",{"trials":3294,"activeCount":103},[],{"trials":3296,"activeCount":103},[],{"trials":3298,"activeCount":103},[],{"trials":3300,"activeCount":103},[3301],{"nctId":3302,"briefTitle":3303,"status":174,"phases":3304,"primaryCompletion":3305,"completion":3305,"start":3306,"enrollment":3307,"conditions":3308,"interventions":3309},"NCT00674570","Veteran Stress and Learning Study",[94],"2015-06-22","2009-01-13",111,[338],[3310,3311],"Hydrocortisone","D-Cycloserine",{"trials":3313,"activeCount":103},[],{"intervention":3315,"totalTrials":132,"cells":3316},"eszopiclone",{"EARLY_PHASE1":3317,"PHASE1":3319,"PHASE2":3321,"PHASE3":3323,"PHASE4":3336,"NA":3346},{"trials":3318,"activeCount":103},[],{"trials":3320,"activeCount":103},[],{"trials":3322,"activeCount":103},[],{"trials":3324,"activeCount":103},[3325],{"nctId":3326,"briefTitle":3327,"status":174,"phases":3328,"primaryCompletion":3329,"completion":3329,"start":3330,"enrollment":3331,"conditions":3332,"interventions":3333},"NCT03668041","National Adaptive Trial for PTSD Related Insomnia",[93],"2026-03-30","2021-02-25",673,[289],[3334,3335],"Trazodone","Eszopiclone",{"trials":3337,"activeCount":103},[3338],{"nctId":3339,"briefTitle":3340,"status":174,"phases":3341,"primaryCompletion":1824,"completion":3269,"start":3342,"enrollment":1558,"conditions":3343,"interventions":3345},"NCT03937713","Effectiveness of Combining Behavioral and Pharmacologic Therapy for Complex Insomnia in Veterans With PTSD",[94],"2019-12-01",[3344],"Complex Insomnia",[3315],{"trials":3347,"activeCount":103},[],{"intervention":1651,"totalTrials":132,"cells":3349},{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3354,"PHASE3":3365,"PHASE4":3367,"NA":3373},{"trials":3351,"activeCount":103},[],{"trials":3353,"activeCount":103},[],{"trials":3355,"activeCount":103},[3356],{"nctId":3357,"briefTitle":3358,"status":2693,"phases":3359,"primaryCompletion":3360,"completion":3360,"start":3361,"enrollment":103,"conditions":3362,"interventions":3364},"NCT05294263","Varenicline for the Treatment of Cannabis and Tobacco Use Disorders in Veterans",[92],"2024-07-17","2023-04-17",[692,3363],"Cannabis Use Disorder",[1651],{"trials":3366,"activeCount":103},[],{"trials":3368,"activeCount":103},[3369],{"nctId":1642,"briefTitle":1643,"status":174,"phases":3370,"primaryCompletion":1645,"completion":1646,"start":663,"enrollment":1647,"conditions":3371,"interventions":3372},[94],[1649,1636],[1638,1651,1652],{"trials":3374,"activeCount":103},[],{"intervention":3376,"totalTrials":240,"cells":3377},"Levothyroxine",{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3384,"PHASE4":3386,"NA":3398},{"trials":3379,"activeCount":103},[],{"trials":3381,"activeCount":103},[],{"trials":3383,"activeCount":103},[],{"trials":3385,"activeCount":103},[],{"trials":3387,"activeCount":103},[3388],{"nctId":3389,"briefTitle":3390,"status":174,"phases":3391,"primaryCompletion":3392,"completion":3393,"start":3394,"enrollment":128,"conditions":3395,"interventions":3397},"NCT04288115","Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism",[94],"2022-10-07","2022-12-31","2021-03-24",[3396],"Subclinical Hypothyroidism",[3376],{"trials":3399,"activeCount":103},[],{"intervention":3401,"totalTrials":240,"cells":3402},"Lanthanum carbonate",{"EARLY_PHASE1":3403,"PHASE1":3405,"PHASE2":3407,"PHASE3":3409,"PHASE4":3411,"NA":3424},{"trials":3404,"activeCount":103},[],{"trials":3406,"activeCount":103},[],{"trials":3408,"activeCount":103},[],{"trials":3410,"activeCount":103},[],{"trials":3412,"activeCount":103},[3413],{"nctId":3414,"briefTitle":3415,"status":174,"phases":3416,"primaryCompletion":3417,"completion":3418,"start":3419,"enrollment":2030,"conditions":3420,"interventions":3421},"NCT02209636","Phosphate Lowering in CKD Trial",[94],"2019-06-28","2019-12-20","2014-09-15",[159,147],[3401,3422,3423],"Ascorbic Acid","Nitroglycerin",{"trials":3425,"activeCount":103},[],{"intervention":3422,"totalTrials":240,"cells":3427},{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3432,"PHASE3":3434,"PHASE4":3436,"NA":3442},{"trials":3429,"activeCount":103},[],{"trials":3431,"activeCount":103},[],{"trials":3433,"activeCount":103},[],{"trials":3435,"activeCount":103},[],{"trials":3437,"activeCount":103},[3438],{"nctId":3414,"briefTitle":3415,"status":174,"phases":3439,"primaryCompletion":3417,"completion":3418,"start":3419,"enrollment":2030,"conditions":3440,"interventions":3441},[94],[159,147],[3401,3422,3423],{"trials":3443,"activeCount":103},[],{"intervention":3423,"totalTrials":240,"cells":3445},{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3450,"PHASE3":3452,"PHASE4":3454,"NA":3460},{"trials":3447,"activeCount":103},[],{"trials":3449,"activeCount":103},[],{"trials":3451,"activeCount":103},[],{"trials":3453,"activeCount":103},[],{"trials":3455,"activeCount":103},[3456],{"nctId":3414,"briefTitle":3415,"status":174,"phases":3457,"primaryCompletion":3417,"completion":3418,"start":3419,"enrollment":2030,"conditions":3458,"interventions":3459},[94],[159,147],[3401,3422,3423],{"trials":3461,"activeCount":103},[],{"intervention":3463,"totalTrials":240,"cells":3464},"Oral Albuterol Extended Release",{"EARLY_PHASE1":3465,"PHASE1":3467,"PHASE2":3469,"PHASE3":3471,"PHASE4":3473,"NA":3484},{"trials":3466,"activeCount":103},[],{"trials":3468,"activeCount":103},[],{"trials":3470,"activeCount":103},[],{"trials":3472,"activeCount":103},[],{"trials":3474,"activeCount":103},[3475],{"nctId":3476,"briefTitle":3477,"status":246,"phases":3478,"primaryCompletion":3479,"completion":3480,"start":2659,"enrollment":240,"conditions":3481,"interventions":3483},"NCT02508311","Albuterol to Improve Respiratory Strength in SCI",[94],"2022-03-02","2023-02-28",[30,3482],"Respiratory Muscle Weakness",[3463],{"trials":3485,"activeCount":103},[],{"intervention":3487,"totalTrials":240,"cells":3488},"Mupirocin calcium ointment, 2%",{"EARLY_PHASE1":3489,"PHASE1":3491,"PHASE2":3493,"PHASE3":3495,"PHASE4":3497,"NA":3509},{"trials":3490,"activeCount":103},[],{"trials":3492,"activeCount":103},[],{"trials":3494,"activeCount":103},[],{"trials":3496,"activeCount":103},[],{"trials":3498,"activeCount":103},[3499],{"nctId":3500,"briefTitle":3501,"status":174,"phases":3502,"primaryCompletion":3503,"completion":3503,"start":3504,"enrollment":972,"conditions":3505,"interventions":3507},"NCT04222699","Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization",[94],"2014-11-18","2012-09-18",[3506],"Human Microbiome",[3487,3508],"Topical Chlorhexidine, 4%",{"trials":3510,"activeCount":103},[],{"intervention":3508,"totalTrials":240,"cells":3512},{"EARLY_PHASE1":3513,"PHASE1":3515,"PHASE2":3517,"PHASE3":3519,"PHASE4":3521,"NA":3527},{"trials":3514,"activeCount":103},[],{"trials":3516,"activeCount":103},[],{"trials":3518,"activeCount":103},[],{"trials":3520,"activeCount":103},[],{"trials":3522,"activeCount":103},[3523],{"nctId":3500,"briefTitle":3501,"status":174,"phases":3524,"primaryCompletion":3503,"completion":3503,"start":3504,"enrollment":972,"conditions":3525,"interventions":3526},[94],[3506],[3487,3508],{"trials":3528,"activeCount":103},[],{"intervention":3073,"totalTrials":240,"cells":3530},{"EARLY_PHASE1":3531,"PHASE1":3533,"PHASE2":3535,"PHASE3":3537,"PHASE4":3539,"NA":3545},{"trials":3532,"activeCount":103},[],{"trials":3534,"activeCount":103},[],{"trials":3536,"activeCount":103},[],{"trials":3538,"activeCount":103},[],{"trials":3540,"activeCount":103},[3541],{"nctId":3065,"briefTitle":3066,"status":174,"phases":3542,"primaryCompletion":3068,"completion":3069,"start":971,"enrollment":3070,"conditions":3543,"interventions":3544},[94],[692,2898],[3073,3074,1638],{"trials":3546,"activeCount":103},[],{"intervention":3074,"totalTrials":240,"cells":3548},{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3553,"PHASE3":3555,"PHASE4":3557,"NA":3563},{"trials":3550,"activeCount":103},[],{"trials":3552,"activeCount":103},[],{"trials":3554,"activeCount":103},[],{"trials":3556,"activeCount":103},[],{"trials":3558,"activeCount":103},[3559],{"nctId":3065,"briefTitle":3066,"status":174,"phases":3560,"primaryCompletion":3068,"completion":3069,"start":971,"enrollment":3070,"conditions":3561,"interventions":3562},[94],[692,2898],[3073,3074,1638],{"trials":3564,"activeCount":103},[],{"intervention":3566,"totalTrials":240,"cells":3567},"Diuretic initiation or augmentation",{"EARLY_PHASE1":3568,"PHASE1":3570,"PHASE2":3572,"PHASE3":3574,"PHASE4":3576,"NA":3585},{"trials":3569,"activeCount":103},[],{"trials":3571,"activeCount":103},[],{"trials":3573,"activeCount":103},[],{"trials":3575,"activeCount":103},[],{"trials":3577,"activeCount":103},[3578],{"nctId":3579,"briefTitle":3580,"status":2693,"phases":3581,"primaryCompletion":3582,"completion":3582,"start":3582,"enrollment":103,"conditions":3583,"interventions":3584},"NCT04192110","Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD",[94],"2020-08-11",[159],[3566],{"trials":3586,"activeCount":103},[],{"intervention":3588,"totalTrials":240,"cells":3589},"Diuretic augmentation",{"EARLY_PHASE1":3590,"PHASE1":3592,"PHASE2":3594,"PHASE3":3596,"PHASE4":3598,"NA":3609},{"trials":3591,"activeCount":103},[],{"trials":3593,"activeCount":103},[],{"trials":3595,"activeCount":103},[],{"trials":3597,"activeCount":103},[],{"trials":3599,"activeCount":103},[3600],{"nctId":3601,"briefTitle":3602,"status":174,"phases":3603,"primaryCompletion":3604,"completion":3604,"start":3605,"enrollment":3606,"conditions":3607,"interventions":3608},"NCT05171686","Diuretics and Volume Overload in Early CKD",[94],"2025-10-02","2023-02-01",49,[159,974],[3588],{"trials":3610,"activeCount":103},[],{"intervention":3612,"totalTrials":240,"cells":3613},"Inhaled Fluticasone Propionate",{"EARLY_PHASE1":3614,"PHASE1":3616,"PHASE2":3618,"PHASE3":3620,"PHASE4":3622,"NA":3634},{"trials":3615,"activeCount":103},[],{"trials":3617,"activeCount":103},[],{"trials":3619,"activeCount":103},[],{"trials":3621,"activeCount":103},[],{"trials":3623,"activeCount":103},[3624],{"nctId":3625,"briefTitle":3626,"status":246,"phases":3627,"primaryCompletion":3628,"completion":3629,"start":3630,"enrollment":2319,"conditions":3631,"interventions":3633},"NCT01554488","Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease",[94],"2016-02-03","2016-04-07","2013-03-12",[3632,1805,2614],"Asthma",[3612],{"trials":3635,"activeCount":103},[],{"intervention":3637,"totalTrials":240,"cells":3638},"Prevnar",{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3643,"PHASE3":3645,"PHASE4":3647,"NA":3663},{"trials":3640,"activeCount":103},[],{"trials":3642,"activeCount":103},[],{"trials":3644,"activeCount":103},[],{"trials":3646,"activeCount":103},[],{"trials":3648,"activeCount":103},[3649],{"nctId":3650,"briefTitle":3651,"status":174,"phases":3652,"primaryCompletion":3653,"completion":3654,"start":3655,"enrollment":3656,"conditions":3657,"interventions":3661},"NCT00304382","Humoral Determinants of Immunity to Pneumococcal Infection",[94],"2006-09-01","2012-06-01","2003-01-01",114,[3658,3659,3660],"Pneumonia","Pneumococcal Infections","Infections, Streptococcus Pneumoniae",[3637,3662],"Pneumovax",{"trials":3664,"activeCount":103},[],{"intervention":3662,"totalTrials":240,"cells":3666},{"EARLY_PHASE1":3667,"PHASE1":3669,"PHASE2":3671,"PHASE3":3673,"PHASE4":3675,"NA":3681},{"trials":3668,"activeCount":103},[],{"trials":3670,"activeCount":103},[],{"trials":3672,"activeCount":103},[],{"trials":3674,"activeCount":103},[],{"trials":3676,"activeCount":103},[3677],{"nctId":3650,"briefTitle":3651,"status":174,"phases":3678,"primaryCompletion":3653,"completion":3654,"start":3655,"enrollment":3656,"conditions":3679,"interventions":3680},[94],[3658,3659,3660],[3637,3662],{"trials":3682,"activeCount":103},[],{"intervention":3684,"totalTrials":240,"cells":3685},"allopurinol capsule, 100-800 mg by mouth once daily",{"EARLY_PHASE1":3686,"PHASE1":3688,"PHASE2":3690,"PHASE3":3692,"PHASE4":3694,"NA":3709},{"trials":3687,"activeCount":103},[],{"trials":3689,"activeCount":103},[],{"trials":3691,"activeCount":103},[],{"trials":3693,"activeCount":103},[],{"trials":3695,"activeCount":103},[3696],{"nctId":3697,"briefTitle":3698,"status":174,"phases":3699,"primaryCompletion":3700,"completion":3701,"start":3702,"enrollment":3703,"conditions":3704,"interventions":3707},"NCT02579096","CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat",[94],"2021-02-01","2021-04-15","2017-03-06",950,[3705,3706],"Gout","Chronic Kidney Diseases",[3684,3708],"febuxostat tablet 40-120 mg by mouth once daily",{"trials":3710,"activeCount":103},[],{"intervention":3708,"totalTrials":240,"cells":3712},{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3717,"PHASE3":3719,"PHASE4":3721,"NA":3727},{"trials":3714,"activeCount":103},[],{"trials":3716,"activeCount":103},[],{"trials":3718,"activeCount":103},[],{"trials":3720,"activeCount":103},[],{"trials":3722,"activeCount":103},[3723],{"nctId":3697,"briefTitle":3698,"status":174,"phases":3724,"primaryCompletion":3700,"completion":3701,"start":3702,"enrollment":3703,"conditions":3725,"interventions":3726},[94],[3705,3706],[3684,3708],{"trials":3728,"activeCount":103},[],{"intervention":3730,"totalTrials":240,"cells":3731},"Uridine",{"EARLY_PHASE1":3732,"PHASE1":3734,"PHASE2":3736,"PHASE3":3738,"PHASE4":3740,"NA":3751},{"trials":3733,"activeCount":103},[],{"trials":3735,"activeCount":103},[],{"trials":3737,"activeCount":103},[],{"trials":3739,"activeCount":103},[],{"trials":3741,"activeCount":103},[3742],{"nctId":3743,"briefTitle":3744,"status":174,"phases":3745,"primaryCompletion":3746,"completion":3746,"start":3747,"enrollment":1669,"conditions":3748,"interventions":3750},"NCT03265964","Clinical and Imaging Trial of Uridine for Veterans With Suicidal Ideation",[94],"2024-06-30","2018-04-02",[3749],"Suicidal Ideation",[3730],{"trials":3752,"activeCount":103},[],{"intervention":3754,"totalTrials":240,"cells":3755},"Esketamine",{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3760,"PHASE3":3762,"PHASE4":3764,"NA":3775},{"trials":3757,"activeCount":103},[],{"trials":3759,"activeCount":103},[],{"trials":3761,"activeCount":103},[],{"trials":3763,"activeCount":103},[],{"trials":3765,"activeCount":103},[3766],{"nctId":3767,"briefTitle":3768,"status":2693,"phases":3769,"primaryCompletion":3770,"completion":3770,"start":3770,"enrollment":103,"conditions":3771,"interventions":3773},"NCT05554627","VA Aripiprazole vs Esketamine for Treatment Resistant Depression",[94],"2023-10-27",[3772],"Depressive Disorder, Major",[3754,3774],"Aripiprazole",{"trials":3776,"activeCount":103},[],{"intervention":3774,"totalTrials":240,"cells":3778},{"EARLY_PHASE1":3779,"PHASE1":3781,"PHASE2":3783,"PHASE3":3785,"PHASE4":3787,"NA":3793},{"trials":3780,"activeCount":103},[],{"trials":3782,"activeCount":103},[],{"trials":3784,"activeCount":103},[],{"trials":3786,"activeCount":103},[],{"trials":3788,"activeCount":103},[3789],{"nctId":3767,"briefTitle":3768,"status":2693,"phases":3790,"primaryCompletion":3770,"completion":3770,"start":3770,"enrollment":103,"conditions":3791,"interventions":3792},[94],[3772],[3754,3774],{"trials":3794,"activeCount":103},[],{"intervention":3310,"totalTrials":240,"cells":3796},{"EARLY_PHASE1":3797,"PHASE1":3799,"PHASE2":3801,"PHASE3":3803,"PHASE4":3805,"NA":3811},{"trials":3798,"activeCount":103},[],{"trials":3800,"activeCount":103},[],{"trials":3802,"activeCount":103},[],{"trials":3804,"activeCount":103},[],{"trials":3806,"activeCount":103},[3807],{"nctId":3302,"briefTitle":3303,"status":174,"phases":3808,"primaryCompletion":3305,"completion":3305,"start":3306,"enrollment":3307,"conditions":3809,"interventions":3810},[94],[338],[3310,3311],{"trials":3812,"activeCount":103},[],{"intervention":3814,"totalTrials":240,"cells":3815},"Indigo carmine",{"EARLY_PHASE1":3816,"PHASE1":3818,"PHASE2":3820,"PHASE3":3822,"PHASE4":3824,"NA":3837},{"trials":3817,"activeCount":103},[],{"trials":3819,"activeCount":103},[],{"trials":3821,"activeCount":103},[],{"trials":3823,"activeCount":103},[],{"trials":3825,"activeCount":103},[3826],{"nctId":3827,"briefTitle":3828,"status":174,"phases":3829,"primaryCompletion":3830,"completion":3831,"start":3832,"enrollment":3833,"conditions":3834,"interventions":3836},"NCT01607255","Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT)",[94],"2017-06-30","2017-09-30","2013-05-16",480,[3835],"Colorectal Neoplasms",[3814],{"trials":3838,"activeCount":103},[],{"intervention":3840,"totalTrials":240,"cells":3841},"5-fluorouracil",{"EARLY_PHASE1":3842,"PHASE1":3844,"PHASE2":3846,"PHASE3":3848,"PHASE4":3850,"NA":3869},{"trials":3843,"activeCount":103},[],{"trials":3845,"activeCount":103},[],{"trials":3847,"activeCount":103},[],{"trials":3849,"activeCount":103},[],{"trials":3851,"activeCount":103},[3852],{"nctId":3853,"briefTitle":3854,"status":174,"phases":3855,"primaryCompletion":3856,"completion":3857,"start":3858,"enrollment":3859,"conditions":3860,"interventions":3868},"NCT00847912","CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial",[94],"2013-06-28","2016-07-30","2009-06-26",954,[3861,3862,3863,3864,3865,3866,3867],"Carcinoma, Basal Cell","Carcinoma, Squamous Cell","Skin Neoplasms","Skin Diseases","Neoplasms, Basal Cell","Neoplasms, Squamous Cell","Carcinoma",[3840],{"trials":3870,"activeCount":103},[],{"intervention":3872,"totalTrials":240,"cells":3873},"Rifampin",{"EARLY_PHASE1":3874,"PHASE1":3876,"PHASE2":3878,"PHASE3":3880,"PHASE4":3882,"NA":3896},{"trials":3875,"activeCount":103},[],{"trials":3877,"activeCount":103},[],{"trials":3879,"activeCount":103},[],{"trials":3881,"activeCount":103},[],{"trials":3883,"activeCount":103},[3884],{"nctId":3885,"briefTitle":3886,"status":174,"phases":3887,"primaryCompletion":3888,"completion":3888,"start":3889,"enrollment":3890,"conditions":3891,"interventions":3894},"NCT03012529","Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics",[94],"2025-11-05","2018-01-22",843,[3892,975,3893],"Osteomyelitis","Amputation",[3872,3895],"Riboflavin Placebo",{"trials":3897,"activeCount":103},[],{"intervention":3895,"totalTrials":240,"cells":3899},{"EARLY_PHASE1":3900,"PHASE1":3902,"PHASE2":3904,"PHASE3":3906,"PHASE4":3908,"NA":3914},{"trials":3901,"activeCount":103},[],{"trials":3903,"activeCount":103},[],{"trials":3905,"activeCount":103},[],{"trials":3907,"activeCount":103},[],{"trials":3909,"activeCount":103},[3910],{"nctId":3885,"briefTitle":3886,"status":174,"phases":3911,"primaryCompletion":3888,"completion":3888,"start":3889,"enrollment":3890,"conditions":3912,"interventions":3913},[94],[3892,975,3893],[3872,3895],{"trials":3915,"activeCount":103},[],{"intervention":3917,"totalTrials":240,"cells":3918},"sertraline 50 mg daily",{"EARLY_PHASE1":3919,"PHASE1":3921,"PHASE2":3923,"PHASE3":3925,"PHASE4":3927,"NA":3941},{"trials":3920,"activeCount":103},[],{"trials":3922,"activeCount":103},[],{"trials":3924,"activeCount":103},[],{"trials":3926,"activeCount":103},[],{"trials":3928,"activeCount":103},[3929],{"nctId":3930,"briefTitle":3931,"status":174,"phases":3932,"primaryCompletion":3933,"completion":3934,"start":3935,"enrollment":3936,"conditions":3937,"interventions":3939},"NCT00701675","Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly",[94],"2009-07","2009-09","2005-10",42,[3938],"Generalized Anxiety Disorder",[3917,3940],"sertraline 100 mg daily",{"trials":3942,"activeCount":103},[],{"intervention":3940,"totalTrials":240,"cells":3944},{"EARLY_PHASE1":3945,"PHASE1":3947,"PHASE2":3949,"PHASE3":3951,"PHASE4":3953,"NA":3959},{"trials":3946,"activeCount":103},[],{"trials":3948,"activeCount":103},[],{"trials":3950,"activeCount":103},[],{"trials":3952,"activeCount":103},[],{"trials":3954,"activeCount":103},[3955],{"nctId":3930,"briefTitle":3931,"status":174,"phases":3956,"primaryCompletion":3933,"completion":3934,"start":3935,"enrollment":3936,"conditions":3957,"interventions":3958},[94],[3938],[3917,3940],{"trials":3960,"activeCount":103},[],{"intervention":3962,"totalTrials":240,"cells":3963},"Miralax-Gatorade Prep",{"EARLY_PHASE1":3964,"PHASE1":3966,"PHASE2":3968,"PHASE3":3970,"PHASE4":3972,"NA":3985},{"trials":3965,"activeCount":103},[],{"trials":3967,"activeCount":103},[],{"trials":3969,"activeCount":103},[],{"trials":3971,"activeCount":103},[],{"trials":3973,"activeCount":103},[3974],{"nctId":3975,"briefTitle":3976,"status":174,"phases":3977,"primaryCompletion":3978,"completion":3746,"start":3979,"enrollment":3980,"conditions":3981,"interventions":3983},"NCT03298945","Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens",[94],"2023-12-30","2018-12-13",2239,[3982],"Colorectal Cancer",[3962,3984],"Golytely",{"trials":3986,"activeCount":103},[],{"intervention":3984,"totalTrials":240,"cells":3988},{"EARLY_PHASE1":3989,"PHASE1":3991,"PHASE2":3993,"PHASE3":3995,"PHASE4":3997,"NA":4003},{"trials":3990,"activeCount":103},[],{"trials":3992,"activeCount":103},[],{"trials":3994,"activeCount":103},[],{"trials":3996,"activeCount":103},[],{"trials":3998,"activeCount":103},[3999],{"nctId":3975,"briefTitle":3976,"status":174,"phases":4000,"primaryCompletion":3978,"completion":3746,"start":3979,"enrollment":3980,"conditions":4001,"interventions":4002},[94],[3982],[3962,3984],{"trials":4004,"activeCount":103},[],{"intervention":4006,"totalTrials":240,"cells":4007},"pioglitazone-placebo",{"EARLY_PHASE1":4008,"PHASE1":4010,"PHASE2":4012,"PHASE3":4014,"PHASE4":4016,"NA":4030},{"trials":4009,"activeCount":103},[],{"trials":4011,"activeCount":103},[],{"trials":4013,"activeCount":103},[],{"trials":4015,"activeCount":103},[],{"trials":4017,"activeCount":103},[4018],{"nctId":4019,"briefTitle":4020,"status":174,"phases":4021,"primaryCompletion":4022,"completion":4023,"start":4024,"enrollment":4025,"conditions":4026,"interventions":4027},"NCT01002547","Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment",[94],"2016-09-30","2016-12-31","2010-06-24",105,[2365],[4006,4028,4006,4029],"pioglitazone","Vitamin E-placebo",{"trials":4031,"activeCount":103},[],{"intervention":4029,"totalTrials":240,"cells":4033},{"EARLY_PHASE1":4034,"PHASE1":4036,"PHASE2":4038,"PHASE3":4040,"PHASE4":4042,"NA":4048},{"trials":4035,"activeCount":103},[],{"trials":4037,"activeCount":103},[],{"trials":4039,"activeCount":103},[],{"trials":4041,"activeCount":103},[],{"trials":4043,"activeCount":103},[4044],{"nctId":4019,"briefTitle":4020,"status":174,"phases":4045,"primaryCompletion":4022,"completion":4023,"start":4024,"enrollment":4025,"conditions":4046,"interventions":4047},[94],[2365],[4006,4028,4006,4029],{"trials":4049,"activeCount":103},[],{"intervention":4051,"totalTrials":240,"cells":4052},"buprenorphine\u002Fnaloxone",{"EARLY_PHASE1":4053,"PHASE1":4055,"PHASE2":4057,"PHASE3":4059,"PHASE4":4061,"NA":4072},{"trials":4054,"activeCount":103},[],{"trials":4056,"activeCount":103},[],{"trials":4058,"activeCount":103},[],{"trials":4060,"activeCount":103},[],{"trials":4062,"activeCount":103},[4063],{"nctId":4064,"briefTitle":4065,"status":246,"phases":4066,"primaryCompletion":3144,"completion":3144,"start":2626,"enrollment":4067,"conditions":4068,"interventions":4070},"NCT01875848","Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain",[94],7,[4069],"Pain",[4051,4071],"opioid dose escalation",{"trials":4073,"activeCount":103},[],{"intervention":4071,"totalTrials":240,"cells":4075},{"EARLY_PHASE1":4076,"PHASE1":4078,"PHASE2":4080,"PHASE3":4082,"PHASE4":4084,"NA":4090},{"trials":4077,"activeCount":103},[],{"trials":4079,"activeCount":103},[],{"trials":4081,"activeCount":103},[],{"trials":4083,"activeCount":103},[],{"trials":4085,"activeCount":103},[4086],{"nctId":4064,"briefTitle":4065,"status":246,"phases":4087,"primaryCompletion":3144,"completion":3144,"start":2626,"enrollment":4067,"conditions":4088,"interventions":4089},[94],[4069],[4051,4071],{"trials":4091,"activeCount":103},[],{"intervention":4093,"totalTrials":240,"cells":4094},"Testosterone gel 1.62%",{"EARLY_PHASE1":4095,"PHASE1":4097,"PHASE2":4099,"PHASE3":4101,"PHASE4":4103,"NA":4113},{"trials":4096,"activeCount":103},[],{"trials":4098,"activeCount":103},[],{"trials":4100,"activeCount":103},[],{"trials":4102,"activeCount":103},[],{"trials":4104,"activeCount":103},[4105],{"nctId":4106,"briefTitle":4107,"status":174,"phases":4108,"primaryCompletion":3060,"completion":3060,"start":2053,"enrollment":4109,"conditions":4110,"interventions":4112},"NCT03887936","Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism",[94],92,[4111,380],"Type 2 Diabetes Mellitus",[4093],{"trials":4114,"activeCount":103},[],{"intervention":4116,"totalTrials":240,"cells":4117},"hydrocodone\u002FAPAP w placebo PRN",{"EARLY_PHASE1":4118,"PHASE1":4120,"PHASE2":4122,"PHASE3":4124,"PHASE4":4126,"NA":4140},{"trials":4119,"activeCount":103},[],{"trials":4121,"activeCount":103},[],{"trials":4123,"activeCount":103},[],{"trials":4125,"activeCount":103},[],{"trials":4127,"activeCount":103},[4128],{"nctId":4129,"briefTitle":4130,"status":174,"phases":4131,"primaryCompletion":249,"completion":4132,"start":4133,"enrollment":4134,"conditions":4135,"interventions":4138},"NCT00385684","Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)",[94],"2014-06","2007-10",11,[4136,196,4137,4069],"Alzheimer Disease","Dementia, Vascular",[4116,4139],"hydrocodone\u002FAPAP",{"trials":4141,"activeCount":103},[],{"intervention":4139,"totalTrials":240,"cells":4143},{"EARLY_PHASE1":4144,"PHASE1":4146,"PHASE2":4148,"PHASE3":4150,"PHASE4":4152,"NA":4158},{"trials":4145,"activeCount":103},[],{"trials":4147,"activeCount":103},[],{"trials":4149,"activeCount":103},[],{"trials":4151,"activeCount":103},[],{"trials":4153,"activeCount":103},[4154],{"nctId":4129,"briefTitle":4130,"status":174,"phases":4155,"primaryCompletion":249,"completion":4132,"start":4133,"enrollment":4134,"conditions":4156,"interventions":4157},[94],[4136,196,4137,4069],[4116,4139],{"trials":4159,"activeCount":103},[],{"intervention":416,"totalTrials":240,"cells":4161},{"EARLY_PHASE1":4162,"PHASE1":4164,"PHASE2":4166,"PHASE3":4168,"PHASE4":4170,"NA":4176},{"trials":4163,"activeCount":103},[],{"trials":4165,"activeCount":103},[],{"trials":4167,"activeCount":103},[],{"trials":4169,"activeCount":103},[],{"trials":4171,"activeCount":103},[4172],{"nctId":406,"briefTitle":407,"status":174,"phases":4173,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":4174,"interventions":4175},[94],[414,36],[416,307],{"trials":4177,"activeCount":103},[],{"intervention":4179,"totalTrials":240,"cells":4180},"Propranolol",{"EARLY_PHASE1":4181,"PHASE1":4183,"PHASE2":4185,"PHASE3":4187,"PHASE4":4189,"NA":4201},{"trials":4182,"activeCount":103},[],{"trials":4184,"activeCount":103},[],{"trials":4186,"activeCount":103},[],{"trials":4188,"activeCount":103},[],{"trials":4190,"activeCount":103},[4191],{"nctId":4192,"briefTitle":4193,"status":246,"phases":4194,"primaryCompletion":4195,"completion":4196,"start":4197,"enrollment":3236,"conditions":4198,"interventions":4200},"NCT00645450","PTSD Symptom Reduction by Propranolol Given After Trauma Memory Activation",[94],"2010-07","2010-12","2008-04",[4199],"Posttraumatic Stress Disorders",[4179],{"trials":4202,"activeCount":103},[],{"intervention":4204,"totalTrials":240,"cells":4205},"Personalized Smoking Cessation Pharmacotherapy",{"EARLY_PHASE1":4206,"PHASE1":4208,"PHASE2":4210,"PHASE3":4212,"PHASE4":4214,"NA":4225},{"trials":4207,"activeCount":103},[],{"trials":4209,"activeCount":103},[],{"trials":4211,"activeCount":103},[],{"trials":4213,"activeCount":103},[],{"trials":4215,"activeCount":103},[4216],{"nctId":4217,"briefTitle":4218,"status":174,"phases":4219,"primaryCompletion":4220,"completion":4220,"start":4221,"enrollment":2185,"conditions":4222,"interventions":4224},"NCT05277207","Tobacco Cessation Treatment Preferences Among Veteran Smokers",[94],"2023-09-27","2022-05-02",[4223],"Tobacco Use",[4204],{"trials":4226,"activeCount":103},[],{"intervention":4228,"totalTrials":240,"cells":4229},"Atomoxetine 80 MG",{"EARLY_PHASE1":4230,"PHASE1":4232,"PHASE2":4234,"PHASE3":4236,"PHASE4":4238,"NA":4250},{"trials":4231,"activeCount":103},[],{"trials":4233,"activeCount":103},[],{"trials":4235,"activeCount":103},[],{"trials":4237,"activeCount":103},[],{"trials":4239,"activeCount":103},[4240],{"nctId":4241,"briefTitle":4242,"status":174,"phases":4243,"primaryCompletion":4244,"completion":4245,"start":4246,"enrollment":31,"conditions":4247,"interventions":4249},"NCT02287038","Atomoxetine in Veterans With Comorbid ADHD\u002FPTSD",[94],"2017-03-02","2017-04-14","2014-10-15",[1328,4248],"Attention Deficit Hyperactivity Disorder",[4228],{"trials":4251,"activeCount":103},[],{"intervention":4253,"totalTrials":240,"cells":4254},"Blinded clopidogrel",{"EARLY_PHASE1":4255,"PHASE1":4257,"PHASE2":4259,"PHASE3":4261,"PHASE4":4263,"NA":4275},{"trials":4256,"activeCount":103},[],{"trials":4258,"activeCount":103},[],{"trials":4260,"activeCount":103},[],{"trials":4262,"activeCount":103},[],{"trials":4264,"activeCount":103},[4265],{"nctId":4266,"briefTitle":4267,"status":174,"phases":4268,"primaryCompletion":4023,"completion":4023,"start":4269,"enrollment":4270,"conditions":4271,"interventions":4273},"NCT01121224","Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty",[94],"2012-01-11",597,[4272],"Saphenous Vein Graft Atherosclerosis",[4253,4274],"Thienopyridine",{"trials":4276,"activeCount":103},[],{"intervention":4274,"totalTrials":240,"cells":4278},{"EARLY_PHASE1":4279,"PHASE1":4281,"PHASE2":4283,"PHASE3":4285,"PHASE4":4287,"NA":4293},{"trials":4280,"activeCount":103},[],{"trials":4282,"activeCount":103},[],{"trials":4284,"activeCount":103},[],{"trials":4286,"activeCount":103},[],{"trials":4288,"activeCount":103},[4289],{"nctId":4266,"briefTitle":4267,"status":174,"phases":4290,"primaryCompletion":4023,"completion":4023,"start":4269,"enrollment":4270,"conditions":4291,"interventions":4292},[94],[4272],[4253,4274],{"trials":4294,"activeCount":103},[],{"intervention":4296,"totalTrials":240,"cells":4297},"Colchicine vs Placebo",{"EARLY_PHASE1":4298,"PHASE1":4300,"PHASE2":4302,"PHASE3":4304,"PHASE4":4306,"NA":4317},{"trials":4299,"activeCount":103},[],{"trials":4301,"activeCount":103},[],{"trials":4303,"activeCount":103},[],{"trials":4305,"activeCount":103},[],{"trials":4307,"activeCount":103},[4308],{"nctId":4309,"briefTitle":4310,"status":174,"phases":4311,"primaryCompletion":334,"completion":3168,"start":4312,"enrollment":4313,"conditions":4314,"interventions":4316},"NCT02594111","Colchicine in Percutaneous Coronary Intervention",[94],"2013-05-30",714,[445,4315],"Acute Coronary Syndrome",[4296],{"trials":4318,"activeCount":103},[],{"intervention":4320,"totalTrials":240,"cells":4321},"Low dose erythropoietin",{"EARLY_PHASE1":4322,"PHASE1":4324,"PHASE2":4326,"PHASE3":4328,"PHASE4":4330,"NA":4344},{"trials":4323,"activeCount":103},[],{"trials":4325,"activeCount":103},[],{"trials":4327,"activeCount":103},[],{"trials":4329,"activeCount":103},[],{"trials":4331,"activeCount":103},[4332],{"nctId":4333,"briefTitle":4334,"status":246,"phases":4335,"primaryCompletion":4336,"completion":4336,"start":4337,"enrollment":1544,"conditions":4338,"interventions":4342},"NCT03277183","Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin",[94],"2019-06-03","2017-11-02",[4339,4340,952,4341],"Anemia","CKD","Cardiovascular",[4320,4343],"High dose erythropoietin",{"trials":4345,"activeCount":103},[],{"intervention":4343,"totalTrials":240,"cells":4347},{"EARLY_PHASE1":4348,"PHASE1":4350,"PHASE2":4352,"PHASE3":4354,"PHASE4":4356,"NA":4362},{"trials":4349,"activeCount":103},[],{"trials":4351,"activeCount":103},[],{"trials":4353,"activeCount":103},[],{"trials":4355,"activeCount":103},[],{"trials":4357,"activeCount":103},[4358],{"nctId":4333,"briefTitle":4334,"status":246,"phases":4359,"primaryCompletion":4336,"completion":4336,"start":4337,"enrollment":1544,"conditions":4360,"interventions":4361},[94],[4339,4340,952,4341],[4320,4343],{"trials":4363,"activeCount":103},[],{"intervention":4365,"totalTrials":240,"cells":4366},"Fidaxomicin",{"EARLY_PHASE1":4367,"PHASE1":4369,"PHASE2":4371,"PHASE3":4373,"PHASE4":4375,"NA":4391},{"trials":4368,"activeCount":103},[],{"trials":4370,"activeCount":103},[],{"trials":4372,"activeCount":103},[],{"trials":4374,"activeCount":103},[],{"trials":4376,"activeCount":103},[4377],{"nctId":4378,"briefTitle":4379,"status":246,"phases":4380,"primaryCompletion":4381,"completion":4382,"start":4383,"enrollment":4384,"conditions":4385,"interventions":4389},"NCT02667418","Optimal Treatment for Recurrent Clostridium Difficile",[94],"2024-08-07","2024-08-31","2016-02-19",308,[4386,4387,4365,4388],"Clostridium","Difficile","Vancomycin",[4365,4390,4388],"Vancomycin with Taper\u002FPulse",{"trials":4392,"activeCount":103},[],{"intervention":4390,"totalTrials":240,"cells":4394},{"EARLY_PHASE1":4395,"PHASE1":4397,"PHASE2":4399,"PHASE3":4401,"PHASE4":4403,"NA":4409},{"trials":4396,"activeCount":103},[],{"trials":4398,"activeCount":103},[],{"trials":4400,"activeCount":103},[],{"trials":4402,"activeCount":103},[],{"trials":4404,"activeCount":103},[4405],{"nctId":4378,"briefTitle":4379,"status":246,"phases":4406,"primaryCompletion":4381,"completion":4382,"start":4383,"enrollment":4384,"conditions":4407,"interventions":4408},[94],[4386,4387,4365,4388],[4365,4390,4388],{"trials":4410,"activeCount":103},[],{"intervention":4412,"totalTrials":240,"cells":4413},"Exendin",{"EARLY_PHASE1":4414,"PHASE1":4416,"PHASE2":4418,"PHASE3":4420,"PHASE4":4422,"NA":4434},{"trials":4415,"activeCount":103},[],{"trials":4417,"activeCount":103},[],{"trials":4419,"activeCount":103},[],{"trials":4421,"activeCount":103},[],{"trials":4423,"activeCount":103},[4424],{"nctId":4425,"briefTitle":4426,"status":246,"phases":4427,"primaryCompletion":3168,"completion":3168,"start":4428,"enrollment":4429,"conditions":4430,"interventions":4432},"NCT02844907","Regulation of Insulin Secretion by the GLP-1 Receptor",[94],"2018-07-01",6,[4431],"Insulin Secretion",[4412,4433],"Dexamethasone",{"trials":4435,"activeCount":103},[],{"intervention":4437,"totalTrials":240,"cells":4438},"recombinant human BNP",{"EARLY_PHASE1":4439,"PHASE1":4441,"PHASE2":4443,"PHASE3":4445,"PHASE4":4447,"NA":4457},{"trials":4440,"activeCount":103},[],{"trials":4442,"activeCount":103},[],{"trials":4444,"activeCount":103},[],{"trials":4446,"activeCount":103},[],{"trials":4448,"activeCount":103},[4449],{"nctId":4450,"briefTitle":4451,"status":246,"phases":4452,"primaryCompletion":1590,"completion":1590,"start":4428,"enrollment":1544,"conditions":4453,"interventions":4456},"NCT03397966","Metabolic Effects of Natriuretic Peptide Hormones",[94],[27,4454,4455],"Cardiovascular Physiological Phenomena","Metabolism",[4437],{"trials":4458,"activeCount":103},[],{"intervention":1672,"totalTrials":99,"cells":4460},{"EARLY_PHASE1":4461,"PHASE1":4463,"PHASE2":4465,"PHASE3":4487,"PHASE4":4493,"NA":4495},{"trials":4462,"activeCount":103},[],{"trials":4464,"activeCount":103},[],{"trials":4466,"activeCount":103},[4467,4471,4475],{"nctId":1665,"briefTitle":1666,"status":174,"phases":4468,"primaryCompletion":926,"completion":511,"start":1668,"enrollment":1669,"conditions":4469,"interventions":4470},[92],[18],[1656,1672],{"nctId":1674,"briefTitle":1675,"status":174,"phases":4472,"primaryCompletion":1677,"completion":1678,"start":1679,"enrollment":22,"conditions":4473,"interventions":4474},[92],[1681],[1683,1684],{"nctId":4476,"briefTitle":4477,"status":246,"phases":4478,"primaryCompletion":4479,"completion":4479,"start":4480,"enrollment":240,"conditions":4481,"interventions":4482},"NCT04378426","Nitrous Oxide for PTSD",[92],"2022-08-31","2021-10-07",[18],[4483,1672,4484,4485,4486],"Nitrous Oxide","Nitrogen","Oxygen","Saline",{"trials":4488,"activeCount":103},[4489],{"nctId":1706,"briefTitle":1707,"status":174,"phases":4490,"primaryCompletion":1709,"completion":1709,"start":1710,"enrollment":370,"conditions":4491,"interventions":4492},[93],[1712],[1656,1656,1656,1672],{"trials":4494,"activeCount":103},[],{"trials":4496,"activeCount":103},[],{"intervention":4498,"totalTrials":220,"cells":4499},"metformin",{"EARLY_PHASE1":4500,"PHASE1":4502,"PHASE2":4504,"PHASE3":4523,"PHASE4":4537,"NA":4539},{"trials":4501,"activeCount":103},[],{"trials":4503,"activeCount":103},[],{"trials":4505,"activeCount":103},[4506,4514],{"nctId":4507,"briefTitle":4508,"status":174,"phases":4509,"primaryCompletion":2660,"completion":2660,"start":971,"enrollment":4510,"conditions":4511,"interventions":4513},"NCT02252081","Metformin in Kidney Disease",[92],125,[159,147,4512],"Metabolic Syndrome",[4498],{"nctId":4515,"briefTitle":4516,"status":174,"phases":4517,"primaryCompletion":4518,"completion":4518,"start":4519,"enrollment":2407,"conditions":4520,"interventions":4522},"NCT01804049","Metformin and Muscle in Insulin-resistant Older Veterans",[91,92],"2018-08-31","2014-04-08",[4521],"Prediabetes",[4498],{"trials":4524,"activeCount":103},[4525],{"nctId":4526,"briefTitle":4527,"status":174,"phases":4528,"primaryCompletion":4529,"completion":4529,"start":4530,"enrollment":4531,"conditions":4532,"interventions":4533},"NCT00032487","Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)",[93],"2008-05-30","2000-12-01",1791,[4111],[4534,4535,4536,953],"Insulin","Glimepiride","Rosiglitazone",{"trials":4538,"activeCount":103},[],{"trials":4540,"activeCount":103},[],{"intervention":4542,"totalTrials":132,"cells":4543},"standard statin monotherapy",{"EARLY_PHASE1":4544,"PHASE1":4546,"PHASE2":4548,"PHASE3":4550,"PHASE4":4572,"NA":4574},{"trials":4545,"activeCount":103},[],{"trials":4547,"activeCount":103},[],{"trials":4549,"activeCount":103},[],{"trials":4551,"activeCount":103},[4552,4563],{"nctId":4553,"briefTitle":4554,"status":174,"phases":4555,"primaryCompletion":4556,"completion":4557,"start":4558,"enrollment":4559,"conditions":4560,"interventions":4562},"NCT02347098","Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II",[93],"2018-02-28","2019-09-30","2015-03-30",270,[4561],"Acute Coronary Artery Syndrome",[4542],{"nctId":4564,"briefTitle":4565,"status":174,"phases":4566,"primaryCompletion":4567,"completion":4568,"start":248,"enrollment":4569,"conditions":4570,"interventions":4571},"NCT01004406","Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I",[93],"2013-01","2013-03",59,[4315],[4542],{"trials":4573,"activeCount":103},[],{"trials":4575,"activeCount":103},[],{"intervention":4577,"totalTrials":132,"cells":4578},"Lipoic acid",{"EARLY_PHASE1":4579,"PHASE1":4581,"PHASE2":4583,"PHASE3":4595,"PHASE4":4607,"NA":4609},{"trials":4580,"activeCount":103},[],{"trials":4582,"activeCount":103},[],{"trials":4584,"activeCount":103},[4585],{"nctId":4586,"briefTitle":4587,"status":174,"phases":4588,"primaryCompletion":4589,"completion":3746,"start":4590,"enrollment":4591,"conditions":4592,"interventions":4594},"NCT03161028","Lipoic Acid for Progressive Multiple Sclerosis (MS)",[92],"2023-12-31","2018-08-17",115,[4593],"Multiple Sclerosis",[4577],{"trials":4596,"activeCount":103},[4597],{"nctId":4598,"briefTitle":4599,"status":174,"phases":4600,"primaryCompletion":4601,"completion":4601,"start":3122,"enrollment":4602,"conditions":4603,"interventions":4605},"NCT01188811","Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)",[92,93],"2015-08",54,[4604],"Multiple Sclerosis, Chronic Progressive",[4606],"lipoic acid",{"trials":4608,"activeCount":103},[],{"trials":4610,"activeCount":103},[],{"intervention":4612,"totalTrials":132,"cells":4613},"Naltrexone",{"EARLY_PHASE1":4614,"PHASE1":4616,"PHASE2":4618,"PHASE3":4630,"PHASE4":4639,"NA":4641},{"trials":4615,"activeCount":103},[],{"trials":4617,"activeCount":103},[],{"trials":4619,"activeCount":103},[4620],{"nctId":4621,"briefTitle":4622,"status":174,"phases":4623,"primaryCompletion":2660,"completion":2660,"start":4624,"enrollment":2776,"conditions":4625,"interventions":4629},"NCT03008590","Low Dose Naltrexone for Chronic Pain From Arthritis",[92],"2018-05-01",[4626,4627,4628],"Osteoarthritis","Arthritis, Rheumatoid","Arthritis, Psoriatic",[4612],{"trials":4631,"activeCount":103},[4632],{"nctId":4633,"briefTitle":4634,"status":174,"phases":4635,"primaryCompletion":3144,"completion":3144,"start":248,"enrollment":22,"conditions":4636,"interventions":4637},"NCT01342549","Treatment Strategy for Alcohol Use Disorders in Veterans With TBI",[93],[3147],[4638,4612],"Valproate",{"trials":4640,"activeCount":103},[],{"trials":4642,"activeCount":103},[],{"intervention":4644,"totalTrials":132,"cells":4645},"probenecid",{"EARLY_PHASE1":4646,"PHASE1":4657,"PHASE2":4659,"PHASE3":4661,"PHASE4":4671,"NA":4673},{"trials":4647,"activeCount":103},[4648],{"nctId":4649,"briefTitle":4650,"status":174,"phases":4651,"primaryCompletion":4652,"completion":4652,"start":4246,"enrollment":251,"conditions":4653,"interventions":4655},"NCT02243631","Effect of Probenecid on Synovial Fluid ATP Levels in CPPD",[90],"2021-04-08",[4654],"Calcium Pyrophosphate Deposition Disease",[4656],"Probenecid",{"trials":4658,"activeCount":103},[],{"trials":4660,"activeCount":103},[],{"trials":4662,"activeCount":103},[4663],{"nctId":4664,"briefTitle":4665,"status":174,"phases":4666,"primaryCompletion":52,"completion":52,"start":4667,"enrollment":4668,"conditions":4669,"interventions":4670},"NCT04551222","The Re-Prosper HF Study",[92,93],"2021-06-09",99,[254],[4644],{"trials":4672,"activeCount":103},[],{"trials":4674,"activeCount":103},[],{"intervention":256,"totalTrials":132,"cells":4676},{"EARLY_PHASE1":4677,"PHASE1":4679,"PHASE2":4681,"PHASE3":4691,"PHASE4":4697,"NA":4699},{"trials":4678,"activeCount":103},[],{"trials":4680,"activeCount":103},[],{"trials":4682,"activeCount":103},[4683],{"nctId":4684,"briefTitle":4685,"status":174,"phases":4686,"primaryCompletion":4687,"completion":4687,"start":4688,"enrollment":2797,"conditions":4689,"interventions":4690},"NCT02458469","Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI",[92],"2019-04-12","2015-05-14",[30,238],[256,3334],{"trials":4692,"activeCount":103},[4693],{"nctId":244,"briefTitle":245,"status":246,"phases":4694,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":4695,"interventions":4696},[93],[253,254],[219,256],{"trials":4698,"activeCount":103},[],{"trials":4700,"activeCount":103},[],{"intervention":3334,"totalTrials":132,"cells":4702},{"EARLY_PHASE1":4703,"PHASE1":4705,"PHASE2":4707,"PHASE3":4713,"PHASE4":4719,"NA":4721},{"trials":4704,"activeCount":103},[],{"trials":4706,"activeCount":103},[],{"trials":4708,"activeCount":103},[4709],{"nctId":4684,"briefTitle":4685,"status":174,"phases":4710,"primaryCompletion":4687,"completion":4687,"start":4688,"enrollment":2797,"conditions":4711,"interventions":4712},[92],[30,238],[256,3334],{"trials":4714,"activeCount":103},[4715],{"nctId":3326,"briefTitle":3327,"status":174,"phases":4716,"primaryCompletion":3329,"completion":3329,"start":3330,"enrollment":3331,"conditions":4717,"interventions":4718},[93],[289],[3334,3335],{"trials":4720,"activeCount":103},[],{"trials":4722,"activeCount":103},[],{"intervention":4724,"totalTrials":240,"cells":4725},"Salsalate",{"EARLY_PHASE1":4726,"PHASE1":4728,"PHASE2":4730,"PHASE3":4732,"PHASE4":4745,"NA":4747},{"trials":4727,"activeCount":103},[],{"trials":4729,"activeCount":103},[],{"trials":4731,"activeCount":103},[],{"trials":4733,"activeCount":103},[4734],{"nctId":4735,"briefTitle":4736,"status":174,"phases":4737,"primaryCompletion":4738,"completion":4739,"start":356,"enrollment":4740,"conditions":4741,"interventions":4744},"NCT00330733","Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk",[92,93],"2010-08","2010-09",71,[952,147,1734,4742,4743],"Insulin Resistance","Noninsulin-dependent Diabetes Mellitus",[4724],{"trials":4746,"activeCount":103},[],{"trials":4748,"activeCount":103},[],{"intervention":4750,"totalTrials":240,"cells":4751},"Prasugrel",{"EARLY_PHASE1":4752,"PHASE1":4754,"PHASE2":4756,"PHASE3":4758,"PHASE4":4770,"NA":4772},{"trials":4753,"activeCount":103},[],{"trials":4755,"activeCount":103},[],{"trials":4757,"activeCount":103},[],{"trials":4759,"activeCount":103},[4760],{"nctId":4761,"briefTitle":4762,"status":174,"phases":4763,"primaryCompletion":4764,"completion":4765,"start":4766,"enrollment":1600,"conditions":4767,"interventions":4769},"NCT01560780","Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis",[93],"2018-04-30","2018-05-31","2013-02-01",[4768],"Coronary Artery Bypass",[4750],{"trials":4771,"activeCount":103},[],{"trials":4773,"activeCount":103},[],{"intervention":4775,"totalTrials":240,"cells":4776},"Hydrochlorothiazide",{"EARLY_PHASE1":4777,"PHASE1":4779,"PHASE2":4781,"PHASE3":4783,"PHASE4":4795,"NA":4797},{"trials":4778,"activeCount":103},[],{"trials":4780,"activeCount":103},[],{"trials":4782,"activeCount":103},[],{"trials":4784,"activeCount":103},[4785],{"nctId":4786,"briefTitle":4787,"status":174,"phases":4788,"primaryCompletion":1912,"completion":4789,"start":4790,"enrollment":4791,"conditions":4792,"interventions":4793},"NCT02185417","Diuretic Comparison Project",[93],"2022-12-29","2016-06-15",20723,[974],[4775,4794],"Chlorthalidone",{"trials":4796,"activeCount":103},[],{"trials":4798,"activeCount":103},[],{"intervention":4794,"totalTrials":240,"cells":4800},{"EARLY_PHASE1":4801,"PHASE1":4803,"PHASE2":4805,"PHASE3":4807,"PHASE4":4813,"NA":4815},{"trials":4802,"activeCount":103},[],{"trials":4804,"activeCount":103},[],{"trials":4806,"activeCount":103},[],{"trials":4808,"activeCount":103},[4809],{"nctId":4786,"briefTitle":4787,"status":174,"phases":4810,"primaryCompletion":1912,"completion":4789,"start":4790,"enrollment":4791,"conditions":4811,"interventions":4812},[93],[974],[4775,4794],{"trials":4814,"activeCount":103},[],{"trials":4816,"activeCount":103},[],{"intervention":4818,"totalTrials":240,"cells":4819},"Cholinesterase inhibitor",{"EARLY_PHASE1":4820,"PHASE1":4822,"PHASE2":4824,"PHASE3":4826,"PHASE4":4837,"NA":4839},{"trials":4821,"activeCount":103},[],{"trials":4823,"activeCount":103},[],{"trials":4825,"activeCount":103},[],{"trials":4827,"activeCount":103},[4828],{"nctId":4829,"briefTitle":4830,"status":174,"phases":4831,"primaryCompletion":2053,"completion":2053,"start":4832,"enrollment":4833,"conditions":4834,"interventions":4835},"NCT02248636","Cholinesterase Inhibitor Discontinuation",[92,93],"2015-01-22",72,[196],[4818,4836],"Sham discontinuation",{"trials":4838,"activeCount":103},[],{"trials":4840,"activeCount":103},[],{"intervention":4836,"totalTrials":240,"cells":4842},{"EARLY_PHASE1":4843,"PHASE1":4845,"PHASE2":4847,"PHASE3":4849,"PHASE4":4855,"NA":4857},{"trials":4844,"activeCount":103},[],{"trials":4846,"activeCount":103},[],{"trials":4848,"activeCount":103},[],{"trials":4850,"activeCount":103},[4851],{"nctId":4829,"briefTitle":4830,"status":174,"phases":4852,"primaryCompletion":2053,"completion":2053,"start":4832,"enrollment":4833,"conditions":4853,"interventions":4854},[92,93],[196],[4818,4836],{"trials":4856,"activeCount":103},[],{"trials":4858,"activeCount":103},[],{"intervention":4860,"totalTrials":240,"cells":4861},"Zonisamide",{"EARLY_PHASE1":4862,"PHASE1":4864,"PHASE2":4866,"PHASE3":4868,"PHASE4":4878,"NA":4880},{"trials":4863,"activeCount":103},[],{"trials":4865,"activeCount":103},[],{"trials":4867,"activeCount":103},[],{"trials":4869,"activeCount":103},[4870],{"nctId":4871,"briefTitle":4872,"status":246,"phases":4873,"primaryCompletion":4874,"completion":4874,"start":4875,"enrollment":4109,"conditions":4876,"interventions":4877},"NCT02368431","Effectiveness of Zonisamide in Alcohol Dependent Veterans",[93],"2018-10-01","2015-03-01",[1302],[4860],{"trials":4879,"activeCount":103},[],{"trials":4881,"activeCount":103},[],{"intervention":4883,"totalTrials":240,"cells":4884},"Convalescent Plasma",{"EARLY_PHASE1":4885,"PHASE1":4887,"PHASE2":4889,"PHASE3":4891,"PHASE4":4902,"NA":4904},{"trials":4886,"activeCount":103},[],{"trials":4888,"activeCount":103},[],{"trials":4890,"activeCount":103},[],{"trials":4892,"activeCount":103},[4893],{"nctId":4894,"briefTitle":4895,"status":246,"phases":4896,"primaryCompletion":4897,"completion":4898,"start":1769,"enrollment":1669,"conditions":4899,"interventions":4901},"NCT04539275","VA CoronavirUs Research and Efficacy Studies-1",[93],"2021-06-30","2021-09-30",[4900],"COVID-19",[4883],{"trials":4903,"activeCount":103},[],{"trials":4905,"activeCount":103},[],{"intervention":4638,"totalTrials":240,"cells":4907},{"EARLY_PHASE1":4908,"PHASE1":4910,"PHASE2":4912,"PHASE3":4914,"PHASE4":4920,"NA":4922},{"trials":4909,"activeCount":103},[],{"trials":4911,"activeCount":103},[],{"trials":4913,"activeCount":103},[],{"trials":4915,"activeCount":103},[4916],{"nctId":4633,"briefTitle":4634,"status":174,"phases":4917,"primaryCompletion":3144,"completion":3144,"start":248,"enrollment":22,"conditions":4918,"interventions":4919},[93],[3147],[4638,4612],{"trials":4921,"activeCount":103},[],{"trials":4923,"activeCount":103},[],{"intervention":4925,"totalTrials":240,"cells":4926},"Endocalyx",{"EARLY_PHASE1":4927,"PHASE1":4929,"PHASE2":4931,"PHASE3":4933,"PHASE4":4946,"NA":4948},{"trials":4928,"activeCount":103},[],{"trials":4930,"activeCount":103},[],{"trials":4932,"activeCount":103},[],{"trials":4934,"activeCount":103},[4935],{"nctId":4936,"briefTitle":4937,"status":174,"phases":4938,"primaryCompletion":4939,"completion":4940,"start":4941,"enrollment":4942,"conditions":4943,"interventions":4945},"NCT05205005","Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes",[92,93],"2024-03-31","2024-07-31","2022-05-25",24,[4944],"Diabetes Mellitus, Type 2",[4925],{"trials":4947,"activeCount":103},[],{"trials":4949,"activeCount":103},[],{"intervention":4951,"totalTrials":240,"cells":4952},"Ubiquinol",{"EARLY_PHASE1":4953,"PHASE1":4955,"PHASE2":4957,"PHASE3":4959,"PHASE4":4971,"NA":4973},{"trials":4954,"activeCount":103},[],{"trials":4956,"activeCount":103},[],{"trials":4958,"activeCount":103},[],{"trials":4960,"activeCount":103},[4961],{"nctId":4962,"briefTitle":4963,"status":174,"phases":4964,"primaryCompletion":4965,"completion":4966,"start":4967,"enrollment":265,"conditions":4968,"interventions":4970},"NCT02865460","Coenzyme Q10 Phase III Trial in Gulf War Illness",[93],"2020-10-07","2020-12-31","2017-07-24",[2297,2409,4951,4969],"Coenzyme Q10",[4951],{"trials":4972,"activeCount":103},[],{"trials":4974,"activeCount":103},[],{"intervention":4976,"totalTrials":240,"cells":4977},"Inactive Substance",{"EARLY_PHASE1":4978,"PHASE1":4980,"PHASE2":4982,"PHASE3":4984,"PHASE4":4998,"NA":5000},{"trials":4979,"activeCount":103},[],{"trials":4981,"activeCount":103},[],{"trials":4983,"activeCount":103},[],{"trials":4985,"activeCount":103},[4986],{"nctId":4987,"briefTitle":4988,"status":174,"phases":4989,"primaryCompletion":4990,"completion":4991,"start":4992,"enrollment":4993,"conditions":4994,"interventions":4996},"NCT01283009","Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)",[93],"2016-07-31","2016-08-31","2012-01-09",584,[4995],"Community Acquired Respiratory Disease Syndrome",[4976,4997],"Methylprednisolone",{"trials":4999,"activeCount":103},[],{"trials":5001,"activeCount":103},[],{"intervention":4997,"totalTrials":240,"cells":5003},{"EARLY_PHASE1":5004,"PHASE1":5006,"PHASE2":5008,"PHASE3":5010,"PHASE4":5016,"NA":5018},{"trials":5005,"activeCount":103},[],{"trials":5007,"activeCount":103},[],{"trials":5009,"activeCount":103},[],{"trials":5011,"activeCount":103},[5012],{"nctId":4987,"briefTitle":4988,"status":174,"phases":5013,"primaryCompletion":4990,"completion":4991,"start":4992,"enrollment":4993,"conditions":5014,"interventions":5015},[93],[4995],[4976,4997],{"trials":5017,"activeCount":103},[],{"trials":5019,"activeCount":103},[],{"intervention":5021,"totalTrials":240,"cells":5022},"Testosterone Patches",{"EARLY_PHASE1":5023,"PHASE1":5025,"PHASE2":5027,"PHASE3":5029,"PHASE4":5039,"NA":5041},{"trials":5024,"activeCount":103},[],{"trials":5026,"activeCount":103},[],{"trials":5028,"activeCount":103},[],{"trials":5030,"activeCount":103},[5031],{"nctId":5032,"briefTitle":5033,"status":174,"phases":5034,"primaryCompletion":5035,"completion":5035,"start":5036,"enrollment":3272,"conditions":5037,"interventions":5038},"NCT01652040","Resistance Training and Testosterone After Spinal Cord Injury",[92,93],"2017-12-30","2012-07-02",[30],[5021],{"trials":5040,"activeCount":103},[],{"trials":5042,"activeCount":103},[],{"intervention":4534,"totalTrials":240,"cells":5044},{"EARLY_PHASE1":5045,"PHASE1":5047,"PHASE2":5049,"PHASE3":5051,"PHASE4":5057,"NA":5059},{"trials":5046,"activeCount":103},[],{"trials":5048,"activeCount":103},[],{"trials":5050,"activeCount":103},[],{"trials":5052,"activeCount":103},[5053],{"nctId":4526,"briefTitle":4527,"status":174,"phases":5054,"primaryCompletion":4529,"completion":4529,"start":4530,"enrollment":4531,"conditions":5055,"interventions":5056},[93],[4111],[4534,4535,4536,953],{"trials":5058,"activeCount":103},[],{"trials":5060,"activeCount":103},[],{"intervention":4535,"totalTrials":240,"cells":5062},{"EARLY_PHASE1":5063,"PHASE1":5065,"PHASE2":5067,"PHASE3":5069,"PHASE4":5075,"NA":5077},{"trials":5064,"activeCount":103},[],{"trials":5066,"activeCount":103},[],{"trials":5068,"activeCount":103},[],{"trials":5070,"activeCount":103},[5071],{"nctId":4526,"briefTitle":4527,"status":174,"phases":5072,"primaryCompletion":4529,"completion":4529,"start":4530,"enrollment":4531,"conditions":5073,"interventions":5074},[93],[4111],[4534,4535,4536,953],{"trials":5076,"activeCount":103},[],{"trials":5078,"activeCount":103},[],{"intervention":4536,"totalTrials":240,"cells":5080},{"EARLY_PHASE1":5081,"PHASE1":5083,"PHASE2":5085,"PHASE3":5087,"PHASE4":5093,"NA":5095},{"trials":5082,"activeCount":103},[],{"trials":5084,"activeCount":103},[],{"trials":5086,"activeCount":103},[],{"trials":5088,"activeCount":103},[5089],{"nctId":4526,"briefTitle":4527,"status":174,"phases":5090,"primaryCompletion":4529,"completion":4529,"start":4530,"enrollment":4531,"conditions":5091,"interventions":5092},[93],[4111],[4534,4535,4536,953],{"trials":5094,"activeCount":103},[],{"trials":5096,"activeCount":103},[],{"intervention":5098,"totalTrials":240,"cells":5099},"solifenacin",{"EARLY_PHASE1":5100,"PHASE1":5102,"PHASE2":5104,"PHASE3":5106,"PHASE4":5117,"NA":5119},{"trials":5101,"activeCount":103},[],{"trials":5103,"activeCount":103},[],{"trials":5105,"activeCount":103},[],{"trials":5107,"activeCount":103},[5108],{"nctId":5109,"briefTitle":5110,"status":174,"phases":5111,"primaryCompletion":5112,"completion":5112,"start":5113,"enrollment":5114,"conditions":5115,"interventions":5116},"NCT03149809","Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease",[93],"2023-09-08","2018-03-01",77,[814,815],[5098],{"trials":5118,"activeCount":103},[],{"trials":5120,"activeCount":103},[],{"intervention":5122,"totalTrials":240,"cells":5123},"Divalproex",{"EARLY_PHASE1":5124,"PHASE1":5126,"PHASE2":5128,"PHASE3":5130,"PHASE4":5142,"NA":5144},{"trials":5125,"activeCount":103},[],{"trials":5127,"activeCount":103},[],{"trials":5129,"activeCount":103},[],{"trials":5131,"activeCount":103},[5132],{"nctId":5133,"briefTitle":5134,"status":174,"phases":5135,"primaryCompletion":5136,"completion":5137,"start":5138,"enrollment":5139,"conditions":5140,"interventions":5141},"NCT00108576","Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder)",[93],"2005-08","2005-09","2003-10",101,[18],[5122],{"trials":5143,"activeCount":103},[],{"trials":5145,"activeCount":103},[],{"intervention":5147,"totalTrials":240,"cells":5148},"Paroxetine",{"EARLY_PHASE1":5149,"PHASE1":5151,"PHASE2":5153,"PHASE3":5155,"PHASE4":5166,"NA":5168},{"trials":5150,"activeCount":103},[],{"trials":5152,"activeCount":103},[],{"trials":5154,"activeCount":103},[],{"trials":5156,"activeCount":103},[5157],{"nctId":5158,"briefTitle":5159,"status":174,"phases":5160,"primaryCompletion":5161,"completion":5161,"start":5162,"enrollment":5163,"conditions":5164,"interventions":5165},"NCT00403455","Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities",[93],"2011-07","2006-10",38,[18],[5147],{"trials":5167,"activeCount":103},[],{"trials":5169,"activeCount":103},[],{"intervention":5171,"totalTrials":240,"cells":5172},"IV isotonic saline",{"EARLY_PHASE1":5173,"PHASE1":5175,"PHASE2":5177,"PHASE3":5179,"PHASE4":5194,"NA":5196},{"trials":5174,"activeCount":103},[],{"trials":5176,"activeCount":103},[],{"trials":5178,"activeCount":103},[],{"trials":5180,"activeCount":103},[5181],{"nctId":5182,"briefTitle":5183,"status":174,"phases":5184,"primaryCompletion":5185,"completion":5186,"start":5187,"enrollment":5188,"conditions":5189,"interventions":5191},"NCT01467466","Prevention of Serious Adverse Events Following Angiography",[93],"2017-09-29","2017-10-17","2013-10-07",5177,[5190,148,445],"Acute Renal Failure",[5171,5192,5193],"IV isotonic bicarbonate","N-acetylcysteine",{"trials":5195,"activeCount":103},[],{"trials":5197,"activeCount":103},[],{"intervention":5192,"totalTrials":240,"cells":5199},{"EARLY_PHASE1":5200,"PHASE1":5202,"PHASE2":5204,"PHASE3":5206,"PHASE4":5212,"NA":5214},{"trials":5201,"activeCount":103},[],{"trials":5203,"activeCount":103},[],{"trials":5205,"activeCount":103},[],{"trials":5207,"activeCount":103},[5208],{"nctId":5182,"briefTitle":5183,"status":174,"phases":5209,"primaryCompletion":5185,"completion":5186,"start":5187,"enrollment":5188,"conditions":5210,"interventions":5211},[93],[5190,148,445],[5171,5192,5193],{"trials":5213,"activeCount":103},[],{"trials":5215,"activeCount":103},[],{"intervention":5193,"totalTrials":240,"cells":5217},{"EARLY_PHASE1":5218,"PHASE1":5220,"PHASE2":5222,"PHASE3":5224,"PHASE4":5230,"NA":5232},{"trials":5219,"activeCount":103},[],{"trials":5221,"activeCount":103},[],{"trials":5223,"activeCount":103},[],{"trials":5225,"activeCount":103},[5226],{"nctId":5182,"briefTitle":5183,"status":174,"phases":5227,"primaryCompletion":5185,"completion":5186,"start":5187,"enrollment":5188,"conditions":5228,"interventions":5229},[93],[5190,148,445],[5171,5192,5193],{"trials":5231,"activeCount":103},[],{"trials":5233,"activeCount":103},[],{"intervention":5235,"totalTrials":240,"cells":5236},"Lithium",{"EARLY_PHASE1":5237,"PHASE1":5239,"PHASE2":5241,"PHASE3":5243,"PHASE4":5258,"NA":5260},{"trials":5238,"activeCount":103},[],{"trials":5240,"activeCount":103},[],{"trials":5242,"activeCount":103},[],{"trials":5244,"activeCount":103},[5245],{"nctId":5246,"briefTitle":5247,"status":246,"phases":5248,"primaryCompletion":5249,"completion":5249,"start":5250,"enrollment":5251,"conditions":5252,"interventions":5257},"NCT01928446","Lithium for Suicidal Behavior in Mood Disorders",[92,93],"2019-08-13","2015-07-08",519,[5253,5254,5255,5256],"Depressive Disorder","Bipolar Disorder","Suicide","Suicide, Attempted",[5235],{"trials":5259,"activeCount":103},[],{"trials":5261,"activeCount":103},[],{"intervention":5263,"totalTrials":240,"cells":5264},"Fecal Microbiota Therapy",{"EARLY_PHASE1":5265,"PHASE1":5267,"PHASE2":5269,"PHASE3":5271,"PHASE4":5283,"NA":5285},{"trials":5266,"activeCount":103},[],{"trials":5268,"activeCount":103},[],{"trials":5270,"activeCount":103},[],{"trials":5272,"activeCount":103},[5273],{"nctId":5274,"briefTitle":5275,"status":246,"phases":5276,"primaryCompletion":5277,"completion":2695,"start":5278,"enrollment":5279,"conditions":5280,"interventions":5282},"NCT03005379","Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)",[92,93],"2022-08-30","2018-11-15",153,[5281],"Clostridium Difficile Infection",[5263],{"trials":5284,"activeCount":103},[],{"trials":5286,"activeCount":103},[],{"intervention":3113,"totalTrials":240,"cells":5288},{"EARLY_PHASE1":5289,"PHASE1":5291,"PHASE2":5293,"PHASE3":5295,"PHASE4":5301,"NA":5303},{"trials":5290,"activeCount":103},[],{"trials":5292,"activeCount":103},[],{"trials":5294,"activeCount":103},[],{"trials":5296,"activeCount":103},[5297],{"nctId":3104,"briefTitle":3105,"status":174,"phases":5298,"primaryCompletion":3107,"completion":3107,"start":3108,"enrollment":3109,"conditions":5299,"interventions":5300},[93],[3111],[3082,3113],{"trials":5302,"activeCount":103},[],{"trials":5304,"activeCount":103},[],{"intervention":5306,"totalTrials":240,"cells":5307},"icosapent ethyl",{"EARLY_PHASE1":5308,"PHASE1":5310,"PHASE2":5312,"PHASE3":5314,"PHASE4":5325,"NA":5327},{"trials":5309,"activeCount":103},[],{"trials":5311,"activeCount":103},[],{"trials":5313,"activeCount":103},[],{"trials":5315,"activeCount":103},[5316],{"nctId":5317,"briefTitle":5318,"status":174,"phases":5319,"primaryCompletion":5320,"completion":5320,"start":5321,"enrollment":5322,"conditions":5323,"interventions":5324},"NCT02719327","Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid",[92,93],"2023-09-29","2017-06-08",131,[194],[5306],{"trials":5326,"activeCount":103},[],{"trials":5328,"activeCount":103},[],{"intervention":5330,"totalTrials":240,"cells":5331},"Metformin Hydrochloride",{"EARLY_PHASE1":5332,"PHASE1":5334,"PHASE2":5336,"PHASE3":5338,"PHASE4":5349,"NA":5351},{"trials":5333,"activeCount":103},[],{"trials":5335,"activeCount":103},[],{"trials":5337,"activeCount":103},[],{"trials":5339,"activeCount":103},[5340],{"nctId":5341,"briefTitle":5342,"status":174,"phases":5343,"primaryCompletion":5344,"completion":5344,"start":5345,"enrollment":3656,"conditions":5346,"interventions":5348},"NCT04221750","Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors",[93],"2025-07-31","2021-05-14",[2697,5347,2924],"Sarcopenic Obesity",[5330],{"trials":5350,"activeCount":103},[],{"trials":5352,"activeCount":103},[],{"intervention":5354,"totalTrials":240,"cells":5355},"Vitamin D",{"EARLY_PHASE1":5356,"PHASE1":5358,"PHASE2":5360,"PHASE3":5362,"PHASE4":5372,"NA":5374},{"trials":5357,"activeCount":103},[],{"trials":5359,"activeCount":103},[],{"trials":5361,"activeCount":103},[],{"trials":5363,"activeCount":103},[5364],{"nctId":5365,"briefTitle":5366,"status":174,"phases":5367,"primaryCompletion":5368,"completion":5368,"start":5369,"enrollment":4429,"conditions":5370,"interventions":5371},"NCT05008484","Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury.",[92,93],"2024-06-13","2021-10-01",[30],[5354],{"trials":5373,"activeCount":103},[],{"trials":5375,"activeCount":103},[],{"intervention":5377,"totalTrials":240,"cells":5378},"Switching: Bupropion-SR",{"EARLY_PHASE1":5379,"PHASE1":5381,"PHASE2":5383,"PHASE3":5385,"PHASE4":5398,"NA":5400},{"trials":5380,"activeCount":103},[],{"trials":5382,"activeCount":103},[],{"trials":5384,"activeCount":103},[],{"trials":5386,"activeCount":103},[5387],{"nctId":5388,"briefTitle":5389,"status":174,"phases":5390,"primaryCompletion":4601,"completion":5391,"start":5392,"enrollment":5393,"conditions":5394,"interventions":5395},"NCT01421342","VA Augmentation and Switching Treatments for Improving Depression Outcomes",[93],"2016-06","2012-12",1522,[3274],[5377,5396,5397],"Augmenting: Antidepressant + Bupropion-SR","Augmenting: Antidepressant + Aripiprazole",{"trials":5399,"activeCount":103},[],{"trials":5401,"activeCount":103},[],{"intervention":5396,"totalTrials":240,"cells":5403},{"EARLY_PHASE1":5404,"PHASE1":5406,"PHASE2":5408,"PHASE3":5410,"PHASE4":5416,"NA":5418},{"trials":5405,"activeCount":103},[],{"trials":5407,"activeCount":103},[],{"trials":5409,"activeCount":103},[],{"trials":5411,"activeCount":103},[5412],{"nctId":5388,"briefTitle":5389,"status":174,"phases":5413,"primaryCompletion":4601,"completion":5391,"start":5392,"enrollment":5393,"conditions":5414,"interventions":5415},[93],[3274],[5377,5396,5397],{"trials":5417,"activeCount":103},[],{"trials":5419,"activeCount":103},[],{"intervention":5397,"totalTrials":240,"cells":5421},{"EARLY_PHASE1":5422,"PHASE1":5424,"PHASE2":5426,"PHASE3":5428,"PHASE4":5434,"NA":5436},{"trials":5423,"activeCount":103},[],{"trials":5425,"activeCount":103},[],{"trials":5427,"activeCount":103},[],{"trials":5429,"activeCount":103},[5430],{"nctId":5388,"briefTitle":5389,"status":174,"phases":5431,"primaryCompletion":4601,"completion":5391,"start":5392,"enrollment":5393,"conditions":5432,"interventions":5433},[93],[3274],[5377,5396,5397],{"trials":5435,"activeCount":103},[],{"trials":5437,"activeCount":103},[],{"intervention":5439,"totalTrials":240,"cells":5440},"gemfibrozil",{"EARLY_PHASE1":5441,"PHASE1":5443,"PHASE2":5445,"PHASE3":5447,"PHASE4":5460,"NA":5462},{"trials":5442,"activeCount":103},[],{"trials":5444,"activeCount":103},[],{"trials":5446,"activeCount":103},[],{"trials":5448,"activeCount":103},[5449],{"nctId":5450,"briefTitle":5451,"status":174,"phases":5452,"primaryCompletion":5453,"completion":5454,"start":5455,"enrollment":5456,"conditions":5457,"interventions":5459},"NCT00283335","The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol",[93],"1998-09","1999-08","1991-06",2531,[5458],"Coronary Heart Disease",[5439],{"trials":5461,"activeCount":103},[],{"trials":5463,"activeCount":103},[],{"intervention":5465,"totalTrials":240,"cells":5466},"Docetaxel",{"EARLY_PHASE1":5467,"PHASE1":5469,"PHASE2":5471,"PHASE3":5473,"PHASE4":5486,"NA":5488},{"trials":5468,"activeCount":103},[],{"trials":5470,"activeCount":103},[],{"trials":5472,"activeCount":103},[],{"trials":5474,"activeCount":103},[5475],{"nctId":5476,"briefTitle":5477,"status":174,"phases":5478,"primaryCompletion":5479,"completion":5480,"start":5481,"enrollment":5482,"conditions":5483,"interventions":5484},"NCT00132301","Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma",[93],"2015-10","2016-09","2006-06",298,[1373],[5465,5485],"Prednisone",{"trials":5487,"activeCount":103},[],{"trials":5489,"activeCount":103},[],{"intervention":5485,"totalTrials":240,"cells":5491},{"EARLY_PHASE1":5492,"PHASE1":5494,"PHASE2":5496,"PHASE3":5498,"PHASE4":5504,"NA":5506},{"trials":5493,"activeCount":103},[],{"trials":5495,"activeCount":103},[],{"trials":5497,"activeCount":103},[],{"trials":5499,"activeCount":103},[5500],{"nctId":5476,"briefTitle":5477,"status":174,"phases":5501,"primaryCompletion":5479,"completion":5480,"start":5481,"enrollment":5482,"conditions":5502,"interventions":5503},[93],[1373],[5465,5485],{"trials":5505,"activeCount":103},[],{"trials":5507,"activeCount":103},[],{"intervention":5509,"totalTrials":240,"cells":5510},"Rivastigmine Transdermal Patch",{"EARLY_PHASE1":5511,"PHASE1":5513,"PHASE2":5515,"PHASE3":5517,"PHASE4":5528,"NA":5530},{"trials":5512,"activeCount":103},[],{"trials":5514,"activeCount":103},[],{"trials":5516,"activeCount":103},[],{"trials":5518,"activeCount":103},[5519],{"nctId":5520,"briefTitle":5521,"status":174,"phases":5522,"primaryCompletion":5391,"completion":5523,"start":5392,"enrollment":5524,"conditions":5525,"interventions":5527},"NCT01670526","Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI",[93],"2017-09",94,[2865,5526],"Cognitive Impairment",[5509],{"trials":5529,"activeCount":103},[],{"trials":5531,"activeCount":103},[],{"intervention":5533,"totalTrials":240,"cells":5534},"N-Nitro L-arginine-methylester",{"EARLY_PHASE1":5535,"PHASE1":5537,"PHASE2":5539,"PHASE3":5541,"PHASE4":5552,"NA":5554},{"trials":5536,"activeCount":103},[],{"trials":5538,"activeCount":103},[],{"trials":5540,"activeCount":103},[],{"trials":5542,"activeCount":103},[5543],{"nctId":5544,"briefTitle":5545,"status":174,"phases":5546,"primaryCompletion":4738,"completion":4738,"start":5547,"enrollment":5548,"conditions":5549,"interventions":5551},"NCT00753948","Exhaled Levels of Nitric Oxide",[92,93],"2006-12",23,[5550,3632],"Tetraplegia",[5533],{"trials":5553,"activeCount":103},[],{"trials":5555,"activeCount":103},[],{"intervention":5557,"totalTrials":240,"cells":5558},"Timolol",{"EARLY_PHASE1":5559,"PHASE1":5561,"PHASE2":5563,"PHASE3":5565,"PHASE4":5580,"NA":5582},{"trials":5560,"activeCount":103},[],{"trials":5562,"activeCount":103},[],{"trials":5564,"activeCount":103},[],{"trials":5566,"activeCount":103},[5567],{"nctId":5568,"briefTitle":5569,"status":174,"phases":5570,"primaryCompletion":5571,"completion":5572,"start":5573,"enrollment":2270,"conditions":5574,"interventions":5578},"NCT03282981","Beta Adrenergic Antagonist for the Healing of Chronic DFU",[93],"2023-12-01","2024-04-30","2018-07-24",[5575,5576,5577],"Chronic Diabetic Foot Ulcers","Diabetic Neuropathic Ulcers","Non Healing Wound",[5557,5579],"Non biologically active gel",{"trials":5581,"activeCount":103},[],{"trials":5583,"activeCount":103},[],{"intervention":5579,"totalTrials":240,"cells":5585},{"EARLY_PHASE1":5586,"PHASE1":5588,"PHASE2":5590,"PHASE3":5592,"PHASE4":5598,"NA":5600},{"trials":5587,"activeCount":103},[],{"trials":5589,"activeCount":103},[],{"trials":5591,"activeCount":103},[],{"trials":5593,"activeCount":103},[5594],{"nctId":5568,"briefTitle":5569,"status":174,"phases":5595,"primaryCompletion":5571,"completion":5572,"start":5573,"enrollment":2270,"conditions":5596,"interventions":5597},[93],[5575,5576,5577],[5557,5579],{"trials":5599,"activeCount":103},[],{"trials":5601,"activeCount":103},[],{"intervention":5603,"totalTrials":240,"cells":5604},"Soy Supplement",{"EARLY_PHASE1":5605,"PHASE1":5607,"PHASE2":5609,"PHASE3":5611,"PHASE4":5623,"NA":5625},{"trials":5606,"activeCount":103},[],{"trials":5608,"activeCount":103},[],{"trials":5610,"activeCount":103},[],{"trials":5612,"activeCount":103},[5613],{"nctId":5614,"briefTitle":5615,"status":174,"phases":5616,"primaryCompletion":5617,"completion":5618,"start":5137,"enrollment":5619,"conditions":5620,"interventions":5622},"NCT00255125","Role of Soy Supplementation in Prostate Cancer Development",[93],"2009-04","2009-10",86,[5621],"Prostate Neoplasm",[5603],{"trials":5624,"activeCount":103},[],{"trials":5626,"activeCount":103},[],{"intervention":5628,"totalTrials":240,"cells":5629},"Testosterone Transdermal System",{"EARLY_PHASE1":5630,"PHASE1":5632,"PHASE2":5634,"PHASE3":5636,"PHASE4":5647,"NA":5649},{"trials":5631,"activeCount":103},[],{"trials":5633,"activeCount":103},[],{"trials":5635,"activeCount":103},[],{"trials":5637,"activeCount":103},[5638],{"nctId":5639,"briefTitle":5640,"status":174,"phases":5641,"primaryCompletion":5642,"completion":5392,"start":5643,"enrollment":5644,"conditions":5645,"interventions":5646},"NCT00266864","Testosterone Replacement Therapy in Chronic Spinal Cord Injury",[92,93],"2012-08","2003-08",31,[30,380],[5628],{"trials":5648,"activeCount":103},[],{"trials":5650,"activeCount":103},[],{"intervention":5652,"totalTrials":220,"cells":5653},"Vitamin D3",{"EARLY_PHASE1":5654,"PHASE1":5656,"PHASE2":5658,"PHASE3":5688,"PHASE4":5690,"NA":5692},{"trials":5655,"activeCount":103},[],{"trials":5657,"activeCount":103},[],{"trials":5659,"activeCount":103},[5660,5670,5679],{"nctId":5661,"briefTitle":5662,"status":174,"phases":5663,"primaryCompletion":5664,"completion":5665,"start":5666,"enrollment":9,"conditions":5667,"interventions":5668},"NCT00953225","Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer",[92],"2013-12-15","2014-10-30","2010-01-07",[1373],[5669],"vitamin D3",{"nctId":5671,"briefTitle":5672,"status":174,"phases":5673,"primaryCompletion":5674,"completion":5675,"start":5676,"enrollment":2922,"conditions":5677,"interventions":5678},"NCT01759771","Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial",[92],"2018-10-18","2020-05-11","2013-01-03",[1373],[5652],{"nctId":5680,"briefTitle":5681,"status":174,"phases":5682,"primaryCompletion":5683,"completion":5683,"start":5684,"enrollment":5139,"conditions":5685,"interventions":5687},"NCT01119131","Effects of Vitamin D in Parkinson's Disease (PD)",[92],"2015-01","2011-05",[815,5686],"Accidental Falls",[5652],{"trials":5689,"activeCount":103},[],{"trials":5691,"activeCount":103},[],{"trials":5693,"activeCount":103},[],{"intervention":5695,"totalTrials":132,"cells":5696},"Oxytocin",{"EARLY_PHASE1":5697,"PHASE1":5699,"PHASE2":5701,"PHASE3":5719,"PHASE4":5721,"NA":5723},{"trials":5698,"activeCount":103},[],{"trials":5700,"activeCount":103},[],{"trials":5702,"activeCount":103},[5703,5710],{"nctId":5704,"briefTitle":5705,"status":246,"phases":5706,"primaryCompletion":1731,"completion":1731,"start":5707,"enrollment":3272,"conditions":5708,"interventions":5709},"NCT03900754","A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia",[92],"2020-01-13",[33],[5695],{"nctId":5711,"briefTitle":5712,"status":174,"phases":5713,"primaryCompletion":5714,"completion":5715,"start":5716,"enrollment":3123,"conditions":5717,"interventions":5718},"NCT04228289","Oxytocin to Treat PTSD",[92],"2025-02-28","2025-08-31","2021-01-01",[18],[5695],{"trials":5720,"activeCount":103},[],{"trials":5722,"activeCount":103},[],{"trials":5724,"activeCount":103},[],{"intervention":5726,"totalTrials":132,"cells":5727},"Doxazosin",{"EARLY_PHASE1":5728,"PHASE1":5730,"PHASE2":5732,"PHASE3":5753,"PHASE4":5755,"NA":5757},{"trials":5729,"activeCount":103},[],{"trials":5731,"activeCount":103},[],{"trials":5733,"activeCount":103},[5734,5744],{"nctId":5735,"briefTitle":5736,"status":174,"phases":5737,"primaryCompletion":5738,"completion":5739,"start":5740,"enrollment":34,"conditions":5741,"interventions":5743},"NCT01953432","Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse",[92],"2017-09-01","2017-10-01","2014-04-01",[5742],"Cocaine Dependence",[5726],{"nctId":5745,"briefTitle":5746,"status":174,"phases":5747,"primaryCompletion":5748,"completion":5748,"start":2659,"enrollment":5749,"conditions":5750,"interventions":5751},"NCT02500602","CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders",[92],"2019-12-16",144,[24,3126],[5752],"doxazosin",{"trials":5754,"activeCount":103},[],{"trials":5756,"activeCount":103},[],{"trials":5758,"activeCount":103},[],{"intervention":5760,"totalTrials":132,"cells":5761},"Valacyclovir",{"EARLY_PHASE1":5762,"PHASE1":5764,"PHASE2":5776,"PHASE3":5788,"PHASE4":5790,"NA":5792},{"trials":5763,"activeCount":103},[],{"trials":5765,"activeCount":103},[5766],{"nctId":5767,"briefTitle":5768,"status":174,"phases":5769,"primaryCompletion":5770,"completion":5771,"start":5772,"enrollment":5644,"conditions":5773,"interventions":5775},"NCT01453075","Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)",[91],"2015-07","2015-12","2011-11",[5774],"Chronic Hepatitis C Infection",[5760],{"trials":5777,"activeCount":103},[5778],{"nctId":5779,"briefTitle":5780,"status":174,"phases":5781,"primaryCompletion":5782,"completion":5783,"start":5784,"enrollment":5785,"conditions":5786,"interventions":5787},"NCT01580995","Herpes Simplex Type 1 Suppression in Hepatitis C",[92],"2014-12","2015-03","2012-04",19,[5774],[5760],{"trials":5789,"activeCount":103},[],{"trials":5791,"activeCount":103},[],{"trials":5793,"activeCount":103},[],{"intervention":363,"totalTrials":132,"cells":5795},{"EARLY_PHASE1":5796,"PHASE1":5798,"PHASE2":5800,"PHASE3":5810,"PHASE4":5812,"NA":5814},{"trials":5797,"activeCount":103},[],{"trials":5799,"activeCount":103},[],{"trials":5801,"activeCount":103},[5802,5806],{"nctId":351,"briefTitle":352,"status":174,"phases":5803,"primaryCompletion":354,"completion":355,"start":356,"enrollment":192,"conditions":5804,"interventions":5805},[92],[358,359,360,361],[363,269],{"nctId":365,"briefTitle":366,"status":246,"phases":5807,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":5808,"interventions":5809},[92],[30,372,373,374,375,376,377,378,379,380,381],[363,269],{"trials":5811,"activeCount":103},[],{"trials":5813,"activeCount":103},[],{"trials":5815,"activeCount":103},[],{"intervention":5817,"totalTrials":240,"cells":5818},"Cannabidiol",{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5833,"PHASE4":5835,"NA":5837},{"trials":5820,"activeCount":103},[],{"trials":5822,"activeCount":103},[],{"trials":5824,"activeCount":103},[5825],{"nctId":5826,"briefTitle":5827,"status":174,"phases":5828,"primaryCompletion":5829,"completion":5829,"start":2053,"enrollment":5830,"conditions":5831,"interventions":5832},"NCT03518801","Cannabidiol and Prolonged Exposure",[92],"2025-09-30",136,[18],[5817],{"trials":5834,"activeCount":103},[],{"trials":5836,"activeCount":103},[],{"trials":5838,"activeCount":103},[],{"intervention":5840,"totalTrials":240,"cells":5841},"N-acetylcysteine + high-dose naltrexone",{"EARLY_PHASE1":5842,"PHASE1":5844,"PHASE2":5846,"PHASE3":5860,"PHASE4":5862,"NA":5864},{"trials":5843,"activeCount":103},[],{"trials":5845,"activeCount":103},[],{"trials":5847,"activeCount":103},[5848],{"nctId":5849,"briefTitle":5850,"status":174,"phases":5851,"primaryCompletion":5852,"completion":5853,"start":5854,"enrollment":3307,"conditions":5855,"interventions":5857},"NCT01214083","N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence",[92],"2015-09-30","2016-10-30","2010-10-15",[5856],"Alcoholism",[5840,5858,5859],"High-dose naltrexone (150 mg) alone","Low-dose naltrexone (50 mg) alone",{"trials":5861,"activeCount":103},[],{"trials":5863,"activeCount":103},[],{"trials":5865,"activeCount":103},[],{"intervention":5858,"totalTrials":240,"cells":5867},{"EARLY_PHASE1":5868,"PHASE1":5870,"PHASE2":5872,"PHASE3":5878,"PHASE4":5880,"NA":5882},{"trials":5869,"activeCount":103},[],{"trials":5871,"activeCount":103},[],{"trials":5873,"activeCount":103},[5874],{"nctId":5849,"briefTitle":5850,"status":174,"phases":5875,"primaryCompletion":5852,"completion":5853,"start":5854,"enrollment":3307,"conditions":5876,"interventions":5877},[92],[5856],[5840,5858,5859],{"trials":5879,"activeCount":103},[],{"trials":5881,"activeCount":103},[],{"trials":5883,"activeCount":103},[],{"intervention":5859,"totalTrials":240,"cells":5885},{"EARLY_PHASE1":5886,"PHASE1":5888,"PHASE2":5890,"PHASE3":5896,"PHASE4":5898,"NA":5900},{"trials":5887,"activeCount":103},[],{"trials":5889,"activeCount":103},[],{"trials":5891,"activeCount":103},[5892],{"nctId":5849,"briefTitle":5850,"status":174,"phases":5893,"primaryCompletion":5852,"completion":5853,"start":5854,"enrollment":3307,"conditions":5894,"interventions":5895},[92],[5856],[5840,5858,5859],{"trials":5897,"activeCount":103},[],{"trials":5899,"activeCount":103},[],{"trials":5901,"activeCount":103},[],{"intervention":5903,"totalTrials":240,"cells":5904},"Ketamine + Naltrexone",{"EARLY_PHASE1":5905,"PHASE1":5907,"PHASE2":5909,"PHASE3":5921,"PHASE4":5923,"NA":5925},{"trials":5906,"activeCount":103},[],{"trials":5908,"activeCount":103},[],{"trials":5910,"activeCount":103},[5911],{"nctId":5912,"briefTitle":5913,"status":174,"phases":5914,"primaryCompletion":5915,"completion":5915,"start":5916,"enrollment":5917,"conditions":5918,"interventions":5919},"NCT02461927","Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder",[91,92],"2023-10-30","2015-01-01",65,[3274,1302],[5903,5920],"Ketamine + Placebo",{"trials":5922,"activeCount":103},[],{"trials":5924,"activeCount":103},[],{"trials":5926,"activeCount":103},[],{"intervention":5920,"totalTrials":240,"cells":5928},{"EARLY_PHASE1":5929,"PHASE1":5931,"PHASE2":5933,"PHASE3":5939,"PHASE4":5941,"NA":5943},{"trials":5930,"activeCount":103},[],{"trials":5932,"activeCount":103},[],{"trials":5934,"activeCount":103},[5935],{"nctId":5912,"briefTitle":5913,"status":174,"phases":5936,"primaryCompletion":5915,"completion":5915,"start":5916,"enrollment":5917,"conditions":5937,"interventions":5938},[91,92],[3274,1302],[5903,5920],{"trials":5940,"activeCount":103},[],{"trials":5942,"activeCount":103},[],{"trials":5944,"activeCount":103},[],{"intervention":5946,"totalTrials":240,"cells":5947},"anakinra",{"EARLY_PHASE1":5948,"PHASE1":5950,"PHASE2":5952,"PHASE3":5964,"PHASE4":5966,"NA":5968},{"trials":5949,"activeCount":103},[],{"trials":5951,"activeCount":103},[],{"trials":5953,"activeCount":103},[5954],{"nctId":5955,"briefTitle":5956,"status":174,"phases":5957,"primaryCompletion":5958,"completion":5958,"start":5959,"enrollment":370,"conditions":5960,"interventions":5962},"NCT02278562","Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2",[92],"2017-03-01","2014-10-22",[5961],"ESRD",[5946,5963],"actos",{"trials":5965,"activeCount":103},[],{"trials":5967,"activeCount":103},[],{"trials":5969,"activeCount":103},[],{"intervention":5963,"totalTrials":240,"cells":5971},{"EARLY_PHASE1":5972,"PHASE1":5974,"PHASE2":5976,"PHASE3":5982,"PHASE4":5984,"NA":5986},{"trials":5973,"activeCount":103},[],{"trials":5975,"activeCount":103},[],{"trials":5977,"activeCount":103},[5978],{"nctId":5955,"briefTitle":5956,"status":174,"phases":5979,"primaryCompletion":5958,"completion":5958,"start":5959,"enrollment":370,"conditions":5980,"interventions":5981},[92],[5961],[5946,5963],{"trials":5983,"activeCount":103},[],{"trials":5985,"activeCount":103},[],{"trials":5987,"activeCount":103},[],{"intervention":5989,"totalTrials":240,"cells":5990},"Cyclo-Z",{"EARLY_PHASE1":5991,"PHASE1":5993,"PHASE2":5995,"PHASE3":6006,"PHASE4":6008,"NA":6010},{"trials":5992,"activeCount":103},[],{"trials":5994,"activeCount":103},[],{"trials":5996,"activeCount":103},[5997],{"nctId":5998,"briefTitle":5999,"status":246,"phases":6000,"primaryCompletion":6001,"completion":6002,"start":6003,"enrollment":5163,"conditions":6004,"interventions":6005},"NCT00878605","Development of A Novel Anti-Hyperglycemic Agent",[92],"2013-06-01","2013-09-30","2010-04-01",[975],[5989],{"trials":6007,"activeCount":103},[],{"trials":6009,"activeCount":103},[],{"trials":6011,"activeCount":103},[],{"intervention":6013,"totalTrials":240,"cells":6014},"sildenafil",{"EARLY_PHASE1":6015,"PHASE1":6017,"PHASE2":6019,"PHASE3":6033,"PHASE4":6035,"NA":6037},{"trials":6016,"activeCount":103},[],{"trials":6018,"activeCount":103},[],{"trials":6020,"activeCount":103},[6021],{"nctId":6022,"briefTitle":6023,"status":174,"phases":6024,"primaryCompletion":6025,"completion":6026,"start":6027,"enrollment":2776,"conditions":6028,"interventions":6032},"NCT00359736","Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis",[92],"2008-10","2009-06","2006-07",[6029,6030,6031],"Alveolitis, Fibrosing","Fibrosis, Pulmonary","Hypertension, Pulmonary",[6013],{"trials":6034,"activeCount":103},[],{"trials":6036,"activeCount":103},[],{"trials":6038,"activeCount":103},[],{"intervention":6040,"totalTrials":240,"cells":6041},"conjugated estrogens\u002Fbazedoxifene",{"EARLY_PHASE1":6042,"PHASE1":6044,"PHASE2":6046,"PHASE3":6056,"PHASE4":6058,"NA":6060},{"trials":6043,"activeCount":103},[],{"trials":6045,"activeCount":103},[],{"trials":6047,"activeCount":103},[6048],{"nctId":6049,"briefTitle":6050,"status":2693,"phases":6051,"primaryCompletion":6052,"completion":6052,"start":6052,"enrollment":103,"conditions":6053,"interventions":6055},"NCT05073237","Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans",[92],"2024-04-08",[6054,4521,27],"Menopause",[6040],{"trials":6057,"activeCount":103},[],{"trials":6059,"activeCount":103},[],{"trials":6061,"activeCount":103},[],{"intervention":6063,"totalTrials":240,"cells":6064},"Chlorhexidine",{"EARLY_PHASE1":6065,"PHASE1":6067,"PHASE2":6069,"PHASE3":6082,"PHASE4":6084,"NA":6086},{"trials":6066,"activeCount":103},[],{"trials":6068,"activeCount":103},[],{"trials":6070,"activeCount":103},[6071],{"nctId":6072,"briefTitle":6073,"status":174,"phases":6074,"primaryCompletion":6075,"completion":6076,"start":6077,"enrollment":6078,"conditions":6079,"interventions":6081},"NCT03503370","Preventing Diabetic Foot Ulcers Through Cleaner Feet",[92],"2022-12-30","2023-01-06","2019-01-02",175,[6080],"Diabetic Foot Ulcer",[6063],{"trials":6083,"activeCount":103},[],{"trials":6085,"activeCount":103},[],{"trials":6087,"activeCount":103},[],{"intervention":6089,"totalTrials":240,"cells":6090},"leucoselect phytosome",{"EARLY_PHASE1":6091,"PHASE1":6093,"PHASE2":6095,"PHASE3":6106,"PHASE4":6108,"NA":6110},{"trials":6092,"activeCount":103},[],{"trials":6094,"activeCount":103},[],{"trials":6096,"activeCount":103},[6097],{"nctId":6098,"briefTitle":6099,"status":246,"phases":6100,"primaryCompletion":6101,"completion":3270,"start":6102,"enrollment":4429,"conditions":6103,"interventions":6105},"NCT04515004","Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer",[92],"2024-11-01","2023-11-20",[6104],"Early Stage Lung Cancer (I and II)",[6089],{"trials":6107,"activeCount":103},[],{"trials":6109,"activeCount":103},[],{"trials":6111,"activeCount":103},[],{"intervention":6113,"totalTrials":240,"cells":6114},"20mg ezetimibe",{"EARLY_PHASE1":6115,"PHASE1":6117,"PHASE2":6119,"PHASE3":6131,"PHASE4":6133,"NA":6135},{"trials":6116,"activeCount":103},[],{"trials":6118,"activeCount":103},[],{"trials":6120,"activeCount":103},[6121],{"nctId":6122,"briefTitle":6123,"status":246,"phases":6124,"primaryCompletion":6125,"completion":6125,"start":6126,"enrollment":132,"conditions":6127,"interventions":6129},"NCT02971033","Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C",[92],"2021-03-31","2018-04-16",[6128],"Chronic Hepatitis C",[6113,6130],"40mg ezetimibe",{"trials":6132,"activeCount":103},[],{"trials":6134,"activeCount":103},[],{"trials":6136,"activeCount":103},[],{"intervention":6130,"totalTrials":240,"cells":6138},{"EARLY_PHASE1":6139,"PHASE1":6141,"PHASE2":6143,"PHASE3":6149,"PHASE4":6151,"NA":6153},{"trials":6140,"activeCount":103},[],{"trials":6142,"activeCount":103},[],{"trials":6144,"activeCount":103},[6145],{"nctId":6122,"briefTitle":6123,"status":246,"phases":6146,"primaryCompletion":6125,"completion":6125,"start":6126,"enrollment":132,"conditions":6147,"interventions":6148},[92],[6128],[6113,6130],{"trials":6150,"activeCount":103},[],{"trials":6152,"activeCount":103},[],{"trials":6154,"activeCount":103},[],{"intervention":6156,"totalTrials":240,"cells":6157},"Ibudilast",{"EARLY_PHASE1":6158,"PHASE1":6160,"PHASE2":6162,"PHASE3":6173,"PHASE4":6175,"NA":6177},{"trials":6159,"activeCount":103},[],{"trials":6161,"activeCount":103},[],{"trials":6163,"activeCount":103},[6164],{"nctId":6165,"briefTitle":6166,"status":174,"phases":6167,"primaryCompletion":6168,"completion":6168,"start":1590,"enrollment":6169,"conditions":6170,"interventions":6172},"NCT03341078","Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users",[92],"2025-10-15",176,[6171],"Methamphetamine-dependence",[6156],{"trials":6174,"activeCount":103},[],{"trials":6176,"activeCount":103},[],{"trials":6178,"activeCount":103},[],{"intervention":6180,"totalTrials":240,"cells":6181},"onaBoNT-A + placebo",{"EARLY_PHASE1":6182,"PHASE1":6184,"PHASE2":6186,"PHASE3":6198,"PHASE4":6200,"NA":6202},{"trials":6183,"activeCount":103},[],{"trials":6185,"activeCount":103},[],{"trials":6187,"activeCount":103},[6188],{"nctId":6189,"briefTitle":6190,"status":174,"phases":6191,"primaryCompletion":4557,"completion":4557,"start":3654,"enrollment":6192,"conditions":6193,"interventions":6196},"NCT01589263","Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS",[92],63,[6194,6195],"Benign Prostatic Hyperplasia","Lower Urinary Track Symptoms",[6180,6197],"Tamsulosin + placebo",{"trials":6199,"activeCount":103},[],{"trials":6201,"activeCount":103},[],{"trials":6203,"activeCount":103},[],{"intervention":6197,"totalTrials":240,"cells":6205},{"EARLY_PHASE1":6206,"PHASE1":6208,"PHASE2":6210,"PHASE3":6216,"PHASE4":6218,"NA":6220},{"trials":6207,"activeCount":103},[],{"trials":6209,"activeCount":103},[],{"trials":6211,"activeCount":103},[6212],{"nctId":6189,"briefTitle":6190,"status":174,"phases":6213,"primaryCompletion":4557,"completion":4557,"start":3654,"enrollment":6192,"conditions":6214,"interventions":6215},[92],[6194,6195],[6180,6197],{"trials":6217,"activeCount":103},[],{"trials":6219,"activeCount":103},[],{"trials":6221,"activeCount":103},[],{"intervention":6223,"totalTrials":240,"cells":6224},"Enalapril",{"EARLY_PHASE1":6225,"PHASE1":6227,"PHASE2":6229,"PHASE3":6241,"PHASE4":6243,"NA":6245},{"trials":6226,"activeCount":103},[],{"trials":6228,"activeCount":103},[],{"trials":6230,"activeCount":103},[6231],{"nctId":6232,"briefTitle":6233,"status":174,"phases":6234,"primaryCompletion":6235,"completion":6235,"start":6236,"enrollment":116,"conditions":6237,"interventions":6240},"NCT01754909","Mitigation of Radiation Pneumonitis and Fibrosis",[92],"2018-04-01","2013-11-01",[6238,6239],"Lung Cancer","Radiation Pneumonitis",[6223],{"trials":6242,"activeCount":103},[],{"trials":6244,"activeCount":103},[],{"trials":6246,"activeCount":103},[],{"intervention":6248,"totalTrials":240,"cells":6249},"copanlisib",{"EARLY_PHASE1":6250,"PHASE1":6252,"PHASE2":6254,"PHASE3":6265,"PHASE4":6267,"NA":6269},{"trials":6251,"activeCount":103},[],{"trials":6253,"activeCount":103},[],{"trials":6255,"activeCount":103},[6256],{"nctId":6257,"briefTitle":6258,"status":2693,"phases":6259,"primaryCompletion":6260,"completion":6260,"start":6260,"enrollment":103,"conditions":6261,"interventions":6263},"NCT05687721","Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer",[91,92],"2025-06-02",[6262],"Advanced Urothelial Carcinoma",[6248,6264],"Avelumab",{"trials":6266,"activeCount":103},[],{"trials":6268,"activeCount":103},[],{"trials":6270,"activeCount":103},[],{"intervention":6264,"totalTrials":240,"cells":6272},{"EARLY_PHASE1":6273,"PHASE1":6275,"PHASE2":6277,"PHASE3":6283,"PHASE4":6285,"NA":6287},{"trials":6274,"activeCount":103},[],{"trials":6276,"activeCount":103},[],{"trials":6278,"activeCount":103},[6279],{"nctId":6257,"briefTitle":6258,"status":2693,"phases":6280,"primaryCompletion":6260,"completion":6260,"start":6260,"enrollment":103,"conditions":6281,"interventions":6282},[91,92],[6262],[6248,6264],{"trials":6284,"activeCount":103},[],{"trials":6286,"activeCount":103},[],{"trials":6288,"activeCount":103},[],{"intervention":6290,"totalTrials":240,"cells":6291},"Risperidone plus Placebo",{"EARLY_PHASE1":6292,"PHASE1":6294,"PHASE2":6296,"PHASE3":6306,"PHASE4":6308,"NA":6310},{"trials":6293,"activeCount":103},[],{"trials":6295,"activeCount":103},[],{"trials":6297,"activeCount":103},[6298],{"nctId":6299,"briefTitle":6300,"status":2693,"phases":6301,"primaryCompletion":6302,"completion":6302,"start":4601,"enrollment":103,"conditions":6303,"interventions":6304},"NCT02538081","Nicotinic Receptors and Schizophrenia",[91,92],"2016-08",[33],[6290,6305],"Risperidone plus DMXB-A",{"trials":6307,"activeCount":103},[],{"trials":6309,"activeCount":103},[],{"trials":6311,"activeCount":103},[],{"intervention":6305,"totalTrials":240,"cells":6313},{"EARLY_PHASE1":6314,"PHASE1":6316,"PHASE2":6318,"PHASE3":6324,"PHASE4":6326,"NA":6328},{"trials":6315,"activeCount":103},[],{"trials":6317,"activeCount":103},[],{"trials":6319,"activeCount":103},[6320],{"nctId":6299,"briefTitle":6300,"status":2693,"phases":6321,"primaryCompletion":6302,"completion":6302,"start":4601,"enrollment":103,"conditions":6322,"interventions":6323},[91,92],[33],[6290,6305],{"trials":6325,"activeCount":103},[],{"trials":6327,"activeCount":103},[],{"trials":6329,"activeCount":103},[],{"intervention":6331,"totalTrials":240,"cells":6332},"Dexamthasone",{"EARLY_PHASE1":6333,"PHASE1":6335,"PHASE2":6337,"PHASE3":6348,"PHASE4":6350,"NA":6352},{"trials":6334,"activeCount":103},[],{"trials":6336,"activeCount":103},[],{"trials":6338,"activeCount":103},[6339],{"nctId":6340,"briefTitle":6341,"status":246,"phases":6342,"primaryCompletion":6343,"completion":6344,"start":6345,"enrollment":132,"conditions":6346,"interventions":6347},"NCT04037462","Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy",[91,92],"2022-02-23","2023-02-23","2021-07-07",[2321,2972],[6331],{"trials":6349,"activeCount":103},[],{"trials":6351,"activeCount":103},[],{"trials":6353,"activeCount":103},[],{"intervention":6355,"totalTrials":240,"cells":6356},"20 mg MitoQ",{"EARLY_PHASE1":6357,"PHASE1":6359,"PHASE2":6361,"PHASE3":6374,"PHASE4":6376,"NA":6378},{"trials":6358,"activeCount":103},[],{"trials":6360,"activeCount":103},[],{"trials":6362,"activeCount":103},[6363],{"nctId":6364,"briefTitle":6365,"status":174,"phases":6366,"primaryCompletion":6367,"completion":6368,"start":6369,"enrollment":6370,"conditions":6371,"interventions":6372},"NCT04267926","MitoQ for Fatigue in Multiple Sclerosis (MS)",[91,92],"2024-10-15","2026-03-31","2020-04-01",45,[4593,1580],[6355,6373],"40mg of MitoQ",{"trials":6375,"activeCount":103},[],{"trials":6377,"activeCount":103},[],{"trials":6379,"activeCount":103},[],{"intervention":6373,"totalTrials":240,"cells":6381},{"EARLY_PHASE1":6382,"PHASE1":6384,"PHASE2":6386,"PHASE3":6392,"PHASE4":6394,"NA":6396},{"trials":6383,"activeCount":103},[],{"trials":6385,"activeCount":103},[],{"trials":6387,"activeCount":103},[6388],{"nctId":6364,"briefTitle":6365,"status":174,"phases":6389,"primaryCompletion":6367,"completion":6368,"start":6369,"enrollment":6370,"conditions":6390,"interventions":6391},[91,92],[4593,1580],[6355,6373],{"trials":6393,"activeCount":103},[],{"trials":6395,"activeCount":103},[],{"trials":6397,"activeCount":103},[],{"intervention":6399,"totalTrials":240,"cells":6400},"Testosterone and standard NMES",{"EARLY_PHASE1":6401,"PHASE1":6403,"PHASE2":6405,"PHASE3":6415,"PHASE4":6417,"NA":6419},{"trials":6402,"activeCount":103},[],{"trials":6404,"activeCount":103},[],{"trials":6406,"activeCount":103},[6407],{"nctId":6408,"briefTitle":6409,"status":174,"phases":6410,"primaryCompletion":6411,"completion":6412,"start":4428,"enrollment":1647,"conditions":6413,"interventions":6414},"NCT03345576","Testosterone and Long Pulse Stimulation After SCI",[92],"2023-06-30","2023-11-30",[30],[6399],{"trials":6416,"activeCount":103},[],{"trials":6418,"activeCount":103},[],{"trials":6420,"activeCount":103},[],{"intervention":6422,"totalTrials":240,"cells":6423},"Intranasal oxytocin",{"EARLY_PHASE1":6424,"PHASE1":6426,"PHASE2":6428,"PHASE3":6440,"PHASE4":6442,"NA":6444},{"trials":6425,"activeCount":103},[],{"trials":6427,"activeCount":103},[],{"trials":6429,"activeCount":103},[6430],{"nctId":6431,"briefTitle":6432,"status":174,"phases":6433,"primaryCompletion":6434,"completion":6434,"start":6435,"enrollment":3936,"conditions":6436,"interventions":6438},"NCT03016598","Stimulant Oxytocin Study",[92],"2020-02-14","2018-01-26",[6437],"Stimulant Use & Co-occuring Opioid Use Disorders",[6422,6439],"Intranasal placebo",{"trials":6441,"activeCount":103},[],{"trials":6443,"activeCount":103},[],{"trials":6445,"activeCount":103},[],{"intervention":6439,"totalTrials":240,"cells":6447},{"EARLY_PHASE1":6448,"PHASE1":6450,"PHASE2":6452,"PHASE3":6458,"PHASE4":6460,"NA":6462},{"trials":6449,"activeCount":103},[],{"trials":6451,"activeCount":103},[],{"trials":6453,"activeCount":103},[6454],{"nctId":6431,"briefTitle":6432,"status":174,"phases":6455,"primaryCompletion":6434,"completion":6434,"start":6435,"enrollment":3936,"conditions":6456,"interventions":6457},[92],[6437],[6422,6439],{"trials":6459,"activeCount":103},[],{"trials":6461,"activeCount":103},[],{"trials":6463,"activeCount":103},[],{"intervention":6465,"totalTrials":240,"cells":6466},"Curcumin",{"EARLY_PHASE1":6467,"PHASE1":6469,"PHASE2":6471,"PHASE3":6483,"PHASE4":6485,"NA":6487},{"trials":6468,"activeCount":103},[],{"trials":6470,"activeCount":103},[],{"trials":6472,"activeCount":103},[6473],{"nctId":6474,"briefTitle":6475,"status":6476,"phases":6477,"primaryCompletion":6478,"completion":4966,"start":6479,"enrollment":1326,"conditions":6480,"interventions":6482},"NCT01811381","Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease","UNKNOWN",[92],"2020-03-16","2014-01-20",[6481],"Mild Cognitive Impairment",[6465],{"trials":6484,"activeCount":103},[],{"trials":6486,"activeCount":103},[],{"trials":6488,"activeCount":103},[],{"intervention":6490,"totalTrials":240,"cells":6491},"Dietary Supplement: Pregnenolone",{"EARLY_PHASE1":6492,"PHASE1":6494,"PHASE2":6496,"PHASE3":6506,"PHASE4":6508,"NA":6510},{"trials":6493,"activeCount":103},[],{"trials":6495,"activeCount":103},[],{"trials":6497,"activeCount":103},[6498],{"nctId":6499,"briefTitle":6500,"status":174,"phases":6501,"primaryCompletion":5783,"completion":5771,"start":2628,"enrollment":6502,"conditions":6503,"interventions":6505},"NCT00728728","Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia",[92],88,[33,6504],"Schizoaffective Disorder",[6490],{"trials":6507,"activeCount":103},[],{"trials":6509,"activeCount":103},[],{"trials":6511,"activeCount":103},[],{"intervention":6513,"totalTrials":240,"cells":6514},"Rilonacept",{"EARLY_PHASE1":6515,"PHASE1":6517,"PHASE2":6519,"PHASE3":6530,"PHASE4":6532,"NA":6534},{"trials":6516,"activeCount":103},[],{"trials":6518,"activeCount":103},[],{"trials":6520,"activeCount":103},[6521],{"nctId":6522,"briefTitle":6523,"status":174,"phases":6524,"primaryCompletion":6525,"completion":6526,"start":6527,"enrollment":2797,"conditions":6528,"interventions":6529},"NCT00897715","Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)",[92],"2015-02-25","2015-05-08","2013-01-01",[159,147],[6513],{"trials":6531,"activeCount":103},[],{"trials":6533,"activeCount":103},[],{"trials":6535,"activeCount":103},[],{"intervention":6537,"totalTrials":240,"cells":6538},"GSK561679",{"EARLY_PHASE1":6539,"PHASE1":6541,"PHASE2":6543,"PHASE3":6555,"PHASE4":6557,"NA":6559},{"trials":6540,"activeCount":103},[],{"trials":6542,"activeCount":103},[],{"trials":6544,"activeCount":103},[6545],{"nctId":6546,"briefTitle":6547,"status":174,"phases":6548,"primaryCompletion":6549,"completion":6550,"start":6551,"enrollment":2363,"conditions":6552,"interventions":6554},"NCT01814332","Analyzing Female Trauma Exposed Responses to a Medication",[92],"2014-06-30","2014-10-31","2010-01-01",[6553],"Stress Disorders, Post-traumatic",[6537],{"trials":6556,"activeCount":103},[],{"trials":6558,"activeCount":103},[],{"trials":6560,"activeCount":103},[],{"intervention":6562,"totalTrials":240,"cells":6563},"Yohimbine",{"EARLY_PHASE1":6564,"PHASE1":6566,"PHASE2":6568,"PHASE3":6579,"PHASE4":6581,"NA":6583},{"trials":6565,"activeCount":103},[],{"trials":6567,"activeCount":103},[],{"trials":6569,"activeCount":103},[6570],{"nctId":6571,"briefTitle":6572,"status":174,"phases":6573,"primaryCompletion":1679,"completion":6574,"start":6575,"enrollment":3272,"conditions":6576,"interventions":6578},"NCT01031979","Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With\u002FWithout Yohimbine",[92],"2015-07-07","2010-12-01",[6577],"Post-Traumatic Stress Disorder",[6562],{"trials":6580,"activeCount":103},[],{"trials":6582,"activeCount":103},[],{"trials":6584,"activeCount":103},[],{"intervention":6586,"totalTrials":240,"cells":6587},"TTI-0102",{"EARLY_PHASE1":6588,"PHASE1":6590,"PHASE2":6592,"PHASE3":6602,"PHASE4":6604,"NA":6606},{"trials":6589,"activeCount":103},[],{"trials":6591,"activeCount":103},[],{"trials":6593,"activeCount":103},[6594],{"nctId":6595,"briefTitle":6596,"status":2693,"phases":6597,"primaryCompletion":6598,"completion":6598,"start":5369,"enrollment":103,"conditions":6599,"interventions":6601},"NCT04262895","TTI-0102 for Veterans With TBI",[91,92],"2021-10-15",[6600,24],"Mild to Moderate TBI",[6586],{"trials":6603,"activeCount":103},[],{"trials":6605,"activeCount":103},[],{"trials":6607,"activeCount":103},[],{"intervention":6609,"totalTrials":240,"cells":6610},"Anamorelin HCl",{"EARLY_PHASE1":6611,"PHASE1":6613,"PHASE2":6615,"PHASE3":6628,"PHASE4":6630,"NA":6632},{"trials":6612,"activeCount":103},[],{"trials":6614,"activeCount":103},[],{"trials":6616,"activeCount":103},[6617],{"nctId":6618,"briefTitle":6619,"status":246,"phases":6620,"primaryCompletion":6621,"completion":6622,"start":6623,"enrollment":6624,"conditions":6625,"interventions":6627},"NCT01505764","The Role of Ghrelin in Cancer Cachexia",[92],"2016-01","2016-03","2012-06",10,[6626],"Cancer Cachexia",[6609],{"trials":6629,"activeCount":103},[],{"trials":6631,"activeCount":103},[],{"trials":6633,"activeCount":103},[],{"intervention":6635,"totalTrials":240,"cells":6636},"Degarelix",{"EARLY_PHASE1":6637,"PHASE1":6639,"PHASE2":6641,"PHASE3":6651,"PHASE4":6653,"NA":6655},{"trials":6638,"activeCount":103},[],{"trials":6640,"activeCount":103},[],{"trials":6642,"activeCount":103},[6643],{"nctId":6644,"briefTitle":6645,"status":174,"phases":6646,"primaryCompletion":6647,"completion":6647,"start":6648,"enrollment":1591,"conditions":6649,"interventions":6650},"NCT04397718","Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization",[92],"2021-06-08","2020-07-06",[4900],[6635],{"trials":6652,"activeCount":103},[],{"trials":6654,"activeCount":103},[],{"trials":6656,"activeCount":103},[],{"intervention":6658,"totalTrials":240,"cells":6659},"Fecal Microbial transplant",{"EARLY_PHASE1":6660,"PHASE1":6662,"PHASE2":6664,"PHASE3":6676,"PHASE4":6678,"NA":6680},{"trials":6661,"activeCount":103},[],{"trials":6663,"activeCount":103},[],{"trials":6665,"activeCount":103},[6666],{"nctId":6667,"briefTitle":6668,"status":174,"phases":6669,"primaryCompletion":6670,"completion":6671,"start":6672,"enrollment":192,"conditions":6673,"interventions":6674},"NCT03796598","FMT in Cirrhosis and Hepatic Encephalopathy",[91,92],"2023-12-19","2023-12-20","2019-07-29",[1277,1964],[6658,6675],"Fecal Microbial Transplant Enema",{"trials":6677,"activeCount":103},[],{"trials":6679,"activeCount":103},[],{"trials":6681,"activeCount":103},[],{"intervention":6675,"totalTrials":240,"cells":6683},{"EARLY_PHASE1":6684,"PHASE1":6686,"PHASE2":6688,"PHASE3":6694,"PHASE4":6696,"NA":6698},{"trials":6685,"activeCount":103},[],{"trials":6687,"activeCount":103},[],{"trials":6689,"activeCount":103},[6690],{"nctId":6667,"briefTitle":6668,"status":174,"phases":6691,"primaryCompletion":6670,"completion":6671,"start":6672,"enrollment":192,"conditions":6692,"interventions":6693},[91,92],[1277,1964],[6658,6675],{"trials":6695,"activeCount":103},[],{"trials":6697,"activeCount":103},[],{"trials":6699,"activeCount":103},[],{"intervention":6701,"totalTrials":240,"cells":6702},"Meloxicam 15 mg po QD",{"EARLY_PHASE1":6703,"PHASE1":6705,"PHASE2":6707,"PHASE3":6719,"PHASE4":6721,"NA":6723},{"trials":6704,"activeCount":103},[],{"trials":6706,"activeCount":103},[],{"trials":6708,"activeCount":103},[6709],{"nctId":6710,"briefTitle":6711,"status":174,"phases":6712,"primaryCompletion":6713,"completion":6713,"start":6714,"enrollment":6715,"conditions":6716,"interventions":6718},"NCT01799213","Discontinuing NSAIDs in Veterans With Knee Osteoarthritis",[92],"2018-10-05","2013-09-02",490,[6717],"Knee Osteoarthritis",[6701],{"trials":6720,"activeCount":103},[],{"trials":6722,"activeCount":103},[],{"trials":6724,"activeCount":103},[],{"intervention":6726,"totalTrials":240,"cells":6727},"Levetiracetam",{"EARLY_PHASE1":6728,"PHASE1":6730,"PHASE2":6732,"PHASE3":6742,"PHASE4":6744,"NA":6746},{"trials":6729,"activeCount":103},[],{"trials":6731,"activeCount":103},[],{"trials":6733,"activeCount":103},[6734],{"nctId":6735,"briefTitle":6736,"status":174,"phases":6737,"primaryCompletion":3746,"completion":3746,"start":6738,"enrollment":6739,"conditions":6740,"interventions":6741},"NCT03034356","Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia",[91,92],"2018-09-01",67,[33],[6726],{"trials":6743,"activeCount":103},[],{"trials":6745,"activeCount":103},[],{"trials":6747,"activeCount":103},[],{"intervention":6749,"totalTrials":240,"cells":6750},"Celecoxib",{"EARLY_PHASE1":6751,"PHASE1":6753,"PHASE2":6755,"PHASE3":6768,"PHASE4":6770,"NA":6772},{"trials":6752,"activeCount":103},[],{"trials":6754,"activeCount":103},[],{"trials":6756,"activeCount":103},[6757],{"nctId":6758,"briefTitle":6759,"status":174,"phases":6760,"primaryCompletion":5771,"completion":5771,"start":6761,"enrollment":6762,"conditions":6763,"interventions":6765},"NCT00953849","Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity",[91,92],"2009-11",21,[6764],"Mouth Neoplasms",[6749,6766,6767],"Calcitriol","Celecoxib plus Calcitriol",{"trials":6769,"activeCount":103},[],{"trials":6771,"activeCount":103},[],{"trials":6773,"activeCount":103},[],{"intervention":6766,"totalTrials":240,"cells":6775},{"EARLY_PHASE1":6776,"PHASE1":6778,"PHASE2":6780,"PHASE3":6786,"PHASE4":6788,"NA":6790},{"trials":6777,"activeCount":103},[],{"trials":6779,"activeCount":103},[],{"trials":6781,"activeCount":103},[6782],{"nctId":6758,"briefTitle":6759,"status":174,"phases":6783,"primaryCompletion":5771,"completion":5771,"start":6761,"enrollment":6762,"conditions":6784,"interventions":6785},[91,92],[6764],[6749,6766,6767],{"trials":6787,"activeCount":103},[],{"trials":6789,"activeCount":103},[],{"trials":6791,"activeCount":103},[],{"intervention":6767,"totalTrials":240,"cells":6793},{"EARLY_PHASE1":6794,"PHASE1":6796,"PHASE2":6798,"PHASE3":6804,"PHASE4":6806,"NA":6808},{"trials":6795,"activeCount":103},[],{"trials":6797,"activeCount":103},[],{"trials":6799,"activeCount":103},[6800],{"nctId":6758,"briefTitle":6759,"status":174,"phases":6801,"primaryCompletion":5771,"completion":5771,"start":6761,"enrollment":6762,"conditions":6802,"interventions":6803},[91,92],[6764],[6749,6766,6767],{"trials":6805,"activeCount":103},[],{"trials":6807,"activeCount":103},[],{"trials":6809,"activeCount":103},[],{"intervention":6811,"totalTrials":240,"cells":6812},"fluticasone nasal",{"EARLY_PHASE1":6813,"PHASE1":6815,"PHASE2":6817,"PHASE3":6830,"PHASE4":6832,"NA":6834},{"trials":6814,"activeCount":103},[],{"trials":6816,"activeCount":103},[],{"trials":6818,"activeCount":103},[6819],{"nctId":6820,"briefTitle":6821,"status":174,"phases":6822,"primaryCompletion":6823,"completion":6823,"start":6824,"enrollment":6825,"conditions":6826,"interventions":6828},"NCT02885025","Effects of Broccoli Sprout Extract on Allergy Rhinitis",[92],"2019-03-12","2016-10-01",47,[6827],"Rhinitis,Allergic",[6811,6829],"normal saline nasal spray",{"trials":6831,"activeCount":103},[],{"trials":6833,"activeCount":103},[],{"trials":6835,"activeCount":103},[],{"intervention":6829,"totalTrials":240,"cells":6837},{"EARLY_PHASE1":6838,"PHASE1":6840,"PHASE2":6842,"PHASE3":6848,"PHASE4":6850,"NA":6852},{"trials":6839,"activeCount":103},[],{"trials":6841,"activeCount":103},[],{"trials":6843,"activeCount":103},[6844],{"nctId":6820,"briefTitle":6821,"status":174,"phases":6845,"primaryCompletion":6823,"completion":6823,"start":6824,"enrollment":6825,"conditions":6846,"interventions":6847},[92],[6827],[6811,6829],{"trials":6849,"activeCount":103},[],{"trials":6851,"activeCount":103},[],{"trials":6853,"activeCount":103},[],{"intervention":6855,"totalTrials":240,"cells":6856},"Duloxetine",{"EARLY_PHASE1":6857,"PHASE1":6859,"PHASE2":6861,"PHASE3":6873,"PHASE4":6875,"NA":6877},{"trials":6858,"activeCount":103},[],{"trials":6860,"activeCount":103},[],{"trials":6862,"activeCount":103},[6863],{"nctId":6864,"briefTitle":6865,"status":246,"phases":6866,"primaryCompletion":6867,"completion":6867,"start":6868,"enrollment":6869,"conditions":6870,"interventions":6871},"NCT01846182","Research Examining Gulf War Illness in Our Nations Service Members",[92],"2019-08-01","2015-06-24",112,[2297],[6855,6872],"Pregabalin",{"trials":6874,"activeCount":103},[],{"trials":6876,"activeCount":103},[],{"trials":6878,"activeCount":103},[],{"intervention":6872,"totalTrials":240,"cells":6880},{"EARLY_PHASE1":6881,"PHASE1":6883,"PHASE2":6885,"PHASE3":6891,"PHASE4":6893,"NA":6895},{"trials":6882,"activeCount":103},[],{"trials":6884,"activeCount":103},[],{"trials":6886,"activeCount":103},[6887],{"nctId":6864,"briefTitle":6865,"status":246,"phases":6888,"primaryCompletion":6867,"completion":6867,"start":6868,"enrollment":6869,"conditions":6889,"interventions":6890},[92],[2297],[6855,6872],{"trials":6892,"activeCount":103},[],{"trials":6894,"activeCount":103},[],{"trials":6896,"activeCount":103},[],{"intervention":6898,"totalTrials":240,"cells":6899},"Mifepristone Oral Tablet [Korlym]",{"EARLY_PHASE1":6900,"PHASE1":6902,"PHASE2":6904,"PHASE3":6916,"PHASE4":6918,"NA":6920},{"trials":6901,"activeCount":103},[],{"trials":6903,"activeCount":103},[],{"trials":6905,"activeCount":103},[6906],{"nctId":6907,"briefTitle":6908,"status":174,"phases":6909,"primaryCompletion":6910,"completion":6911,"start":6912,"enrollment":6913,"conditions":6914,"interventions":6915},"NCT01739335","Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone",[92],"2016-09-19","2016-11-16","2012-11-19",81,[36],[6898],{"trials":6917,"activeCount":103},[],{"trials":6919,"activeCount":103},[],{"trials":6921,"activeCount":103},[],{"intervention":4483,"totalTrials":240,"cells":6923},{"EARLY_PHASE1":6924,"PHASE1":6926,"PHASE2":6928,"PHASE3":6934,"PHASE4":6936,"NA":6938},{"trials":6925,"activeCount":103},[],{"trials":6927,"activeCount":103},[],{"trials":6929,"activeCount":103},[6930],{"nctId":4476,"briefTitle":4477,"status":246,"phases":6931,"primaryCompletion":4479,"completion":4479,"start":4480,"enrollment":240,"conditions":6932,"interventions":6933},[92],[18],[4483,1672,4484,4485,4486],{"trials":6935,"activeCount":103},[],{"trials":6937,"activeCount":103},[],{"trials":6939,"activeCount":103},[],{"intervention":4484,"totalTrials":240,"cells":6941},{"EARLY_PHASE1":6942,"PHASE1":6944,"PHASE2":6946,"PHASE3":6952,"PHASE4":6954,"NA":6956},{"trials":6943,"activeCount":103},[],{"trials":6945,"activeCount":103},[],{"trials":6947,"activeCount":103},[6948],{"nctId":4476,"briefTitle":4477,"status":246,"phases":6949,"primaryCompletion":4479,"completion":4479,"start":4480,"enrollment":240,"conditions":6950,"interventions":6951},[92],[18],[4483,1672,4484,4485,4486],{"trials":6953,"activeCount":103},[],{"trials":6955,"activeCount":103},[],{"trials":6957,"activeCount":103},[],{"intervention":4485,"totalTrials":240,"cells":6959},{"EARLY_PHASE1":6960,"PHASE1":6962,"PHASE2":6964,"PHASE3":6970,"PHASE4":6972,"NA":6974},{"trials":6961,"activeCount":103},[],{"trials":6963,"activeCount":103},[],{"trials":6965,"activeCount":103},[6966],{"nctId":4476,"briefTitle":4477,"status":246,"phases":6967,"primaryCompletion":4479,"completion":4479,"start":4480,"enrollment":240,"conditions":6968,"interventions":6969},[92],[18],[4483,1672,4484,4485,4486],{"trials":6971,"activeCount":103},[],{"trials":6973,"activeCount":103},[],{"trials":6975,"activeCount":103},[],{"intervention":4486,"totalTrials":240,"cells":6977},{"EARLY_PHASE1":6978,"PHASE1":6980,"PHASE2":6982,"PHASE3":6988,"PHASE4":6990,"NA":6992},{"trials":6979,"activeCount":103},[],{"trials":6981,"activeCount":103},[],{"trials":6983,"activeCount":103},[6984],{"nctId":4476,"briefTitle":4477,"status":246,"phases":6985,"primaryCompletion":4479,"completion":4479,"start":4480,"enrollment":240,"conditions":6986,"interventions":6987},[92],[18],[4483,1672,4484,4485,4486],{"trials":6989,"activeCount":103},[],{"trials":6991,"activeCount":103},[],{"trials":6993,"activeCount":103},[],{"intervention":6995,"totalTrials":240,"cells":6996},"N-acetylcysteine placebo and silibin placebo",{"EARLY_PHASE1":6997,"PHASE1":6999,"PHASE2":7001,"PHASE3":7019,"PHASE4":7021,"NA":7023},{"trials":6998,"activeCount":103},[],{"trials":7000,"activeCount":103},[],{"trials":7002,"activeCount":103},[7003],{"nctId":7004,"briefTitle":7005,"status":174,"phases":7006,"primaryCompletion":7007,"completion":7008,"start":7009,"enrollment":1567,"conditions":7010,"interventions":7014},"NCT01265563","N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy",[92],"2015-02","2016-12","2011-01",[7011,7012,7013],"Diabetic Nephropathy","Proteinuria","Oxidative Stress",[6995,7015,7016,7017,7018],"N-acetylcysteine active and silibin placebo","N-acetylcysteine placebo and silibin active","N-acetylcysteine active and silibin active","N-acetylcysteine active + high-dose silibin active",{"trials":7020,"activeCount":103},[],{"trials":7022,"activeCount":103},[],{"trials":7024,"activeCount":103},[],{"intervention":7015,"totalTrials":240,"cells":7026},{"EARLY_PHASE1":7027,"PHASE1":7029,"PHASE2":7031,"PHASE3":7037,"PHASE4":7039,"NA":7041},{"trials":7028,"activeCount":103},[],{"trials":7030,"activeCount":103},[],{"trials":7032,"activeCount":103},[7033],{"nctId":7004,"briefTitle":7005,"status":174,"phases":7034,"primaryCompletion":7007,"completion":7008,"start":7009,"enrollment":1567,"conditions":7035,"interventions":7036},[92],[7011,7012,7013],[6995,7015,7016,7017,7018],{"trials":7038,"activeCount":103},[],{"trials":7040,"activeCount":103},[],{"trials":7042,"activeCount":103},[],{"intervention":7016,"totalTrials":240,"cells":7044},{"EARLY_PHASE1":7045,"PHASE1":7047,"PHASE2":7049,"PHASE3":7055,"PHASE4":7057,"NA":7059},{"trials":7046,"activeCount":103},[],{"trials":7048,"activeCount":103},[],{"trials":7050,"activeCount":103},[7051],{"nctId":7004,"briefTitle":7005,"status":174,"phases":7052,"primaryCompletion":7007,"completion":7008,"start":7009,"enrollment":1567,"conditions":7053,"interventions":7054},[92],[7011,7012,7013],[6995,7015,7016,7017,7018],{"trials":7056,"activeCount":103},[],{"trials":7058,"activeCount":103},[],{"trials":7060,"activeCount":103},[],{"intervention":7017,"totalTrials":240,"cells":7062},{"EARLY_PHASE1":7063,"PHASE1":7065,"PHASE2":7067,"PHASE3":7073,"PHASE4":7075,"NA":7077},{"trials":7064,"activeCount":103},[],{"trials":7066,"activeCount":103},[],{"trials":7068,"activeCount":103},[7069],{"nctId":7004,"briefTitle":7005,"status":174,"phases":7070,"primaryCompletion":7007,"completion":7008,"start":7009,"enrollment":1567,"conditions":7071,"interventions":7072},[92],[7011,7012,7013],[6995,7015,7016,7017,7018],{"trials":7074,"activeCount":103},[],{"trials":7076,"activeCount":103},[],{"trials":7078,"activeCount":103},[],{"intervention":7018,"totalTrials":240,"cells":7080},{"EARLY_PHASE1":7081,"PHASE1":7083,"PHASE2":7085,"PHASE3":7091,"PHASE4":7093,"NA":7095},{"trials":7082,"activeCount":103},[],{"trials":7084,"activeCount":103},[],{"trials":7086,"activeCount":103},[7087],{"nctId":7004,"briefTitle":7005,"status":174,"phases":7088,"primaryCompletion":7007,"completion":7008,"start":7009,"enrollment":1567,"conditions":7089,"interventions":7090},[92],[7011,7012,7013],[6995,7015,7016,7017,7018],{"trials":7092,"activeCount":103},[],{"trials":7094,"activeCount":103},[],{"trials":7096,"activeCount":103},[],{"intervention":7098,"totalTrials":240,"cells":7099},"Darbepoetin",{"EARLY_PHASE1":7100,"PHASE1":7102,"PHASE2":7104,"PHASE3":7116,"PHASE4":7118,"NA":7120},{"trials":7101,"activeCount":103},[],{"trials":7103,"activeCount":103},[],{"trials":7105,"activeCount":103},[7106],{"nctId":7107,"briefTitle":7108,"status":246,"phases":7109,"primaryCompletion":7110,"completion":5344,"start":7111,"enrollment":7112,"conditions":7113,"interventions":7115},"NCT03810911","Mechanisms of EPO-induced Hypertension",[92],"2024-12-31","2021-01-04",27,[159,7114,4339],"Blood Pressure",[7098],{"trials":7117,"activeCount":103},[],{"trials":7119,"activeCount":103},[],{"trials":7121,"activeCount":103},[],{"intervention":7123,"totalTrials":240,"cells":7124},"NIC5-15",{"EARLY_PHASE1":7125,"PHASE1":7127,"PHASE2":7129,"PHASE3":7138,"PHASE4":7140,"NA":7142},{"trials":7126,"activeCount":103},[],{"trials":7128,"activeCount":103},[],{"trials":7130,"activeCount":103},[7131],{"nctId":7132,"briefTitle":7133,"status":174,"phases":7134,"primaryCompletion":7135,"completion":189,"start":356,"enrollment":2797,"conditions":7136,"interventions":7137},"NCT00470418","Development of NIC5-15 in the Treatment of Alzheimer's Disease",[92],"2008-08",[4136,196],[7123],{"trials":7139,"activeCount":103},[],{"trials":7141,"activeCount":103},[],{"trials":7143,"activeCount":103},[],{"intervention":7145,"totalTrials":240,"cells":7146},"desipramine hydrochloride",{"EARLY_PHASE1":7147,"PHASE1":7149,"PHASE2":7151,"PHASE3":7162,"PHASE4":7164,"NA":7166},{"trials":7148,"activeCount":103},[],{"trials":7150,"activeCount":103},[],{"trials":7152,"activeCount":103},[7153],{"nctId":7154,"briefTitle":7155,"status":174,"phases":7156,"primaryCompletion":5782,"completion":5771,"start":7157,"enrollment":1275,"conditions":7158,"interventions":7160},"NCT00964886","Efficacy of Antidepressants in Chronic Back Pain",[92],"2010-01",[7159],"Back Pain",[7145,7161,7145],"benztropine mesylate 0.125 mg daily",{"trials":7163,"activeCount":103},[],{"trials":7165,"activeCount":103},[],{"trials":7167,"activeCount":103},[],{"intervention":7161,"totalTrials":240,"cells":7169},{"EARLY_PHASE1":7170,"PHASE1":7172,"PHASE2":7174,"PHASE3":7180,"PHASE4":7182,"NA":7184},{"trials":7171,"activeCount":103},[],{"trials":7173,"activeCount":103},[],{"trials":7175,"activeCount":103},[7176],{"nctId":7154,"briefTitle":7155,"status":174,"phases":7177,"primaryCompletion":5782,"completion":5771,"start":7157,"enrollment":1275,"conditions":7178,"interventions":7179},[92],[7159],[7145,7161,7145],{"trials":7181,"activeCount":103},[],{"trials":7183,"activeCount":103},[],{"trials":7185,"activeCount":103},[],{"intervention":7187,"totalTrials":240,"cells":7188},"Poly ICLC",{"EARLY_PHASE1":7189,"PHASE1":7191,"PHASE2":7193,"PHASE3":7203,"PHASE4":7205,"NA":7207},{"trials":7190,"activeCount":103},[],{"trials":7192,"activeCount":103},[],{"trials":7194,"activeCount":103},[7195],{"nctId":7196,"briefTitle":7197,"status":2693,"phases":7198,"primaryCompletion":7199,"completion":7199,"start":7199,"enrollment":103,"conditions":7200,"interventions":7201},"NCT06064279","Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC",[91,92],"2024-06-04",[2970],[7187,7202],"IVIG",{"trials":7204,"activeCount":103},[],{"trials":7206,"activeCount":103},[],{"trials":7208,"activeCount":103},[],{"intervention":7202,"totalTrials":240,"cells":7210},{"EARLY_PHASE1":7211,"PHASE1":7213,"PHASE2":7215,"PHASE3":7221,"PHASE4":7223,"NA":7225},{"trials":7212,"activeCount":103},[],{"trials":7214,"activeCount":103},[],{"trials":7216,"activeCount":103},[7217],{"nctId":7196,"briefTitle":7197,"status":2693,"phases":7218,"primaryCompletion":7199,"completion":7199,"start":7199,"enrollment":103,"conditions":7219,"interventions":7220},[91,92],[2970],[7187,7202],{"trials":7222,"activeCount":103},[],{"trials":7224,"activeCount":103},[],{"trials":7226,"activeCount":103},[],{"intervention":7228,"totalTrials":240,"cells":7229},"Lithium Carbonate",{"EARLY_PHASE1":7230,"PHASE1":7232,"PHASE2":7234,"PHASE3":7242,"PHASE4":7244,"NA":7246},{"trials":7231,"activeCount":103},[],{"trials":7233,"activeCount":103},[],{"trials":7235,"activeCount":103},[7236],{"nctId":7237,"briefTitle":7238,"status":174,"phases":7239,"primaryCompletion":4601,"completion":5771,"start":5684,"enrollment":5548,"conditions":7240,"interventions":7241},"NCT01259388","A Pilot Study of Lithium in Progressive Multiple Sclerosis",[91,92],[4593],[7228],{"trials":7243,"activeCount":103},[],{"trials":7245,"activeCount":103},[],{"trials":7247,"activeCount":103},[],{"intervention":7249,"totalTrials":240,"cells":7250},"Leuprolide",{"EARLY_PHASE1":7251,"PHASE1":7253,"PHASE2":7255,"PHASE3":7267,"PHASE4":7269,"NA":7271},{"trials":7252,"activeCount":103},[],{"trials":7254,"activeCount":103},[],{"trials":7256,"activeCount":103},[7257],{"nctId":7258,"briefTitle":7259,"status":174,"phases":7260,"primaryCompletion":4939,"completion":4939,"start":4428,"enrollment":7261,"conditions":7262,"interventions":7264},"NCT03298087","Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer",[92],28,[7263],"Newly Diagnosed Oligometastatic Prostate Cancer",[7249,7265,7266],"apalutamide","abiraterone",{"trials":7268,"activeCount":103},[],{"trials":7270,"activeCount":103},[],{"trials":7272,"activeCount":103},[],{"intervention":7265,"totalTrials":240,"cells":7274},{"EARLY_PHASE1":7275,"PHASE1":7277,"PHASE2":7279,"PHASE3":7285,"PHASE4":7287,"NA":7289},{"trials":7276,"activeCount":103},[],{"trials":7278,"activeCount":103},[],{"trials":7280,"activeCount":103},[7281],{"nctId":7258,"briefTitle":7259,"status":174,"phases":7282,"primaryCompletion":4939,"completion":4939,"start":4428,"enrollment":7261,"conditions":7283,"interventions":7284},[92],[7263],[7249,7265,7266],{"trials":7286,"activeCount":103},[],{"trials":7288,"activeCount":103},[],{"trials":7290,"activeCount":103},[],{"intervention":7266,"totalTrials":240,"cells":7292},{"EARLY_PHASE1":7293,"PHASE1":7295,"PHASE2":7297,"PHASE3":7303,"PHASE4":7305,"NA":7307},{"trials":7294,"activeCount":103},[],{"trials":7296,"activeCount":103},[],{"trials":7298,"activeCount":103},[7299],{"nctId":7258,"briefTitle":7259,"status":174,"phases":7300,"primaryCompletion":4939,"completion":4939,"start":4428,"enrollment":7261,"conditions":7301,"interventions":7302},[92],[7263],[7249,7265,7266],{"trials":7304,"activeCount":103},[],{"trials":7306,"activeCount":103},[],{"trials":7308,"activeCount":103},[],{"intervention":7310,"totalTrials":240,"cells":7311},"Dalfampridine",{"EARLY_PHASE1":7312,"PHASE1":7314,"PHASE2":7316,"PHASE3":7327,"PHASE4":7329,"NA":7331},{"trials":7313,"activeCount":103},[],{"trials":7315,"activeCount":103},[],{"trials":7317,"activeCount":103},[7318],{"nctId":7319,"briefTitle":7320,"status":174,"phases":7321,"primaryCompletion":7322,"completion":7323,"start":1679,"enrollment":5548,"conditions":7324,"interventions":7326},"NCT02391961","Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis",[92],"2019-01-31","2019-03-31",[4593,7325,1580],"Internuclear Ophthalmoplegia",[7310],{"trials":7328,"activeCount":103},[],{"trials":7330,"activeCount":103},[],{"trials":7332,"activeCount":103},[],{"intervention":7334,"totalTrials":240,"cells":7335},"Buprenorphine",{"EARLY_PHASE1":7336,"PHASE1":7338,"PHASE2":7340,"PHASE3":7351,"PHASE4":7353,"NA":7355},{"trials":7337,"activeCount":103},[],{"trials":7339,"activeCount":103},[],{"trials":7341,"activeCount":103},[7342],{"nctId":7343,"briefTitle":7344,"status":246,"phases":7345,"primaryCompletion":7346,"completion":7346,"start":4874,"enrollment":5163,"conditions":7347,"interventions":7350},"NCT03605342","Optimal Treatment of Veterans With PTSD and Comorbid OUD",[92],"2023-04-14",[7348,7349],"Post-Traumatic Stress Disorders","Opiate Use Disorder",[7334],{"trials":7352,"activeCount":103},[],{"trials":7354,"activeCount":103},[],{"trials":7356,"activeCount":103},[],{"intervention":7358,"totalTrials":240,"cells":7359},"PIOGLITAZONE VS. PLACEBO 30 mg",{"EARLY_PHASE1":7360,"PHASE1":7362,"PHASE2":7364,"PHASE3":7375,"PHASE4":7377,"NA":7379},{"trials":7361,"activeCount":103},[],{"trials":7363,"activeCount":103},[],{"trials":7365,"activeCount":103},[7366],{"nctId":7367,"briefTitle":7368,"status":174,"phases":7369,"primaryCompletion":5391,"completion":7370,"start":7371,"enrollment":4109,"conditions":7372,"interventions":7374},"NCT00780234","Pioglitazone for Lung Cancer Chemoprevention",[92],"2017-08","2009-08",[6238,7373],"Endobronchial Dysplasia",[7358],{"trials":7376,"activeCount":103},[],{"trials":7378,"activeCount":103},[],{"trials":7380,"activeCount":103},[],{"intervention":7382,"totalTrials":240,"cells":7383},"Active Ethanol",{"EARLY_PHASE1":7384,"PHASE1":7386,"PHASE2":7404,"PHASE3":7406,"PHASE4":7408,"NA":7410},{"trials":7385,"activeCount":103},[],{"trials":7387,"activeCount":103},[7388],{"nctId":7389,"briefTitle":7390,"status":174,"phases":7391,"primaryCompletion":7392,"completion":7392,"start":7393,"enrollment":370,"conditions":7394,"interventions":7402},"NCT01590277","Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans",[91],"2018-11-02","2012-12-14",[7395,7396,7397,7398,7399,7400,7401],"Active Ethanol and Active Iomazenil","Active Ethanol and Placebo Iomazenil","Placebo Ethanol and Active Iomazenil","Placebo Ethanol and Placebo Iomazenil","Alcohol Effect","Driving Under the Influence","Alcohol Impairment",[7382,7403],"Active Iomazenil",{"trials":7405,"activeCount":103},[],{"trials":7407,"activeCount":103},[],{"trials":7409,"activeCount":103},[],{"trials":7411,"activeCount":103},[],{"intervention":7403,"totalTrials":240,"cells":7413},{"EARLY_PHASE1":7414,"PHASE1":7416,"PHASE2":7422,"PHASE3":7424,"PHASE4":7426,"NA":7428},{"trials":7415,"activeCount":103},[],{"trials":7417,"activeCount":103},[7418],{"nctId":7389,"briefTitle":7390,"status":174,"phases":7419,"primaryCompletion":7392,"completion":7392,"start":7393,"enrollment":370,"conditions":7420,"interventions":7421},[91],[7395,7396,7397,7398,7399,7400,7401],[7382,7403],{"trials":7423,"activeCount":103},[],{"trials":7425,"activeCount":103},[],{"trials":7427,"activeCount":103},[],{"trials":7429,"activeCount":103},[],{"intervention":7431,"totalTrials":240,"cells":7432},"EC17 imaging contrast agent",{"EARLY_PHASE1":7433,"PHASE1":7435,"PHASE2":7444,"PHASE3":7446,"PHASE4":7448,"NA":7450},{"trials":7434,"activeCount":103},[],{"trials":7436,"activeCount":103},[7437],{"nctId":7438,"briefTitle":7439,"status":2693,"phases":7440,"primaryCompletion":7441,"completion":7441,"start":2661,"enrollment":103,"conditions":7442,"interventions":7443},"NCT02653612","Intraoperative Imaging of Pulmonary Adenocarcinoma",[91],"2018-02-26",[6238],[7431],{"trials":7445,"activeCount":103},[],{"trials":7447,"activeCount":103},[],{"trials":7449,"activeCount":103},[],{"trials":7451,"activeCount":103},[],{"intervention":7453,"totalTrials":240,"cells":7454},"citalopram",{"EARLY_PHASE1":7455,"PHASE1":7457,"PHASE2":7467,"PHASE3":7469,"PHASE4":7471,"NA":7473},{"trials":7456,"activeCount":103},[],{"trials":7458,"activeCount":103},[7459],{"nctId":7460,"briefTitle":7461,"status":174,"phases":7462,"primaryCompletion":7463,"completion":5738,"start":7464,"enrollment":5644,"conditions":7465,"interventions":7466},"NCT01657760","Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics",[91],"2017-08-31","2014-05-01",[3147],[7453],{"trials":7468,"activeCount":103},[],{"trials":7470,"activeCount":103},[],{"trials":7472,"activeCount":103},[],{"trials":7474,"activeCount":103},[],{"intervention":7476,"totalTrials":240,"cells":7477},"autologous dendritic cell adenovirus CCL21 vaccine",{"EARLY_PHASE1":7478,"PHASE1":7480,"PHASE2":7490,"PHASE3":7492,"PHASE4":7494,"NA":7496},{"trials":7479,"activeCount":103},[],{"trials":7481,"activeCount":103},[7482],{"nctId":7483,"briefTitle":7484,"status":246,"phases":7485,"primaryCompletion":5958,"completion":5958,"start":7486,"enrollment":240,"conditions":7487,"interventions":7489},"NCT01574222","A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer",[91],"2011-10-01",[7488],"Non-Small Cell Lung Cancer (NSCLC)",[7476],{"trials":7491,"activeCount":103},[],{"trials":7493,"activeCount":103},[],{"trials":7495,"activeCount":103},[],{"trials":7497,"activeCount":103},[],{"intervention":7499,"totalTrials":240,"cells":7500},"Docosahexaenoic Acid",{"EARLY_PHASE1":7501,"PHASE1":7503,"PHASE2":7512,"PHASE3":7514,"PHASE4":7516,"NA":7518},{"trials":7502,"activeCount":103},[],{"trials":7504,"activeCount":103},[7505],{"nctId":7506,"briefTitle":7507,"status":174,"phases":7508,"primaryCompletion":5391,"completion":5391,"start":7509,"enrollment":370,"conditions":7510,"interventions":7511},"NCT01563913","Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids",[91],"2012-10",[1700],[7499],{"trials":7513,"activeCount":103},[],{"trials":7515,"activeCount":103},[],{"trials":7517,"activeCount":103},[],{"trials":7519,"activeCount":103},[],{"intervention":7521,"totalTrials":240,"cells":7522},"Sham rTMS+Exercise",{"EARLY_PHASE1":7523,"PHASE1":7525,"PHASE2":7535,"PHASE3":7537,"PHASE4":7539,"NA":7541},{"trials":7524,"activeCount":103},[],{"trials":7526,"activeCount":103},[7527],{"nctId":7528,"briefTitle":7529,"status":174,"phases":7530,"primaryCompletion":7531,"completion":7531,"start":177,"enrollment":3236,"conditions":7532,"interventions":7534},"NCT04672044","TMS and Exercise for Post-stroke Pain",[91],"2024-12-30",[7533],"Chronic Post-stroke Headache",[7521],{"trials":7536,"activeCount":103},[],{"trials":7538,"activeCount":103},[],{"trials":7540,"activeCount":103},[],{"trials":7542,"activeCount":103},[],{"intervention":7544,"totalTrials":240,"cells":7545},"Testosterone Cypionate",{"EARLY_PHASE1":7546,"PHASE1":7548,"PHASE2":7558,"PHASE3":7560,"PHASE4":7562,"NA":7564},{"trials":7547,"activeCount":103},[],{"trials":7549,"activeCount":103},[7550],{"nctId":7551,"briefTitle":7552,"status":174,"phases":7553,"primaryCompletion":7554,"completion":7555,"start":7486,"enrollment":4025,"conditions":7556,"interventions":7557},"NCT01378299","CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy",[91],"2016-11-07","2017-11-07",[380],[7544],{"trials":7559,"activeCount":103},[],{"trials":7561,"activeCount":103},[],{"trials":7563,"activeCount":103},[],{"trials":7565,"activeCount":103},[],{"intervention":7567,"totalTrials":240,"cells":7568},"Pharmacokinetic",{"EARLY_PHASE1":7569,"PHASE1":7571,"PHASE2":7578,"PHASE3":7580,"PHASE4":7582,"NA":7584},{"trials":7570,"activeCount":103},[],{"trials":7572,"activeCount":103},[7573],{"nctId":7574,"briefTitle":6300,"status":174,"phases":7575,"primaryCompletion":355,"completion":355,"start":7157,"enrollment":6624,"conditions":7576,"interventions":7577},"NCT00952393",[91],[33],[7567],{"trials":7579,"activeCount":103},[],{"trials":7581,"activeCount":103},[],{"trials":7583,"activeCount":103},[],{"trials":7585,"activeCount":103},[],{"intervention":7587,"totalTrials":240,"cells":7588},"1 million MSCs\u002Fkg",{"EARLY_PHASE1":7589,"PHASE1":7591,"PHASE2":7602,"PHASE3":7604,"PHASE4":7606,"NA":7608},{"trials":7590,"activeCount":103},[],{"trials":7592,"activeCount":103},[7593],{"nctId":7594,"briefTitle":7595,"status":246,"phases":7596,"primaryCompletion":4898,"completion":4898,"start":7597,"enrollment":7261,"conditions":7598,"interventions":7600},"NCT02846883","Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms",[91],"2016-12-05",[7599],"Abdominal Aortic Aneurysm",[7587,7601],"3 million MSCs\u002Fkg",{"trials":7603,"activeCount":103},[],{"trials":7605,"activeCount":103},[],{"trials":7607,"activeCount":103},[],{"trials":7609,"activeCount":103},[],{"intervention":7601,"totalTrials":240,"cells":7611},{"EARLY_PHASE1":7612,"PHASE1":7614,"PHASE2":7620,"PHASE3":7622,"PHASE4":7624,"NA":7626},{"trials":7613,"activeCount":103},[],{"trials":7615,"activeCount":103},[7616],{"nctId":7594,"briefTitle":7595,"status":246,"phases":7617,"primaryCompletion":4898,"completion":4898,"start":7597,"enrollment":7261,"conditions":7618,"interventions":7619},[91],[7599],[7587,7601],{"trials":7621,"activeCount":103},[],{"trials":7623,"activeCount":103},[],{"trials":7625,"activeCount":103},[],{"trials":7627,"activeCount":103},[],{"intervention":7629,"totalTrials":240,"cells":7630},"APLA12",{"EARLY_PHASE1":7631,"PHASE1":7633,"PHASE2":7642,"PHASE3":7644,"PHASE4":7646,"NA":7648},{"trials":7632,"activeCount":103},[],{"trials":7634,"activeCount":103},[7635],{"nctId":7636,"briefTitle":7637,"status":174,"phases":7638,"primaryCompletion":3121,"completion":3121,"start":5618,"enrollment":7639,"conditions":7640,"interventions":7641},"NCT01123655","Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients",[91],22,[2521],[7629],{"trials":7643,"activeCount":103},[],{"trials":7645,"activeCount":103},[],{"trials":7647,"activeCount":103},[],{"trials":7649,"activeCount":103},[],{"intervention":7651,"totalTrials":240,"cells":7652},"Intrathecal Fentanyl",{"EARLY_PHASE1":7653,"PHASE1":7664,"PHASE2":7666,"PHASE3":7668,"PHASE4":7670,"NA":7672},{"trials":7654,"activeCount":103},[7655],{"nctId":7656,"briefTitle":7657,"status":174,"phases":7658,"primaryCompletion":7659,"completion":7659,"start":7660,"enrollment":7661,"conditions":7662,"interventions":7663},"NCT02209610","Premature Fatigue in Veterans With Heart Failure: Neuronal Influences",[90],"2017-01-15","2015-07-01",32,[254],[7651],{"trials":7665,"activeCount":103},[],{"trials":7667,"activeCount":103},[],{"trials":7669,"activeCount":103},[],{"trials":7671,"activeCount":103},[],{"trials":7673,"activeCount":103},[],{"intervention":7675,"totalTrials":240,"cells":7676},"BQ-123",{"EARLY_PHASE1":7677,"PHASE1":7686,"PHASE2":7688,"PHASE3":7690,"PHASE4":7692,"NA":7694},{"trials":7678,"activeCount":103},[7679],{"nctId":7680,"briefTitle":7681,"status":174,"phases":7682,"primaryCompletion":7323,"completion":7323,"start":7683,"enrollment":2185,"conditions":7684,"interventions":7685},"NCT02124824","Contribution of Endothelin-1 to Exercise Intolerance in Heart Failure",[90],"2014-09-01",[254],[7675],{"trials":7687,"activeCount":103},[],{"trials":7689,"activeCount":103},[],{"trials":7691,"activeCount":103},[],{"trials":7693,"activeCount":103},[],{"trials":7695,"activeCount":103},[],{"intervention":7697,"totalTrials":240,"cells":7698},"Antioxidant cocktail",{"EARLY_PHASE1":7699,"PHASE1":7709,"PHASE2":7711,"PHASE3":7713,"PHASE4":7715,"NA":7717},{"trials":7700,"activeCount":103},[7701],{"nctId":7702,"briefTitle":7703,"status":174,"phases":7704,"primaryCompletion":7705,"completion":7705,"start":3934,"enrollment":6192,"conditions":7706,"interventions":7708},"NCT00860743","Respiratory and Autonomic Plasticity Following Intermittent Hypoxia",[90],"2013-09",[7707],"Sleep Apnea Syndromes",[7697],{"trials":7710,"activeCount":103},[],{"trials":7712,"activeCount":103},[],{"trials":7714,"activeCount":103},[],{"trials":7716,"activeCount":103},[],{"trials":7718,"activeCount":103},[],{"intervention":3292,"totalTrials":240,"cells":7720},{"EARLY_PHASE1":7721,"PHASE1":7727,"PHASE2":7729,"PHASE3":7731,"PHASE4":7733,"NA":7735},{"trials":7722,"activeCount":103},[7723],{"nctId":3284,"briefTitle":3285,"status":246,"phases":7724,"primaryCompletion":3287,"completion":3287,"start":3288,"enrollment":116,"conditions":7725,"interventions":7726},[90],[3290],[3279,3292],{"trials":7728,"activeCount":103},[],{"trials":7730,"activeCount":103},[],{"trials":7732,"activeCount":103},[],{"trials":7734,"activeCount":103},[],{"trials":7736,"activeCount":103},[],{"intervention":7738,"totalTrials":240,"cells":7739},"23 valent pneumococcal polysaccharide vaccine",{"EARLY_PHASE1":7740,"PHASE1":7753,"PHASE2":7755,"PHASE3":7757,"PHASE4":7759,"NA":7761},{"trials":7741,"activeCount":103},[7742],{"nctId":7743,"briefTitle":7744,"status":246,"phases":7745,"primaryCompletion":7746,"completion":7746,"start":7747,"enrollment":7748,"conditions":7749,"interventions":7751},"NCT03802994","Pneumococcal Conjugate Vaccine in Aging Renal Transplant",[90],"2020-02-28","2018-11-01",57,[7750,2924],"Renal Transplantation",[7738,7752],"13 valent conjugated pneumococcal vaccine",{"trials":7754,"activeCount":103},[],{"trials":7756,"activeCount":103},[],{"trials":7758,"activeCount":103},[],{"trials":7760,"activeCount":103},[],{"trials":7762,"activeCount":103},[],{"intervention":7752,"totalTrials":240,"cells":7764},{"EARLY_PHASE1":7765,"PHASE1":7771,"PHASE2":7773,"PHASE3":7775,"PHASE4":7777,"NA":7779},{"trials":7766,"activeCount":103},[7767],{"nctId":7743,"briefTitle":7744,"status":246,"phases":7768,"primaryCompletion":7746,"completion":7746,"start":7747,"enrollment":7748,"conditions":7769,"interventions":7770},[90],[7750,2924],[7738,7752],{"trials":7772,"activeCount":103},[],{"trials":7774,"activeCount":103},[],{"trials":7776,"activeCount":103},[],{"trials":7778,"activeCount":103},[],{"trials":7780,"activeCount":103},[],{"intervention":7782,"totalTrials":240,"cells":7783},"Tolcapone",{"EARLY_PHASE1":7784,"PHASE1":7794,"PHASE2":7796,"PHASE3":7798,"PHASE4":7800,"NA":7802},{"trials":7785,"activeCount":103},[7786],{"nctId":7787,"briefTitle":7788,"status":174,"phases":7789,"primaryCompletion":4897,"completion":4897,"start":7790,"enrollment":7791,"conditions":7792,"interventions":7793},"NCT02260570","Remediation of Impaired Self-Regulation in Patients With Mild TBI",[90],"2015-08-01",55,[1171],[7782],{"trials":7795,"activeCount":103},[],{"trials":7797,"activeCount":103},[],{"trials":7799,"activeCount":103},[],{"trials":7801,"activeCount":103},[],{"trials":7803,"activeCount":103},[],{"intervention":7805,"totalTrials":132,"cells":7806},"fenofibrate",{"EARLY_PHASE1":7807,"PHASE1":7809,"PHASE2":7811,"PHASE3":7813,"PHASE4":7825,"NA":7827},{"trials":7808,"activeCount":103},[],{"trials":7810,"activeCount":103},[],{"trials":7812,"activeCount":103},[],{"trials":7814,"activeCount":103},[7815],{"nctId":7816,"briefTitle":7817,"status":174,"phases":7818,"primaryCompletion":7819,"completion":7819,"start":7820,"enrollment":5548,"conditions":7821,"interventions":7823},"NCT02455336","Fenofibrate Treatment in SCI",[92,93],"2018-08-01","2015-05-18",[30,7822],"Dyslipidemia",[7824],"Fenofibrate",{"trials":7826,"activeCount":103},[],{"trials":7828,"activeCount":103},[7829],{"nctId":7830,"briefTitle":7831,"status":246,"phases":7832,"primaryCompletion":7833,"completion":7834,"start":3935,"enrollment":4134,"conditions":7835,"interventions":7837},"NCT01289639","Insulin Resistance in Non-alcoholic Fatty Liver Disease",[95],"2013-08","2014-08",[7836],"Fatty Liver",[7805,4028],{"intervention":4028,"totalTrials":132,"cells":7839},{"EARLY_PHASE1":7840,"PHASE1":7842,"PHASE2":7844,"PHASE3":7846,"PHASE4":7848,"NA":7854},{"trials":7841,"activeCount":103},[],{"trials":7843,"activeCount":103},[],{"trials":7845,"activeCount":103},[],{"trials":7847,"activeCount":103},[],{"trials":7849,"activeCount":103},[7850],{"nctId":4019,"briefTitle":4020,"status":174,"phases":7851,"primaryCompletion":4022,"completion":4023,"start":4024,"enrollment":4025,"conditions":7852,"interventions":7853},[94],[2365],[4006,4028,4006,4029],{"trials":7855,"activeCount":103},[7856],{"nctId":7830,"briefTitle":7831,"status":246,"phases":7857,"primaryCompletion":7833,"completion":7834,"start":3935,"enrollment":4134,"conditions":7858,"interventions":7859},[95],[7836],[7805,4028],{"intervention":4433,"totalTrials":132,"cells":7861},{"EARLY_PHASE1":7862,"PHASE1":7864,"PHASE2":7866,"PHASE3":7868,"PHASE4":7870,"NA":7876},{"trials":7863,"activeCount":103},[],{"trials":7865,"activeCount":103},[],{"trials":7867,"activeCount":103},[],{"trials":7869,"activeCount":103},[],{"trials":7871,"activeCount":103},[7872],{"nctId":4425,"briefTitle":4426,"status":246,"phases":7873,"primaryCompletion":3168,"completion":3168,"start":4428,"enrollment":4429,"conditions":7874,"interventions":7875},[94],[4431],[4412,4433],{"trials":7877,"activeCount":103},[7878],{"nctId":7879,"briefTitle":7880,"status":174,"phases":7881,"primaryCompletion":7705,"completion":7705,"start":7882,"enrollment":7883,"conditions":7884,"interventions":7885},"NCT01090180","Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD",[95],"2010-04",129,[24],[4433],{"intervention":7887,"totalTrials":132,"cells":7888},"Testosterone",{"EARLY_PHASE1":7889,"PHASE1":7891,"PHASE2":7893,"PHASE3":7895,"PHASE4":7906,"NA":7908},{"trials":7890,"activeCount":103},[],{"trials":7892,"activeCount":103},[],{"trials":7894,"activeCount":103},[],{"trials":7896,"activeCount":103},[7897],{"nctId":7898,"briefTitle":7899,"status":174,"phases":7900,"primaryCompletion":7901,"completion":2660,"start":7902,"enrollment":9,"conditions":7903,"interventions":7905},"NCT02367105","Lifestyle Intervention and Testosterone Replacement in Obese Seniors",[93],"2019-07-31","2015-02-01",[7904],"Obesity and Hypogonadism",[7887],{"trials":7907,"activeCount":103},[],{"trials":7909,"activeCount":103},[7910],{"nctId":7911,"briefTitle":7912,"status":174,"phases":7913,"primaryCompletion":7914,"completion":4023,"start":7915,"enrollment":370,"conditions":7916,"interventions":7917},"NCT00680797","Metabolic Effects of Androgenicity in Aging Men and Women",[95],"2013-12-31","2005-01-01",[2924,4742],[7887,7918],"Estrogen",{"intervention":4388,"totalTrials":132,"cells":7920},{"EARLY_PHASE1":7921,"PHASE1":7923,"PHASE2":7925,"PHASE3":7927,"PHASE4":7929,"NA":7935},{"trials":7922,"activeCount":103},[],{"trials":7924,"activeCount":103},[],{"trials":7926,"activeCount":103},[],{"trials":7928,"activeCount":103},[],{"trials":7930,"activeCount":103},[7931],{"nctId":4378,"briefTitle":4379,"status":246,"phases":7932,"primaryCompletion":4381,"completion":4382,"start":4383,"enrollment":4384,"conditions":7933,"interventions":7934},[94],[4386,4387,4365,4388],[4365,4390,4388],{"trials":7936,"activeCount":103},[7937],{"nctId":7938,"briefTitle":7939,"status":174,"phases":7940,"primaryCompletion":7941,"completion":7941,"start":5740,"enrollment":7942,"conditions":7943,"interventions":7945},"NCT02216227","Checklist to Prevent MRSA Surgical Site Infections",[95],"2021-02-28",23005,[7944],"Surgical Site Infection",[7946,7947,7948,4388,7949],"Mupirocin","Chlorhexidine gluconate","Cefazolin","Nasal Povidone Iodine",{"intervention":7951,"totalTrials":132,"cells":7952},"simvastatin",{"EARLY_PHASE1":7953,"PHASE1":7955,"PHASE2":7957,"PHASE3":7959,"PHASE4":7961,"NA":7972},{"trials":7954,"activeCount":103},[],{"trials":7956,"activeCount":103},[],{"trials":7958,"activeCount":103},[],{"trials":7960,"activeCount":103},[],{"trials":7962,"activeCount":103},[7963],{"nctId":7964,"briefTitle":7965,"status":174,"phases":7966,"primaryCompletion":7967,"completion":7967,"start":7968,"enrollment":1544,"conditions":7969,"interventions":7971},"NCT01952288","Simvastatin for mTBI",[94],"2017-06-20","2013-09-16",[7970],"TBI-Traumatic Brain Injury",[7951],{"trials":7973,"activeCount":103},[7974],{"nctId":7975,"briefTitle":7976,"status":174,"phases":7977,"primaryCompletion":7978,"completion":7979,"start":7980,"enrollment":3936,"conditions":7981,"interventions":7983},"NCT00572468","Statin Therapy Versus Placebo Prior to Prostatectomy",[95],"2013-04","2017-04-30","2007-12",[7982,1373],"Cancer",[7984],"Simvastatin",{"intervention":7986,"totalTrials":240,"cells":7987},"1.25 mg enalaprilat IV",{"EARLY_PHASE1":7988,"PHASE1":7990,"PHASE2":7992,"PHASE3":7994,"PHASE4":7996,"NA":7998},{"trials":7989,"activeCount":103},[],{"trials":7991,"activeCount":103},[],{"trials":7993,"activeCount":103},[],{"trials":7995,"activeCount":103},[],{"trials":7997,"activeCount":103},[],{"trials":7999,"activeCount":103},[8000],{"nctId":8001,"briefTitle":8002,"status":174,"phases":8003,"primaryCompletion":410,"completion":5784,"start":3935,"enrollment":2185,"conditions":8004,"interventions":8006},"NCT00248807","A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury.",[95],[8005,372],"Orthostatic Hypotension",[7986],{"intervention":8008,"totalTrials":240,"cells":8009},"Sodium bicarbonate",{"EARLY_PHASE1":8010,"PHASE1":8012,"PHASE2":8014,"PHASE3":8016,"PHASE4":8018,"NA":8020},{"trials":8011,"activeCount":103},[],{"trials":8013,"activeCount":103},[],{"trials":8015,"activeCount":103},[],{"trials":8017,"activeCount":103},[],{"trials":8019,"activeCount":103},[],{"trials":8021,"activeCount":103},[8022],{"nctId":8023,"briefTitle":8024,"status":174,"phases":8025,"primaryCompletion":4624,"completion":4624,"start":8026,"enrollment":16,"conditions":8027,"interventions":8030},"NCT01574157","Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.",[95],"2012-11-05",[8028,8029],"Chronic Renal Insufficiency","Diabetes Mellitus",[8008],{"intervention":8032,"totalTrials":240,"cells":8033},"TDAP",{"EARLY_PHASE1":8034,"PHASE1":8036,"PHASE2":8038,"PHASE3":8040,"PHASE4":8042,"NA":8044},{"trials":8035,"activeCount":103},[],{"trials":8037,"activeCount":103},[],{"trials":8039,"activeCount":103},[],{"trials":8041,"activeCount":103},[],{"trials":8043,"activeCount":103},[],{"trials":8045,"activeCount":103},[8046],{"nctId":8047,"briefTitle":8048,"status":174,"phases":8049,"primaryCompletion":8050,"completion":4557,"start":8051,"enrollment":4569,"conditions":8052,"interventions":8054},"NCT02261961","Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults",[95],"2018-12-31","2014-07-23",[360,2924,8053],"Immune Function",[8032],{"intervention":8056,"totalTrials":240,"cells":8057},"Intravenous",{"EARLY_PHASE1":8058,"PHASE1":8060,"PHASE2":8062,"PHASE3":8064,"PHASE4":8066,"NA":8068},{"trials":8059,"activeCount":103},[],{"trials":8061,"activeCount":103},[],{"trials":8063,"activeCount":103},[],{"trials":8065,"activeCount":103},[],{"trials":8067,"activeCount":103},[],{"trials":8069,"activeCount":103},[8070],{"nctId":8071,"briefTitle":8072,"status":174,"phases":8073,"primaryCompletion":4939,"completion":4939,"start":8074,"enrollment":1742,"conditions":8075,"interventions":8077},"NCT04064294","Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors",[],"2019-08-22",[815,8076],"Dyskinesia, Drug-Induced",[8056],{"intervention":2633,"totalTrials":240,"cells":8079},{"EARLY_PHASE1":8080,"PHASE1":8082,"PHASE2":8084,"PHASE3":8086,"PHASE4":8088,"NA":8090},{"trials":8081,"activeCount":103},[],{"trials":8083,"activeCount":103},[],{"trials":8085,"activeCount":103},[],{"trials":8087,"activeCount":103},[],{"trials":8089,"activeCount":103},[],{"trials":8091,"activeCount":103},[8092],{"nctId":2623,"briefTitle":2624,"status":174,"phases":8093,"primaryCompletion":2626,"completion":2627,"start":2628,"enrollment":2629,"conditions":8094,"interventions":8095},[95],[2631],[2600,2633],{"intervention":8097,"totalTrials":240,"cells":8098},"COVID-19 convalescent plasma",{"EARLY_PHASE1":8099,"PHASE1":8101,"PHASE2":8103,"PHASE3":8105,"PHASE4":8107,"NA":8109},{"trials":8100,"activeCount":103},[],{"trials":8102,"activeCount":103},[],{"trials":8104,"activeCount":103},[],{"trials":8106,"activeCount":103},[],{"trials":8108,"activeCount":103},[],{"trials":8110,"activeCount":103},[8111],{"nctId":8112,"briefTitle":8113,"status":174,"phases":8114,"primaryCompletion":5369,"completion":5369,"start":8115,"enrollment":8116,"conditions":8117,"interventions":8119},"NCT04545047","Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19",[],"2020-05-01",5044,[8118],"Coronavirus Disease 2019 (COVID-19)",[8097],{"intervention":8121,"totalTrials":240,"cells":8122},"Imiquimod",{"EARLY_PHASE1":8123,"PHASE1":8125,"PHASE2":8127,"PHASE3":8129,"PHASE4":8131,"NA":8133},{"trials":8124,"activeCount":103},[],{"trials":8126,"activeCount":103},[],{"trials":8128,"activeCount":103},[],{"trials":8130,"activeCount":103},[],{"trials":8132,"activeCount":103},[],{"trials":8134,"activeCount":103},[8135],{"nctId":8136,"briefTitle":8137,"status":246,"phases":8138,"primaryCompletion":4195,"completion":8139,"start":8140,"enrollment":3236,"conditions":8141,"interventions":8143},"NCT00470392","Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis",[95],"2012-07","2007-05",[8142],"Psoriasis",[8121,8144],"Clobetasol",{"intervention":8144,"totalTrials":240,"cells":8146},{"EARLY_PHASE1":8147,"PHASE1":8149,"PHASE2":8151,"PHASE3":8153,"PHASE4":8155,"NA":8157},{"trials":8148,"activeCount":103},[],{"trials":8150,"activeCount":103},[],{"trials":8152,"activeCount":103},[],{"trials":8154,"activeCount":103},[],{"trials":8156,"activeCount":103},[],{"trials":8158,"activeCount":103},[8159],{"nctId":8136,"briefTitle":8137,"status":246,"phases":8160,"primaryCompletion":4195,"completion":8139,"start":8140,"enrollment":3236,"conditions":8161,"interventions":8162},[95],[8142],[8121,8144],{"intervention":7918,"totalTrials":240,"cells":8164},{"EARLY_PHASE1":8165,"PHASE1":8167,"PHASE2":8169,"PHASE3":8171,"PHASE4":8173,"NA":8175},{"trials":8166,"activeCount":103},[],{"trials":8168,"activeCount":103},[],{"trials":8170,"activeCount":103},[],{"trials":8172,"activeCount":103},[],{"trials":8174,"activeCount":103},[],{"trials":8176,"activeCount":103},[8177],{"nctId":7911,"briefTitle":7912,"status":174,"phases":8178,"primaryCompletion":7914,"completion":4023,"start":7915,"enrollment":370,"conditions":8179,"interventions":8180},[95],[2924,4742],[7887,7918],{"intervention":8182,"totalTrials":240,"cells":8183},"Fenofibrate 145mg PO QD",{"EARLY_PHASE1":8184,"PHASE1":8186,"PHASE2":8188,"PHASE3":8190,"PHASE4":8192,"NA":8194},{"trials":8185,"activeCount":103},[],{"trials":8187,"activeCount":103},[],{"trials":8189,"activeCount":103},[],{"trials":8191,"activeCount":103},[],{"trials":8193,"activeCount":103},[],{"trials":8195,"activeCount":103},[8196],{"nctId":8197,"briefTitle":8198,"status":174,"phases":8199,"primaryCompletion":5392,"completion":4132,"start":356,"enrollment":7112,"conditions":8200,"interventions":8202},"NCT00470262","Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation",[95],[8201,951],"Metabolic Syndrome X",[8182,8203],"Pioglitazone 45 mg PO QD",{"intervention":8203,"totalTrials":240,"cells":8205},{"EARLY_PHASE1":8206,"PHASE1":8208,"PHASE2":8210,"PHASE3":8212,"PHASE4":8214,"NA":8216},{"trials":8207,"activeCount":103},[],{"trials":8209,"activeCount":103},[],{"trials":8211,"activeCount":103},[],{"trials":8213,"activeCount":103},[],{"trials":8215,"activeCount":103},[],{"trials":8217,"activeCount":103},[8218],{"nctId":8197,"briefTitle":8198,"status":174,"phases":8219,"primaryCompletion":5392,"completion":4132,"start":356,"enrollment":7112,"conditions":8220,"interventions":8221},[95],[8201,951],[8182,8203],{"intervention":8223,"totalTrials":240,"cells":8224},"Treatment Phase 2",{"EARLY_PHASE1":8225,"PHASE1":8227,"PHASE2":8229,"PHASE3":8231,"PHASE4":8233,"NA":8235},{"trials":8226,"activeCount":103},[],{"trials":8228,"activeCount":103},[],{"trials":8230,"activeCount":103},[],{"trials":8232,"activeCount":103},[],{"trials":8234,"activeCount":103},[],{"trials":8236,"activeCount":103},[8237],{"nctId":8238,"briefTitle":8239,"status":174,"phases":8240,"primaryCompletion":250,"completion":250,"start":8241,"enrollment":8242,"conditions":8243,"interventions":8245},"NCT00117585","Orthostatic Hypotension in Rehabilitation Patients",[95],"2005-11",341,[8244],"Hypotension, Orthostatic",[8223],{"intervention":7946,"totalTrials":240,"cells":8247},{"EARLY_PHASE1":8248,"PHASE1":8250,"PHASE2":8252,"PHASE3":8254,"PHASE4":8256,"NA":8258},{"trials":8249,"activeCount":103},[],{"trials":8251,"activeCount":103},[],{"trials":8253,"activeCount":103},[],{"trials":8255,"activeCount":103},[],{"trials":8257,"activeCount":103},[],{"trials":8259,"activeCount":103},[8260],{"nctId":7938,"briefTitle":7939,"status":174,"phases":8261,"primaryCompletion":7941,"completion":7941,"start":5740,"enrollment":7942,"conditions":8262,"interventions":8263},[95],[7944],[7946,7947,7948,4388,7949],{"intervention":7947,"totalTrials":240,"cells":8265},{"EARLY_PHASE1":8266,"PHASE1":8268,"PHASE2":8270,"PHASE3":8272,"PHASE4":8274,"NA":8276},{"trials":8267,"activeCount":103},[],{"trials":8269,"activeCount":103},[],{"trials":8271,"activeCount":103},[],{"trials":8273,"activeCount":103},[],{"trials":8275,"activeCount":103},[],{"trials":8277,"activeCount":103},[8278],{"nctId":7938,"briefTitle":7939,"status":174,"phases":8279,"primaryCompletion":7941,"completion":7941,"start":5740,"enrollment":7942,"conditions":8280,"interventions":8281},[95],[7944],[7946,7947,7948,4388,7949],{"intervention":7948,"totalTrials":240,"cells":8283},{"EARLY_PHASE1":8284,"PHASE1":8286,"PHASE2":8288,"PHASE3":8290,"PHASE4":8292,"NA":8294},{"trials":8285,"activeCount":103},[],{"trials":8287,"activeCount":103},[],{"trials":8289,"activeCount":103},[],{"trials":8291,"activeCount":103},[],{"trials":8293,"activeCount":103},[],{"trials":8295,"activeCount":103},[8296],{"nctId":7938,"briefTitle":7939,"status":174,"phases":8297,"primaryCompletion":7941,"completion":7941,"start":5740,"enrollment":7942,"conditions":8298,"interventions":8299},[95],[7944],[7946,7947,7948,4388,7949],{"intervention":7949,"totalTrials":240,"cells":8301},{"EARLY_PHASE1":8302,"PHASE1":8304,"PHASE2":8306,"PHASE3":8308,"PHASE4":8310,"NA":8312},{"trials":8303,"activeCount":103},[],{"trials":8305,"activeCount":103},[],{"trials":8307,"activeCount":103},[],{"trials":8309,"activeCount":103},[],{"trials":8311,"activeCount":103},[],{"trials":8313,"activeCount":103},[8314],{"nctId":7938,"briefTitle":7939,"status":174,"phases":8315,"primaryCompletion":7941,"completion":7941,"start":5740,"enrollment":7942,"conditions":8316,"interventions":8317},[95],[7944],[7946,7947,7948,4388,7949],{"intervention":8319,"totalTrials":240,"cells":8320},"Pharmacological",{"EARLY_PHASE1":8321,"PHASE1":8323,"PHASE2":8325,"PHASE3":8327,"PHASE4":8329,"NA":8331},{"trials":8322,"activeCount":103},[],{"trials":8324,"activeCount":103},[],{"trials":8326,"activeCount":103},[],{"trials":8328,"activeCount":103},[],{"trials":8330,"activeCount":103},[],{"trials":8332,"activeCount":103},[8333],{"nctId":8334,"briefTitle":8335,"status":174,"phases":8336,"primaryCompletion":8337,"completion":8338,"start":8339,"enrollment":8340,"conditions":8341,"interventions":8343},"NCT01236521","Care Management for the Effective Use of Opioids",[95],"2015-12-11","2015-12-31","2011-12-01",261,[8342,4069],"Low Back Pain",[8319],{"intervention":8345,"totalTrials":240,"cells":8346},"1mg\u002Fkg sitaxsentan sodium",{"EARLY_PHASE1":8347,"PHASE1":8349,"PHASE2":8351,"PHASE3":8353,"PHASE4":8355,"NA":8357},{"trials":8348,"activeCount":103},[],{"trials":8350,"activeCount":103},[],{"trials":8352,"activeCount":103},[],{"trials":8354,"activeCount":103},[],{"trials":8356,"activeCount":103},[],{"trials":8358,"activeCount":103},[8359],{"nctId":8360,"briefTitle":8361,"status":174,"phases":8362,"primaryCompletion":8363,"completion":7978,"start":8364,"enrollment":2776,"conditions":8365,"interventions":8367},"NCT00744211","Proteolytic Enzyme Induction Within the Human Myocardial Interstitium",[95],"2011-06","2008-07",[8366],"Heart Disease",[8345,8368],"2mg\u002Fkg sitaxsentan sodium",{"intervention":8368,"totalTrials":240,"cells":8370},{"EARLY_PHASE1":8371,"PHASE1":8373,"PHASE2":8375,"PHASE3":8377,"PHASE4":8379,"NA":8381},{"trials":8372,"activeCount":103},[],{"trials":8374,"activeCount":103},[],{"trials":8376,"activeCount":103},[],{"trials":8378,"activeCount":103},[],{"trials":8380,"activeCount":103},[],{"trials":8382,"activeCount":103},[8383],{"nctId":8360,"briefTitle":8361,"status":174,"phases":8384,"primaryCompletion":8363,"completion":7978,"start":8364,"enrollment":2776,"conditions":8385,"interventions":8386},[95],[8366],[8345,8368],{"intervention":8388,"totalTrials":240,"cells":8389},"Result disclosure",{"EARLY_PHASE1":8390,"PHASE1":8392,"PHASE2":8394,"PHASE3":8396,"PHASE4":8398,"NA":8400},{"trials":8391,"activeCount":103},[],{"trials":8393,"activeCount":103},[],{"trials":8395,"activeCount":103},[],{"trials":8397,"activeCount":103},[],{"trials":8399,"activeCount":103},[],{"trials":8401,"activeCount":103},[8402],{"nctId":8403,"briefTitle":8404,"status":174,"phases":8405,"primaryCompletion":8406,"completion":8406,"start":8407,"enrollment":6869,"conditions":8408,"interventions":8409},"NCT04178122","Million Veteran Program Return of Actionable Results",[95],"2024-09-08","2020-02-27",[147],[8388],{"intervention":8411,"totalTrials":240,"cells":8412},"SLCO1B1 Genotype",{"EARLY_PHASE1":8413,"PHASE1":8415,"PHASE2":8417,"PHASE3":8419,"PHASE4":8421,"NA":8423},{"trials":8414,"activeCount":103},[],{"trials":8416,"activeCount":103},[],{"trials":8418,"activeCount":103},[],{"trials":8420,"activeCount":103},[],{"trials":8422,"activeCount":103},[],{"trials":8424,"activeCount":103},[8425],{"nctId":8426,"briefTitle":8427,"status":174,"phases":8428,"primaryCompletion":4966,"completion":4966,"start":8429,"enrollment":8430,"conditions":8431,"interventions":8432},"NCT02871934","Integrating Pharmacogenetics In Clinical Care",[95],"2016-08-01",408,[147],[8411],{"intervention":8434,"totalTrials":240,"cells":8435},"Lithium treatment",{"EARLY_PHASE1":8436,"PHASE1":8438,"PHASE2":8440,"PHASE3":8442,"PHASE4":8444,"NA":8446},{"trials":8437,"activeCount":103},[],{"trials":8439,"activeCount":103},[],{"trials":8441,"activeCount":103},[],{"trials":8443,"activeCount":103},[],{"trials":8445,"activeCount":103},[],{"trials":8447,"activeCount":103},[8448],{"nctId":8449,"briefTitle":8450,"status":174,"phases":8451,"primaryCompletion":6622,"completion":8452,"start":3935,"enrollment":2922,"conditions":8453,"interventions":8454},"NCT00252577","Genetic Predictors of Lithium Response in Bipolar Disorder",[],"2016-05",[5254],[8434],{"intervention":8456,"totalTrials":240,"cells":8457},"re-infusion of biotin labeled cells",{"EARLY_PHASE1":8458,"PHASE1":8460,"PHASE2":8462,"PHASE3":8464,"PHASE4":8466,"NA":8468},{"trials":8459,"activeCount":103},[],{"trials":8461,"activeCount":103},[],{"trials":8463,"activeCount":103},[],{"trials":8465,"activeCount":103},[],{"trials":8467,"activeCount":103},[],{"trials":8469,"activeCount":103},[8470],{"nctId":8471,"briefTitle":8472,"status":246,"phases":8473,"primaryCompletion":8474,"completion":8475,"start":8476,"enrollment":220,"conditions":8477,"interventions":8479},"NCT01204216","Effect of Red Blood Cell Survival on a Commonly Used Diabetes Lab Test-HbA1c",[95],"2016-07-01","2016-09-01","2010-09-01",[8029,8478,4521],"Impaired Fasting Glucose",[8456,8480],"Re-infusion of biotin labeled cells",{"intervention":8482,"totalTrials":240,"cells":8483},"Co-Analgesic Therapy",{"EARLY_PHASE1":8484,"PHASE1":8486,"PHASE2":8488,"PHASE3":8490,"PHASE4":8492,"NA":8494},{"trials":8485,"activeCount":103},[],{"trials":8487,"activeCount":103},[],{"trials":8489,"activeCount":103},[],{"trials":8491,"activeCount":103},[],{"trials":8493,"activeCount":103},[],{"trials":8495,"activeCount":103},[8496],{"nctId":8497,"briefTitle":8498,"status":174,"phases":8499,"primaryCompletion":8500,"completion":8501,"start":7980,"enrollment":8502,"conditions":8503,"interventions":8505},"NCT00386243","Evaluation of Stepped Care for Chronic Pain in Iraq\u002FAfghanistan Veterans (ESCAPE)",[95],"2012-05","2012-09",242,[8342,4069,8504],"Pain, Intractable",[8482,8506],"Opioid Analgesics",{"intervention":8506,"totalTrials":240,"cells":8508},{"EARLY_PHASE1":8509,"PHASE1":8511,"PHASE2":8513,"PHASE3":8515,"PHASE4":8517,"NA":8519},{"trials":8510,"activeCount":103},[],{"trials":8512,"activeCount":103},[],{"trials":8514,"activeCount":103},[],{"trials":8516,"activeCount":103},[],{"trials":8518,"activeCount":103},[],{"trials":8520,"activeCount":103},[8521],{"nctId":8497,"briefTitle":8498,"status":174,"phases":8522,"primaryCompletion":8500,"completion":8501,"start":7980,"enrollment":8502,"conditions":8523,"interventions":8524},[95],[8342,4069,8504],[8482,8506]]